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Here’s to the crazy ones. The rebels. 
The troublemakers. The ones who see 
things differently. While some may see 
them as the crazy ones, we see genius. 
Because the people who are crazy 
enough to think they can change the 
world, are the ones who do. 
- Apple Inc. 1997  
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GENERAL INTRODUCTION 
 
mRNA as a therapeutic modality is becoming increasingly popular in the fields of gene 
therapy and vaccination. mRNA has various advantages over pDNA-based 
therapeutics, for instance, 1) it can immediately express a protein of interest even in 
non-dividing cells, 2) it carries virtually no risk of genomic integration and oncogenic 
mutagenesis, and 3) due to its transient nature, there is no risk of potential side effects 
from permanent production of the therapeutic protein. mRNA has been shown to be 
useful for various applications including vaccination against infectious diseases 1-3, 
cancer immunotherapy 4,5, protein-replacement therapy 6,7, generation of induced 
pluripotent stem (iPS) cells (genetic reprogramming) 8, desensitization of allergies 9,10, 
and genome engineering 11,12. 
However, unmodified mRNA produced by in vitro transcription (IVT) can stimulate 
innate immune receptors upon transfection into cells and cause substantial cell death 
13-16. For instance, toll-like receptors (TLRs) 3 and 7 are stimulated by double- and 
single-stranded RNA (ssRNA and dsRNA), respectively, inside the endosomes. 
Another group of innate immune sensors, the RIG-I-like receptors (RLRs), detect 
exogenous RNA in the cytoplasm. Members of the RLR group include: retinoic acid-
inducible gene I (RIG-I) which recognizes short ssRNA, dsRNA, or uncapped RNA and 
melanoma differentiation-associated protein 5 (MDA-5) which recognizes longer 
dsRNAs or mRNAs without 2’-O-methylation of the penultimate nucleoside. Other 
pattern recognition receptors (PRRs) include the NOD-like receptors (NLRs), which 
bind nucleic acids or peptidoglycans of pathogens and cause the activation of 
inflammasomes leading to caspase-dependent programmed cell death. Stimulation of 
PRRs by exogenous RNA triggers overexpression of type I interferons (IFN-α and IFN-
β) as well as type III IFN (IL-28A and IL-28B) resulting in the activation of interferon-
stimulated genes (ISGs), such as Protein Kinase R (PKR) or RNase L, which play a 
role in the anti-viral response 17. Upon stimulation of PRRs by exogenous RNA, 
mammalian cells use several mechanisms at different phases of the viral lifecycle to 
inhibit the replication of the pathogen. One of the most widely recognized defense 
mechanisms is the phosphorylation of eukaryotic translation initiation factor 2, α 
subunit, (eIF2α); at the serine 51 by PKR and cessation of cellular translation 18. As a 
15 
 
consequence, viral replication is arrested due to deficiencies in essential viral proteins. 
However, many viruses have discovered ways to subvert this response by utilizing 
cap-independent initiation of translation using internal ribosome entry sites (IRESs) 
typically located within the 5’ untranslated region (UTR) of the viral RNA. Additionally, 
activation of OAS2 by dsRNA and subsequent RNase L dimerization/activation causes 
degradation of all viral and cellular RNA, often resulting in cell death 19. 
These antiviral mechanisms limit the therapeutic potential of IVT mRNA. However, the 
realization that nucleotide base modifications greatly improve the properties of mRNA 
as an expression platform by reducing the immunogenicity and increasing the stability 
of the RNA molecule has been pivotal in overcoming these hurdles 6,7,16,20-25. Inclusion 
of specific nucleotide modifications, such as 5-methylcytidine (m5C), pseudouridine 
(Ψ) or 2-thiouridine (s2U) 21 makes the mRNA molecule less recognizable by pattern 
recognition receptors (PRRs). 
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AIMS OF THE STUDY 
 
 
Gene-based immunotherapy has gathered much attention in the last decade as a 
promising approach to treat cancer or genetic disorders. Successful clinical trials led 
to the FDA approval of the first veterinary and human gene- and cell-based 
immunotherapies (OnceptTM and Provenge®, respectively). 
While plasmid DNA (pDNA) is commonly used as the method of choice for vectored 
immunotherapy, it has many caveats including the necessity of the DNA to overcome 
the nuclear barrier, a particularly difficult challenge in an in vivo setting, where cells are 
non- or slowly dividing. Furthermore, the presence of an antibiotic resistance gene in 
pDNA and the possibility of mutagenesis due to integration of the vector into the 
genome raises safety concerns, which makes such therapies particularly difficult to 
obtain regulatory approval. Thus, more recently, mRNA-based approaches have 
become increasingly popular as an alternative to pDNA. In order to improve the stability 
and enable prolonged expression from mRNA, nucleotide modifications have been 
incorporated into therapeutic RNA to evade recognition by endosomal Toll-like 
receptors (TLR3, TLR7 or TLR8) or cytosolic RIG-I-like receptors (RIG-I, MDA-5). 
 
The general goal of this PhD project was to develop a safe yet potent mRNA-based 
protein expression platform. To this end the following questions are addressed in this 
dissertation: 
 
1. What are the advantages and disadvantages of mRNA and pDNA as gene therapy 
platforms? 
2. What are the hurdles of mRNA-based gene therapy and how can we overcome 
them? 
3. What are the molecular mechanisms that underlie the cytotoxic effects caused by 
transfected mRNA? 
4. How can we alleviate the toxicity/immunogenicity of in vitro transcribed mRNA? 
5. Which ribonucleoside modifications enable mRNA to express proteins most robustly 
in vitro and in vivo? 
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INTRODUCTION 
 
mRNA-based therapeutics have the potential to be used for a myriad of applications 
including protein replacement therapy and vaccination. The principles behind the two 
therapies are relatively straightforward: the introduction of wild-type proteins into cells 
to “correct” for an abnormal gene (protein replacement therapy) or expression of 
antigens from RNA to trigger an immune response (vaccination). However, in practice, 
a great amount of optimization is required to transform an mRNA molecule into an 
effective therapeutic. In this introductory chapter, we provide an overview of some of 
the currently understood principles behind how to optimize an mRNA molecule for 
therapy. Furthermore, we discuss various strategies to efficiently deliver RNA into cells 
and then we describe a few possible applications for mRNA therapy. 
 
Half-life and translatability of IVT mRNA 
 
Since the elucidation of mRNA structure and its chemical synthesis 26, it was generally 
believed that, compared to DNA, mRNA is a fairly unstable molecule, especially once 
it reaches the cytoplasm where it is exposed to degrading enzymes. The main reason 
for its instability is the presence of a hydroxyl group on the second carbon atom of the 
sugar moiety, which, due to sterical hindrance, prevents mRNA from adopting a stable 
double β-helix structure and which makes the molecule more prone to hydrolytic 
degradation. Initial reports of intracellular mRNA delivery were subject to skepticism, 
mainly because of the belief that mRNA is extremely labile and could not withstand the 
transfection protocols. 
 
Cap structure 
 
The 5′ ends of mRNA are modified post-transcriptionally in the nucleus with a 
methylated m7GpppN-cap structure. This modification plays a role in mRNA splicing, 
stabilization, transport and, most importantly, it facilitates the translation process by 
recruiting ribosomes. The eukaryotic initiation factor 4G (eIF4G), which is the scaffold 
molecule of the holo-enzyme complex eIF4F, contains a cap-binding eIF4E, an RNA 
helicase eIF4A and eIF3, a complex that associates directly with the 40S ribosomal 
20 
 
subunit. The concept that the cap structure is essentially required for recruitment of 
ribosomes was put to the test with the discovery that internal ribosome entry sites 
(IRES), present in some viral and cellular mRNAs, are able to attract ribosomes even 
when the 5′ cap is blocked or missing 27. Still, the cap structure has proven to be 
imperative for normal mRNA function 28. Initially, the mRNA cap binds to the cap-
binding protein (CBP) heterodimer CBP80-CBP20. This protein complex regulates 
transport of the mRNA from the cytoplasm to the nucleus and plays a crucial role in 
monitoring the quality of the mRNA molecule via nonsense-mediated mRNA decay 
(NMD), a process by which mRNAs with premature stop codons (e.g. due to errors 
introduced by RNA polymerase) become degraded. The degradation of mRNAs takes 
place in the cytoplasm at sites called P-bodies 29. Until now, up to forty P-body proteins 
have been described, including Xrn 5′-3′ exonucleases, decapping and de-adenylating 
enzymes. The cap structure protects against Xrn1 in the cytoplasm and against Xrn2 
in the nucleus because of its 5′-5′ linkage 30. The cap structure is an essential part of 
the mRNA molecule, especially if one wishes to introduce an exogenous mRNA into 
the cell 28. When mRNA is synthesized in vitro, the cap structure may be incorporated 
into the RNA in the reverse orientation, causing only half of the in vitro generated 
mRNAs to be functional. This can be averted by the use of an anti-reverse-cap 
analogue (ARCA), a modified cap structure in which the 3’ OH (closer to the m7G) is 
methylated. This forces the ARCA to be incorporated in the right orientation, leading 
to close 100 % yield of translatable mRNA 31. 
 
Poly(A) tail 
 
Also the 3′ ends of mRNAs are post-transcriptionally tailored by an enzyme which adds 
a series of adenine nucleotides. The length of this poly(A) tail is crucial. It has been 
shown that all actively translated mRNAs in mammalian cells contain 100 to 250 A 
residues 32. To be translated efficiently, the poly(A) tail of exogenously delivered 
mRNAs should consist of at least 20 A residues 33,34. Moreover, it has been described 
that mRNA expression positively correlates with poly(A) tail length 33-35. Several groups 
have reported that mRNAs containing a cytoplasmic polyadenylation element (CPE, a 
specific nucleotide sequence at the 3′ UTR), can initiate a process, which elongates 
the poly(A) tail in the cytoplasm, so that mRNAs can be turned from a repressed into 
an active molecule 36,37. However, up until now, this process has only been shown in 
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cells in early development. Interestingly, a synergistic effect of the cap structure and 
the poly(A) tail on translation efficiency has been demonstrated by several research 
groups 28,38-41. This synergism has been explained by the formation of a cap-eIF4E-
eIF4G-PABP-poly(A) closed loop structure that could facilitate the recycling of 
ribosomes 40 and/or protect the mRNA against exonucleolytic nucleases 42. On the 
other hand it has been reported that disruption of eIF4G–PABP interaction, still leads 
to a synergistic effect, albeit of smaller magnitude 41. The fact that synergy is only seen 
in cells and not in cell-free translation systems, has been proven to be a result of the 
presence of competitor mRNAs in cells, which enforces the combined use of both cap 
and poly(A) 35. This is also supported by the notion that co-delivery of exogenous free 
poly(A) tails results in a 2 to 9-fold higher transfection efficiency 41,43. 
 
3’ and 5’ UTRs 
 
Most eukaryotic mRNAs contain mRNA decay signals in their 3′ untranslated regions 
(3′ UTRs). The most extensively studied are the Adenylate Uridylate Rich Elements 
(AREs). Many AU-rich mRNA sequences exist. They affect mRNA stability to different 
extent. It has been demonstrated that mRNAs that contain ARE are unstable (mostly 
because of rapid removal of the poly(A) tail) 44 and that their half-life increases when 
ARE is replaced by the 3′ UTR of a stable mRNA (e.g. β-globin or Venezuelan Equine 
Encephalitis virus - VEEV)45,46. The mechanism of the destabilizing power of ARE is 
not very well understood. It appears, however, that specific AU sequences destabilize 
mRNA in their own manner, which depends on the mRNA itself, as well as on the cell 
type and growth conditions. Indeed, the destabilizing activity of ARE can be decreased 
or increased due to interactions with other particular mRNA sequences (e.g. U-rich 
region) or with ARE binding proteins. Interestingly, ARE can destabilize constitutively 
or they can work as regulatory elements 47. Another form of 3′ UTRs are the Iron 
Responsive Elements (IREs), present in mRNAs encoding proteins that affect iron 
homeostasis (e.g. transferrin and ferritin). They respond to intracellular iron 
concentration by binding of the IRP (Iron Regulatory Protein). The effect of IREs 
depends on their precise location. They regulate mRNA half-life when present at the 
3′ UTR and will affect translation when located at the 5′ UTR 48. Several other 
destabilizing 3′ UTR, and also 5′ UTR, have been discovered (e.g. stem-loop of insulin-
like growth factor II) 49. 
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In summary, when aiming at transfecting cells with exogenous mRNA, the in vitro 
transcribed mRNA molecule should at least be provided with a cap structure and a 
poly(A) tail containing at least 20 A residues to ensure an acceptable half-life 50. Further 
optimization of the mRNA structure can be done by replacing unstable non-coding 
sequences with non-coding sequences of mRNAs known as stable (e.g. β-globin). Also 
coding mRNA regions can accelerate mRNA decay. To tackle this problem, one could 
change nucleotides so that a different codon triplet is formed, still matching with a tRNA 
carrying the same amino acid (codon optimization) 51. 
 
mRNA platforms: modified and replicating 
 
Modified mRNA and replicating mRNA are two of the most promising platforms on 
which therapeutic genes may be encoded. One of the challenges that must be 
overcome when using such mRNAs for gene expression in mammalian cells is the 
antiviral innate immune response (i.e. activation of the interferon (IFN) and NF-κB 
pathways). mRNAs transfected into mammalian cells are subject to detection by PRRs 
such as the endosomal toll-like receptors (TLRs) TLR3, TLR7, and TLR8 and the 
cytosolic RIG-I-like receptors (RLRs) RIG-I, MDA-5, and LGP2 52. These sensors are 
involved in the recognition of RNA species that are “non-self” (e.g. viral RNA). 
Stimulation of these receptors leads to activation of the IFN and NF-κB signaling 
pathways and subsequent translation inhibition by protein kinase R (PKR), mRNA 
degradation by ribonuclease L (RNase L), inflammatory cytokine expression and 
programmed cell death. The innate immune response is particularly problematic when 
carriers such as cationic liposomes or polymers are used for the delivery of mRNAs 
into cells (for a recent review on nucleic acid delivery methods see 53). Carrier-mRNA 
complexes, which often have a net positive charge, bind the negatively charged cell 
membrane through electrostatic interactions and are subsequently taken up into 
endosomes via endocytosis, where the mRNAs are sensed by TLRs. Depending on 
the efficiency of the carrier, this may result in a very strong innate immune response. 
In contrast, when physical mRNA delivery methods such as electroporation or the gene 
gun approach are used, the mRNA does not encounter endosomal TLRs, and thus, 
the innate immune response may be less severe compared to when chemical carriers 
are used. However, the induction of an innate immune response is still a major concern 
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in cells that are known to possess high levels of PRRs such as epithelial cells as shown 
by us and others 14,54. This problem has now been largely solved by the pioneering 
research of Kariko and colleagues which demonstrated that the immunogenicity of 
mRNA molecules could be greatly reduced by the incorporation of base modifications 
such as pseudouridine (Ψ) into the mRNA 16. Kariko and colleagues showed that 
mRNAs with Ψ can evade PRRs, reduce PKR activation, and are more resistant to 
RNase L 16,20,21,23. Subsequently, others followed suit and identified other combinations 
of base modifications that provide similar types of effects 6,55 as depicted in Figure 
2.1A. For the purpose of mRNA vaccination, however, some level of innate immune 
activation may be beneficial to induce a potent adaptive immune response. 
 
 
 
Figure 2.1. Structures of RNA platforms for vaccination. (A) Unmodified and modified 
(non-replicating) RNA structures. (B) Alphaviral RNA replicon structure. 
m7G: 7-methyl-guanosine; UTR: untranslated region; ORF: open reading frame; AAAn: 
poly(A) tail; Ψ: pseudouridine; m5C: 5-methyl-cytosine; s2U: 2-thiouridine; nsP: 
nonstructural protein; SGP: subgenomic promoter. 
 
 
While cellular antiviral pathways have evolved into very complex innate immune 
signaling networks 52, viruses have also developed a myriad of sophisticated counter-
strategies to dampen the IFN response or to avoid being recognized by the host cell 
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56. Thus, RNAs derived from viruses provide another attractive option for a therapeutic 
platform. In particular, the RNA “replicon” approach in which non-essential structural 
proteins (but not RNA replicase proteins) are deleted from the genome of the virus and 
replaced with a gene of interest has gained popularity as a safe and robust mean of 
exogenous protein expression 57. Major advantages of the RNA replicon approach 
include its strong expression level and long duration of expression due to its “self-
replicating” properties. As an example, the mechanism of replication of an alphaviral 
RNA replicon has been depicted in Figure 2.1 B (for a review see 58). Geall and 
colleagues recently showed that gene expression from alphaviral RNA replicons can 
last for at least seven weeks in vivo when replicon RNA was packaged in lipid 
nanoparticles and injected into the muscle of mice for vaccination 59. Other groups 
have successfully used alphaviral replicons for the purpose of induced pluripotent stem 
cells (iPS) reprogramming 60 or even in vivo artificial miRNA delivery 61 demonstrating 
their potential as a broad-purpose gene expression vector. More recently, to facilitate 
the use of alphaviral replicons as a platform for synthetic gene circuit engineering, our 
collaborating group created a mathematical model for Alphavirus gene expression 
kinetics using high-density time course data 62. 
In Table 2.1, we summarize the differences in the properties of the non-replicating and 
replicating mRNA platforms discussed above. 
 
Platform Size Expression 
level 
 
 
Duration 
of 
expression 
in vivo 
(i.m. 
injection) 
Innate  
immune 
Stimula-
tion 
Amplifica-
tion  
in 
cells 
Ref. 
Unmodi-
fied 
mRNA 
Typically 
> ~500 
nt 
Low ~1 week* High No 
Reviewed  
in 
63-65 
Modified 
mRNA 
Typically 
> ~500 
nt 
Medium ~4 weeks* Low No 6,23,55 
RNA 
replicon 
> ~8000 
nt 
High ~7 weeks High Yes 
Reviewed  
in 65-67 
*Authors’ results presented in Chapter 5. 
i.m.: intramuscular. 
 
Table 2.1: Comparison of RNA platforms for vaccination. 
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It should be emphasized that one mRNA platform is not generally better than the other, 
and the specific application of interest will ultimately determine which platform to 
choose to bring out the maximum potential of mRNA-based therapy. 
 
The nuclear barrier: challenging for pDNA but irrelevant for mRNA  
 
Multiple extracellular and intracellular barriers pose serious limitations to non-viral 
gene delivery. Newly designed lipid and polymer formulations have significantly 
improved the uptake and the endosomal escape of pDNA, leaving the nuclear 
envelope the main obstacle for non-viral pDNA transfer. Indeed, several groups have 
demonstrated that microinjections of plasmid DNA into the cytoplasm of non-dividing 
cells result in very low levels of gene expression. In contrast, intra-nuclear injection of 
the same number of pDNA copies leads to 100 % transfection of the injected cells 68-
70. One possibility for pDNA to enter the nucleus is during cell division, when the 
integrity of the nuclear envelope is temporarily lost. In fact, it has been shown that 
dividing cells are more easily transfected than cell-cycle arrested cells 71-75. However, 
the advantage of the temporary absence of the nuclear envelope during mitosis will 
not be generally applicable in gene therapy because in most cases the target cells will 
divide slowly or not at all. 
The easiest approach to overcome the obstacle presented by the nuclear envelope 
would be to develop a cytoplasmic expression system. mRNA, being translated in the 
cytosol, would seem to serve that purpose perfectly. mRNA does not need to enter the 
nucleus to perform its function and thus avoids a major limiting factor for efficient gene 
transfer. In this way, mRNA allows transfection of different cell types in the human 
body, including quiescent or slowly proliferating cells, such as vascular endothelia, 
muscle cells, hepatocytes or brain cells. 
 
Methods for mRNA delivery 
 
The spontaneous uptake of naked nucleic acids by cells is a very inefficient process. 
In principal two methods of nucleic acid delivery can be distinguished: the viral and the 
non-viral delivery systems. The viral vectors have been studied extensively for pDNA 
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delivery, although reports exist also where mRNA is packaged into RNA viruses 76-78. 
However, gene expression after viral transfection is difficult to control and certain viral 
vectors integrate their genome into that of the host cells. Moreover, the immune system 
is also an important barrier for viral vectors. Finally, the production of clinical grade 
viral vectors is expensive and time consuming. Therefore in this chapter, we will focus 
on non-viral delivery methods (illustrated in Figure 2.2), which can be classified in two 
subgroups; those that physically disturb the barrier function of the cell membrane and 
thus provide a passage for mRNA (electroporation, ultrasound or gene gun) and those 
that employ cationic carriers (lipo- and polyplexes), which are taken up by endocytosis 
and thus facilitate the entry of the mRNA. 
 
 
Figure 2.2. Non-viral delivery methods of mRNA. Electroporation is a physical delivery 
method based on applying of an electrical current to cellular membrane, increasing its 
permeability for gene-based therapeutics. Gene gun (biolistic technique) delivers gold 
particles precoated with nucleic acids straight to the cytoplasm. Lipoplexes and 
polyplexes are non-viral delivery methods in which negatively charged pDNA or mRNA 
is complexed with positively charged lipids or polymers, respectively. 
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Electroporation and gene gun delivery 
 
Electroporation is a gene delivery method which was originally developed for in vitro 
transfection. An external electrical field is applied to a cell in the presence of a nucleic 
acid containing solution, leading to enhanced electrical conductivity and permeability 
of the cell membrane. When the voltage over the plasma membrane becomes higher 
than its dielectric strength, pores are formed resulting in the transmembrane passage 
of the nucleic acids. Both strength and duration of the applied electrical field should be 
chosen carefully, so that pores can close again when extracellular material has been 
introduced into the cell. If not, cells can be severely damaged or even die 79. The in 
vivo applicability of electroporation was first demonstrated by Mir et al. 80, who used 
this technique to deliver a drug (bleomycin) in several types of tumors. Since then, the 
technique has been shown to introduce naked pDNA in vivo into several types of 
tissue; however the limited accessibility of less superficially localized organs remains 
an issue. mRNA electroporation has several advantages over pDNA electroporation. 
First of all, it is less toxic because less stringent electrical settings are required as the 
mRNA has to cross only the cell membrane to perform its function as opposed to both 
the cell and nuclear membrane in the case of pDNA 81. Electroporation with mRNA has 
been explored elaborately in dendritic cells (DCs) because of their possible use in 
vaccination strategies 82. Electroporation of DCs with mRNA is a safe and relatively 
easy method and it has already been tested in clinical trials (e.g. transfection of mRNA 
encoding prostate specific antigen (PSA)) 83. In addition to DCs, also other cell types 
have been successfully electroporated with mRNA and used in adoptive cell therapy 
84,85. 
Another method, which can intracellularly deliver genetic material by breaking the 
existing barriers, is the gene gun, a biolistic delivery system. This transfection device, 
originally designed for plant transformation 86, uses high velocity heavy metal (often 
gold) particles coated with nucleic acids, which are released once they reach the 
aqueous intracellular environment. Since the initial work was performed, the technique 
has been refined: a hand-held device facilitates its use; both transfection efficiency and 
cell viability have been improved. Moreover, the applicability on most tissues, including 
several mammalian, has been demonstrated 87-89. Initial reports about biolistic delivery 
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of mRNA were aimed at the evaluation of mRNA decay rates. Rajagopalan et al. 90 
used a gene gun to deliver exogenous mRNA (encoding granulocyte-macrophage 
colony stimulating factor or β-globin) into peripheral blood mononuclear cells and found 
mRNA half-lives varying between 9 and 80 min, depending on whether or not 
destabilizing factors were present. Gene gun bombardment for successful mRNA 
transfection has been shown both in vitro as in vivo in several cell types and tissues. 
When mRNA encoding alpha-1 antitrypsin was delivered in mice, a strong antibody 
response was seen, indicating the possibility of using this technique as a vaccination 
strategy 91. Sohn et al. used the technique to deliver mRNA encoding human epidermal 
growth factor (hEGF) and observed increased wound healing 92. 
 
Lipo- and polyplexes 
 
The complexation of nucleic acids (negatively charged) with cationic lipids or 
polymers occurs spontaneously through charge–charge interaction, forming lipo- or 
poly-plexes, respectively. The complexes thus formed are usually slightly positive, 
facilitating interaction with the negatively charged cell membrane, after which they 
can be taken up in the cell by endocytosis 93-96. The advantage of net positive charge 
of complexes in vitro is, however, overshadowed in vivo by possible interactions with 
negatively charged serum proteins, which results in the rapid clearance of such formed 
aggregates 97. This hurdle can be partially overcome by shielding the cationic 
complexes with charge-neutralizing polyethylene glycol (PEG). Cationic carriers not 
only serve to condense nucleic acids into small particles (several hundred nm) but 
also to protect them against degradation 98. A wide variety of cationic lipids and 
polymers has been elaborately tested for their potential to complex and deliver pDNA 
into cells, both in vitro and in vivo. It is only since the beginning of the millennium 
that the technique has been implemented for mRNA delivery, although a first report 
where a polymer (DEAE-dextran) is used to complex in vitro synthesized mRNA to 
transduce cells already dates back to 1973 99. The first mRNA transfection by means 
of lipofection was performed by Malone et al. 100. They were able to deliver mRNA 
encoding luciferase to different cell lines by condensing it with DOTMA/DOPE (N-
[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethyl-ammoniumchloride/1,2dioleo-yl-sn-glycero-
3-phosphoethanolamine). The authors observed a linear relationship between activity 
of luciferase and the quantity of introduced mRNA. An overall conclusion when 
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considering all studies on mRNA transfection by means of non-viral cationic carriers 
is that the delivery of mRNA by means of cationic lipids resulted in a significantly 
better outcome than when cationic polymers were used. Bettinger et al. 50 transfected 
different cell types with a variety of cationic carriers that were already tested for pDNA 
delivery. They tested linear and branched polyethylene imine (PEI), poly-L-lysine and 
polyamidoamine dendrimer and demonstrated a very low potency for mRNA 
translation. However, if shorter polymers were used, the electrostatic interaction with 
mRNA was weaker, resulting in a slightly better expression. DOTAP (1,2-dioleoyl-3- 
trimethylam-monium-propane) is one of the most extensively studied lipid carriers for 
cellular delivery of mRNA 50,101-104 and it proved to possess superior efficiency in 
several comparative studies. 
 
 
Applications for mRNA as a drug molecule 
 
mRNA-loaded dendritic cells vaccine 
 
Dendritic cells (DCs) are the most potent cells in presenting antigens through major 
histocompatibility complex (MHC) class I and II proteins and are thus capable of 
eliciting both cellular and humoral immune responses. The pioneered by Gilboa group 
105 principle of classical vaccination is based on pulsing DCs with previously defined 
antigenic peptides. Although this method has proven its relevance in the past, the main 
drawback is the restriction of the immune response to a limited number of human 
leukocyte antigen (HLA) type-restricted leukocytes. This problem can be overcome by 
loading DCs with proteins, cDNAs or mRNAs to induce immune responses to a host 
of immunogenic epitopes. However, in case of cancer vaccination one has to take into 
account that many patients have microscopic amounts of tumor, limiting the 
practicability of loading DCs with whole cell protein extracts. Moreover, whole cell 
protein extracts contain many irrelevant antigens, which can cause autoimmune 
responses or present immunodominance problem. For that reason, nucleic acid 
vaccinations represent an interesting alternative. Moreover, when considering 
vaccination against infectious diseases, mRNA vaccinations eliminate the risk of 
mutation and uncontrollable proliferation of inactivated pathogens 106. 
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Anti-cancer immunotherapy 
 
Cancer is no longer considered a single disease but instead a complex interaction of 
many pathologies that actively change the tumor microenvironment. Tumors are 
heterologous compositions of many cell types in abnormal states. This feature of 
cancer pathology renders cancer vaccines that target just one tumor antigen, less 
effective. On the other hand, vaccination with several antigens may introduce a new 
problem, namely immunodominance, in which CD4+ and/or CD8+ T cells preferentially 
respond to certain epitopes leaving others unattended 107,108. Another hurdle in cancer 
vaccination, especially in tumors diagnosed in an advanced stage, is the 
immunosuppressive network of immune cells, cytokines and other proteins that 
subvert tumor surveillance. Monoclonal antibodies that block T cell inhibitory signaling 
are very effective in immunomodulation of the cancer environment. For example, the 
anti-CTLA-4 antibody (Ipilimumab) enhances activation of antitumor effector T cells 
and has been approved by the FDA as a cancer drug. Immunomodulation has proven 
to boost anti-cancer vaccination and thus should be treated as an essential component 
of immunotherapy. 
Most groups using the mRNA vaccination strategy described earlier, tested its 
application in the immunotherapeutic treatment of different cancers. The precedent 
was set by Conry et al. 109, who measured the immune response in mice after injection 
of a liposome/mRNA vaccine encoding human CEA (carcinoembryonic antigen). Other 
groups showed specific immune responses against OVA (chicken ovalbumin) 110, 
hTERT (human telomerase catalytic subunit) 111, AFP (α-fetoprotein, a protein 
specifically expressed by hepatocellular carcinoma cells) 112, tTERT (truncated TERT 
which can serve as a universal tumor-associated antigen) 113, RHAMM (the receptor 
for hyaluronan-mediated motility, frequently overexpressed in brain tumors) 114 and IL-
13ra2 (often overexpressed in brain tumors) 115 when DCs were loaded with the 
respective mRNA. 
Transfection of DCs with patient's total tumor RNA and their subsequent re-
administration is not only feasible but is also beneficial because of the broad array of 
epitopes that can be presented. The success of this method was demonstrated by 
tumor-specific responses both in vitro 116,117 and in phase I and II clinical trials 118-120. 
Although the patient-specific antigens cannot be presented when non-autologous 
tumor-mRNAs are used, Mu et al. 117 demonstrated an improved clinical outcome of 
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patients treated with DCs electroporated with mRNA from allogeneic prostate cancer 
cell lines. It is worth mentioning that traditional clinical trial designs, aimed at 
assessing the safety of chemotherapeutic or biological agents, are not suited for cell-
based therapies such as DC vaccines. The reason is that in the classical design the 
maximally tolerated dose is defined in phase I and this concentration is then further 
used in phase II and phase III clinical trials. Because DC vaccines seem to be 
inherently safe, it is always possible to increase the dose, however a higher dose will 
not necessarily render the optimal immunological or clinical response. Nonetheless, 
(pre)clinical trials show that DC vaccines are well tolerated and only minimal toxicities 
(such as grade I skin reactions and/or flu-like symptoms) were observed 83,121. 
Therapeutic cancer vaccination with mRNAs that encode tumor-associated antigens 
(TAAs) in vivo has in the last decade gathered much attention as a promising 
alternative for dendritic cell (DC)-based vaccines. Although, clinical trials with the latter 
vaccines have resulted in promising outcomes, they do not allow mass production due 
to their laborious manufacturing process. Recently, the potential of mRNA cancer 
vaccines has been confirmed in several finished and ongoing clinical trials 120,122. 
These trials demonstrated that mRNA cancer vaccines are at least as effective as DC-
based vaccines. 
 
mRNA vaccine against infectious diseases 
 
Different groups have shown that mRNA is at least equally potent as proteins in 
eliciting CD8+ and CD4+ T-cell responses 123,124. Nucleic acid vaccines are easy to 
manufacture and relatively inexpensive. Although pDNA can be taken up and 
expressed by cells in vitro and in vivo, its use as nucleic acid vaccine has some 
disadvantages as compared to the use of mRNA. As mentioned before, DNA can 
integrate into the host genome, causing inactivation of cellular genes or oncogenesis. 
Another disadvantage is the fact that DNA provides a long duration of expression of 
immunizing antigens, while it has been demonstrated that the capacity of mRNA to 
cause a boost in antigen expression is desired when aiming for optimal vaccination 
121,125. 
The mRNA vaccination strategy can be of interest to induce protective anti-viral 
immunity. In 1993, Martinon et al. demonstrated the potential of a liposome-entrapped 
mRNA vaccine against influenza in a mouse model 126. Since then, murine DCs have 
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been electroporated with several viral antigens in the form of their corresponding 
mRNAs (lymphocytic choriomeningitis virus glycoprotein by Zarei et al. 127), HCV–
NS3/4A (Hepatitis C virus type NS3/4A by Yu et al. 128) and HPV16 E7 (human 
papillomavirus type 16 oncoprotein E7 by Dell et al. 129). They all showed a specific 
CTL response. Moreover, Dell et al. 129 demonstrated an enhanced DC migration due 
to higher cytokine production. Very recently, the german RNA vaccine company 
CureVac opened, aside their mRNA cancer vaccination activities, a new Phase I 
clinical trial with an anti-rabies vaccine that is based on their RNActive® platform 130. 
Additionally, different injection sites have been examined (intravenous, intradermal, 
intramuscular, intranodal, intra-pinnal) demonstrating that the administration route of 
the mRNA vaccine is critically important. Hoerr et al. 131 showed in their study a huge 
difference in specific CTL response after intravenous (i.v.), subcutaneous (s.c.), 
intramuscular (i.m.) or intradermal (i.d.) injection of protamine-condensed mRNA into 
the ear pinna. Only the latter administration route showed a significant CTL response. 
Interestingly, mRNA can serve not only as a molecule encoding the antigen but also 
as an adjuvant by enhancing immunological responses and antigen presentation 15. 
Indeed, as mentioned previously, mRNAs can be recognized by TLRs which can 
initiate an innate immune response. Therefore, the use of mRNA to express antigen 
has gained more and more attention in the battle against viral infections and cancer. 
 
Anti-allergy immunotherapy 
 
mRNA-based immunomodulation finds also its application in anti-allergy therapies. In 
2009, Roesler et al. 132 showed a proof-of-concept that vaccination with mRNAs 
encoding 29 different pollens was a preventive measure against type I allergies 10. 
 
Passive immunoprophylaxis 
 
Immunoprophylaxis through vector-based expression of broadly neutralizing 
antibodies is a promising approach for preventing and combating viral infections or 
cancer133-138. Using a viral vector based on an adeno-associated virus (AAV), Balazs 
et al. demonstrated that expression of neutralizing antibodies can provide long-lasting 
protection against influenza challenges in mice139. His and others’ approaches were 
also shown to be successful in fighting HIV and other pathogens140-143. However, 
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possibly due to viral DNA integration into the host genome, AAV injection leads to life-
long protein expression, which is not ideal for immunization against frequently mutating 
viruses. Hence, we believe that RNA-based expression of antibodies in patients will 
soon become a safer alternative. Indeed, during this doctoral research, I was able to 
confirm the feasibility of RNA-based production of antibodies against infectious 
diseases (influenza, HIV) and cancer cells (CD20-positive non-Hodgkin's lymphoma, 
Rituximab), as presented in Figure 2.3. 
 
 
Figure 2.3. Vector-based antibody production in murine muscle cell line (C2C12) 
following electroporation with Synthetic amplified RNAs (SafeR), also called self-
replicating RNA (see Chapter 2 - mRNA platforms: modified and replicating). 
 
 
Tailoring the immune responses for different applications 
 
Numerous modifications were proposed in order to obtain a stronger CTL response 
after mRNA vaccination. Zhang et al. 144 genetically modified DCs with lymphotactin 
prior to mRNA loading and they obtained a stronger immune response. Other 
examples are the incorporation of ubiquitin prior to the TAA sequence in the mRNA 
construct, species-specific codon optimization of mRNA as well as improvement of 
stability by addition of UTR sequences from β-globin 145-147. When developing 
immunotherapeutic strategies, the main focus has been on inducing potent strong 
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CD8+ CTL responses but it has become clear that CD4+ T cells also play an 
important role by providing the tools for the expansion and persistence of these 
CD8+ T cells 121. To ensure the concomitant activation of both arms of the immune 
response, different measures were investigated. A promising technique is co-
transfection, in which mRNAs coding for adjuvants improving the stimulation of the 
CD4+ T-cell response, are delivered in the DCs in addition to the antigen-coding 
mRNAs. Co-transfection with mRNAs encoding cytokines stimulating signaling 
pathways showed a clear enhancement in CD4+ T-cell stimulation 
5,145,146,148-151
. 
 
 
CONCLUSIONS 
 
mRNA has been considered in the past as too labile to ensure protein expression. 
However, numerous studies have demonstrated the contrary; not only is mRNA 
capable of tolerating the impact of transfection protocols and of being translated 
efficiently, but it also has advantages over the use of pDNA. The high expression in 
non-dividing cells and the absence of antibiotic resistance genes are two important 
advantages. Additionally, the higher safety, due to the avoidance of genomic 
insertion, and no need to provide for a promoter and a terminator decide in favor of 
further research to advance mRNA’s performance in the clinics. We are convinced 
that mRNA will prove its utility as a therapeutic molecule for many other objectives. 
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,Laarbeeklaan 101, 1090 Brussels, Belgium 
INTRODUCTION 
 
 
The respiratory tract has been the target of many pre-clinical and clinical gene therapy 
studies. This is due to the fact that the target cells in the respiratory tract are easily 
accessible as they are only separated from the environment by a thin layer of mucus 
or liquid 152. Additionally, a huge variety of lung diseases such as cystic fibrosis (CF), 
asthma, emphysema, lung cancer, α1-antitrypsin deficiency, and surfactant protein-B 
(SP-B) can potentially be treated via gene therapy 152. Promising results have been 
obtained after the pulmonary administration of certain viral gene vectors 153. However, 
the immunogenicity of viral vectors impedes their re-administration, and the risk of 
insertional mutagenesis and recombination with wild type viruses restrict their clinical 
use 153. Therefore, non-viral vectors complexed with pDNAs have been extensively 
evaluated as safer and less immunogenic alternatives. A major disadvantage of non-
viral vectors is their low gene transfer efficacy, which is caused to a large extent by 
their inability to deliver pDNA into the nucleus of non-dividing cells. It has been shown 
that after cytoplasmatic microinjection of pDNA less than 0.1 % of the pDNA molecules 
reached the nucleus 154. In line with this, Capechhi et al. demonstrated that 
microinjection of pDNA in the nucleus resulted in a gene expression in most of the 
cells, while no significant expression was detected after microinjection of pDNA in the 
cytosol 68. Many strategies have been evaluated to increase the nuclear delivery of 
pDNA 155,156. Unfortunately, none of them have resulted in a significant increase of the 
nuclear localization of pDNA 157,158. Therefore, we and others consider that the use of 
mRNA instead of pDNA may overcome this serious obstacle limiting pDNA-mediated 
gene delivery. In contrast to pDNA, mRNA is translated into proteins in the cytoplasm 
and hence, it does not have to cross the nuclear membrane to be effective. The idea 
of using mRNA is not entirely new. In 1985 Mizutani et al. already bypassed the nuclear 
membrane by using mRNA instead of pDNA 159. Nevertheless, the concept of mRNA 
delivery has not been picked up by the gene therapy community. Indeed, the use of 
mRNA to transfect cells is currently only reported in a limited number of papers. The 
limited interest in mRNA is probably due to the general perception that mRNA is a very 
labile molecule and hence difficult to handle. However, under RNase-free conditions it 
is possible to produce and store mRNA without major problems. Moreover, mRNA can 
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be protected against RNases by complexation with cationic carriers 160. An overview 
of the different cationic carriers, that have been evaluated for mRNA delivery, can be 
found in the recent reviews of Yamamoto et al. 161 and Tavernier et al. 162. In general, 
the intracellular delivery of mRNA seems to be much more efficient with cationic lipids 
than with cationic polymers 50,163. Until now, the highest mRNA transfection efficacy 
has been obtained with Lipofectamine2000, which resulted in transfection of almost 90 
% of the cells 163. 
In studies that compared delivery of mRNA and pDNA, transfection with mRNA was 
shown to lead to a faster but shorter lasting expression of a transgene 50,163-165. 
Therefore, mRNA transfection is especially suited for applications that do not require 
a long-term expression of a protein. For this reason mRNA delivery has mainly been 
considered for vaccination purposes 166. Nevertheless, there are many other possible 
applications for mRNA, such as the expression of “suicide genes”, growth factors, 
protein hormones, and proteins that modulate immune or stem cells. 
The potential of mRNA delivery urged us to compare the performance of mRNA and 
pDNA containing nanoparticles in respiratory cells both in vitro and in vivo. Many 
different non-viral gene carriers have been used for pDNA delivery to the respiratory 
system. However, cationic liposomes based on the GL67 lipid are still considered as 
the “golden standard” in non-viral respiratory gene transfer. Indeed, their therapeutic 
potential, their low toxicity and safety have been extensively demonstrated in many 
pre-clinical and clinical trials 153. Therefore, in this paper we evaluated the 
GL67:DOPE:DMPE-PEG5000 (GL67-lipid formulation) as a carrier for the delivery of 
mRNA to respiratory cells. We first studied the physicochemical properties of 
mRNA/GL67 complexes and identified the optimal ratio between mRNA and GL67. 
After these experiments we compared the expression kinetics of mRNA and pDNA 
complexed with GL67 liposomes. Additionally, the efficacy of mRNA and pDNA 
complexed with GL67 was studied in dividing and non-dividing cells. Finally, 
mRNA/GL67 and pDNA/GL67 complexes were administered to the lungs of mice and 
the expression of the luciferase reporter protein was determined via in vivo optical 
imaging. 
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MATERIALS AND METHODS 
 
Reagents 
 
HEPES, MOPS and Roscovitine were purchased at Sigma (Bornem, Belgium). 
Lipofectamine2000 and Ultra Pure Agarose were from Invitrogen (Merelbeke, 
Belgium). Vials containing GL67:DOPE:DMPE-PEG5000 (1:2:0.05 molar ratio) as a 
lyophilized powder were obtained from Dr. Seng Cheng (Genzyme Corporation, 
Framingham, MA, USA). The amount of GL67 lipid in GL67-lipid formulation in one vial 
is 4 µmol. 2X Formamide-Loading Dye and RiboRuler™ RNA Ladder (High Range) 
were purchased at Fermentas (St. Leon-Rot, Germany). D-Luciferin was from Caliper 
Life Sciences (Teralfene, Belgium). 
 
Plasmids 
 
The pBlue-LucA50 containing the cDNA of firefly luciferase was used for the in vitro 
transcription (IVT) of mRNA. This pDNA was a kind gift of Dr. Peter Ponsaerts 
(University of Antwerp, Antwerp, Belgium) and was previously described by Sheets et 
al. 167. Messenger RNA encoding GFP was obtained via IVT from pGEM4Z[eGFP]A64. 
The latter was provided by Prof. dr. Smita Nair (Duke University Medical Center, NC, 
USA). All the DNA templates have the T7 RNA polymerase promoter site upstream of 
the sequence to be transcribed. 
pCpG-hCMV-Luc, which contains a reduced number of immunostimulatory CpG-
islands was a generous gift from Prof. Ernst Wagner and dr. Manfred Ogris (Ludwig-
Maximilians-University, München, Germany) and was previously described by Navarro 
et al. 168. eGFP-N1 plasmid coding for mutant Aequorea victoria green fluorescent 
protein (GFP) was purchased from Clontech Laboratories (Mountain View, CA, USA). 
The pDNAs were isolated and purified from Escherichia coli using Qiagen Plasmid 
Giga Kit (Qiagen, Venlo, Netherlands). The pDNA used in the in vivo experiments was 
purified using the EndoFree Plasmid Giga Kit (Qiagen, Venlo, Netherlands). After 
purification, the DNA concentration was determined spectrophotometrically by the 
measurement of the UV absorbance at 260 nm. Purity was confirmed by checking the 
260 nm/280 nm ratio as well as by 1 % agarose gel electrophoresis. 
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In vitro transcription of mRNA 
 
pBlue-LucA50 was sequenced on a 3130xl DNA Analyzer with the BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, Halle, Belgium) and confirmed to 
contain a luciferase gene (firefly) and a poly(A)-tail of 50 adenosines. Prior to in vitro 
transcription pBlue-LucA50 and pGEM4Z[eGFP]A64 were linearized downstream of 
the insert with DraI and SpeI restriction enzyme (Promega, WI, USA), respectively, 
and examined on an agarose gel. mRNA was transcribed with a mMESSAGE 
mMACHINE kit according to the manufacturer’s instructions (Ambion, Austin, TX, 
USA). mRNA was dissolved in RNase-free water (Ambion, Austin, TX, USA). The 
concentration was determined by measuring the absorbance at 260 nm and its purity 
was assessed by measuring the 260/280 nm absorbance ratio. Additionally, the purity 
and size of mRNA was checked by formaldehyde gel electrophoresis. Briefly, 1 g of 
Ultra Pure Agarose (Invitrogen, Merelbeke, Belgium) was dissolved in 100 ml of 1x 
MOPS-Buffer prepared in RNase-free DEPC-treated water, containing 18 ml of 37 % 
formaldehyde (Sigma, Bornem, Belgium). As a reference, a RiboRulerTM High Range 
RNA Ladder was used (Fermentas, St. Leon-Rot, Germany). 
 
Preparation and characterization of mRNA/GL67 and pDNA/GL67 complexes 
 
The GL67:DOPE:DMPE-PEG5000 liposomes (1:2:0.05; molar ratios) were prepared 
by adding 2.667 ml of RNAse-free water (Ambion, Austin, TX, USA) to the vials 
containing 4 µmol GL67, 8 µmol DOPE and 0,2 µmol DMPE-PEG5000. mRNA/GL67 
complexes were prepared at different ratios by mixing 3 µg of mRNA dissolved in 12.5 
µl RNase-free water with different amounts of GL67-liposomes dispersed in 12.5 µl 
RNase-free water. After mixing, the complexes were incubated for 15 min at 30°C. 
pDNA/GL67 complexes with a molar ratio of 1.33 169 were prepared in a similar way. 
The mRNA/GL67 or pDNA/GL67 molar ratios were calculated based on the nucleotide 
concentration in the mRNA or pDNA solutions using an average nucleotide molecular 
mass of 340 g/mol (for pDNA we used 330 g/mol) as well as the molar concentration 
of GL67 lipid in the liposome formulation. The lipoplexes were used immediately after 
preparation. The average hydrodynamic size and zeta potential of the complexes were 
determined on basis of dynamic light scattering and laser Doppler electrophoresis 
using a Zetasizer Nano ZS (Malvern, Worcestershire, UK). Prior to the measurement 
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the complexes were dissolved in Hepes buffer 20 mM, pH7.4 and prewarmed up to 
37°C to mimic the conditions during in vivo delivery. A gel retardation assay was 
performed to determine to what extent mRNA was bound to cationic liposomes. 
 
In vitro transfection and protein expression measurements 
 
The human alveolar type-II-like cell line A549 (ATCC #CCL-185) was cultured in 75 
cm2 flasks in DMEM supplemented with 10 % fetal bovine serum (FBS), 50 μg 
penicillin/ml, 50 μg streptomycin/ml and 2 mM L-glutamine at 37°C in a humidified 
atmosphere containing 5 % CO2. One day before transfection the cells were plated 
onto 24 well plates (24WPs). At the moment of transfection their confluency was 
around 80 %. Lipoplexes were prepared right before transfection. If not mentioned 
differently, the transfections were made in the reduced-serum medium OptiMem 
(Invitrogen, Merelbeke, Belgium). After 4 h of incubation, the complexes were removed 
and regular culture medium was added to the cells. Transfection efficiency of 
lipoplexes containing mRNA or pDNA encoding GFP was determined by flow 
cytometry (FACSCalibur, Becton Dickinson, Erembodegem, Belgium). To that end, 
A549 cells were washed with PBS and subsequently resuspended in a flow buffer (BD 
FACSFlow). Percentages of GFP positive cells and their mean fluorescence intensity 
were used for analysis. 10000 cells per sample were analyzed. Data analysis was 
performed with CellQuest software (Becton Dickinson). The expression of luciferase 
was examined by the Luciferase Assay (Promega, WI, USA) 8 hours after adding the 
complexes on the cells for mRNA/GL67 complexes and 24 hours for pDNA/GL67 
complexes. The luciferase activity was expressed as relative light units (RLU). Cell 
viability was measured 8 or 24 hours post-transfection using an MTT Cell Proliferation 
Kit (Roche, Vilvoorde, Belgium). 
 
Mice and pulmonary delivery of the complexes 
 
BALB/c mice were obtained from Janvier (Le Genest St Isle, France). The mice were 
housed in individually ventilated cages with a 12:12 h dark-light cycle. Access to food 
and water was maintained ad libitum. All experiments were carried out with the 
approval of the local Ethics Committees of the Vrije Universiteit Brussel and Ghent 
University. 
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Mice were anesthetized with 4 % isoflurane and 80 µg of mRNA/GL67 (ratio 2) or 
pDNA/GL67 (ratio 1.33) divided in 2 doses of 40 µg, with a delay of 2 hours, were 
instilled intranasally. Animals that received mRNA/GL67 and pDNA/GL67 complexes 
were imaged 6 hours and 24 hours after instillation, respectively. The mice were 
shaved before imaging. 
 
In Vivo Bioluminescence Imaging (BLI) 
 
Prior to imaging, mice were anesthetized with isoflurane (3 % induction and 2.5 % 
maintenance) with oxygen as carrier gas. Mice were imaged after intraperitoneal 
administration of D-luciferin at a dose of 150 mg/kg body weight. Subsequently, 30 µl 
of D-luciferin (15 mg/ml) was also instilled intranasally ten minutes before imaging. The 
emitted photons were measured for 2 minutes using the IVIS Lumina II (Caliper Life 
Sciences) at binning 4 and f-stop 1. The data analysis was performed with the Living 
Image software (Caliper Life Sciences). 
 
Statistical Analysis 
 
All obtained data had a normal distribution what was checked by the Kolmogorov–
Smirnov test. An independent-samples t-test was performed in order to compare two 
groups. ANOVA followed by the Bonferroni test were conducted for multiple group 
analysis. The differences were considered significant when p<0.05. The results are 
presented as the mean ± standard deviation (SD). 
 
 
RESULTS 
 
Physicochemical characterization of mRNA/GL67 complexes prepared at different ratios 
 
To gain insight into the capacity of the GL67-lipid formulation to form self-assembled 
nanoparticles with mRNA we prepared mRNA/GL67 complexes at different 
mRNA/GL67 molar ratios and determined their physicochemical properties. The extent 
of mRNA complexation by the GL67-lipid formulation is shown in Figure 3.1. The GL67-
lipid formulation was able to complex all the mRNA up to an mRNA/GL67 ratio of 4. 
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When the amount of mRNA was 5 times higher than the amount of GL67-lipids, a 
fraction of unbound mRNA was clearly visible. The free mRNA band was located 
between 1.5 and 2.0 kb, which is in agreement with the calculated length of the Luc-
mRNA, i.e. ≈1.7 kb. 
 
 
Figure 3.1. Gel retardation assay of mRNA/GL67 complexes prepared at different 
ratios. mRNA/GL67 complexes, containing 1 µg mRNA, were prepared at different 
mRNA/GL67 ratios and then loaded on a formaldehyde-agarose gel. A RNA ladder was 
run in a lane M. Next to the RNA ladder, 1 μg of mRNA was run as a reference. 
 
 
We next determined the size and zeta potential of the mRNA/GL67 complexes. Figure 
3.2 shows that upon hydration of the lyophilized GL67-lipid formulation liposomes are 
formed. Their mean diameter and zeta potential were 280 nm ± 10 nm and 17.0 mV ± 
0.4 mV, respectively. When mRNA and GL67 vesicles were mixed at an mRNA/GL67 
molar ratio 0.5, the zeta potential of the complexes decreased sharply to almost zero. 
The complexes became slightly negative at ratios ≥ 2. The complex sizes varied 
between 350 and 750 nm, reaching a maximum at an mRNA/GL67 ratio of 2. 
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Figure 3.2. Size (closed squares) and zeta potential (ζ; open squares) of mRNA/GL67 
complexes. The size and ζ of mRNA/GL67 complexes prepared at different molar ratios 
was measured after dilution of mRNA/GL67 complexes containing 1 µg of mRNA in 
1ml of Hepes buffer (pH 7.4). The size and ζ of the GL67-liposomes diluted in the same 
buffer is shown at the left. The results are represented as the mean of 3 measurements 
± SD. 
 
 
Transfection efficiency and cytotoxicity of the mRNA/GL67 complexes at different ratios 
in alveolar cells 
 
To determine the optimal ratio for transfection, type II lung epithelial cells (A549) were 
transfected with mRNA encoding eGFP complexed with the GL67-lipid formulation at 
different ratios. The transfection efficacy was studied on a single-cell basis using flow 
cytometry. 
The percentages of GFP-positive cells as well as the mean fluorescence intensity 
(MFI) of the transfected cells were quite comparable for all the tested ratios (Figure 
3.3). Nevertheless, a higher number of positive cells were found when the mRNA/GL67 
complexes were prepared at a ratio 2 (31 %). The experiment was also performed 
using luciferase-encoding mRNA and the ratio 2 was confirmed to give the highest 
reporter gene expression (data not shown). 
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Figure 3.3. Determination of the most optimal mRNA/GL67 ratio. A549 cells plated in 
24-well plates were transfected with 500 ng of mRNA/GL67 complexes prepared at 
different ratios. The percentage of GFP-positive cells (bars) and the mean fluorescence 
intensity (line) were measured 4 hours after addition of the complexes on the cells by 
flow cytometry. The results are presented as the mean ± SD (n≥4; * indicates p<0.05 
and n.s. indicates non-significant; ANOVA). 
 
 
In order to assess the cytotoxicity of mRNA/GL67 complexes, the MTT test was 
performed 8 hours after adding the complexes on the cells. None of the tested 
formulations caused a significant drop in the cell viability in reference to the untreated 
control (Figure 3.4). Based on these results, we prepared the mRNA/GL67 complexes 
at their optimal ratio, i.e. 2 in all subsequent experiments. Additional transfection 
experiments at higher mRNA doses resulted in a significant drop of the cell viability in 
comparison to a dose of 500 ng/well and hence confirmed that this amount provides a 
balance between toxicity and transfection efficacy (see supplementary Figure SB.1). 
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Figure 3.4. Cell viability following transfection of A549 cells plated in 24-well plates 
were transfected with 500 ng of mRNA/GL67 complexes prepared at different ratios. 
Cell viability was assessed 8 hours after adding the complexes to the cells with an 
MTT assay. Viability of untreated cells was set as 100 %. The data are presented as the 
mean ± SD (n=3) and considered significant, if p<0.05 compared to the untreated 
control (n.s. indicates non-significant; ANOVA). 
 
 
Comparison of expression kinetics of mRNA/GL67 and pDNA/GL67 complexes 
 
Subsequently, we studied the expression kinetics after transfection of A549 cells with 
mRNA/GL67 and pDNA/GL67 complexes prepared at their optimal ratios, i.e. 2 and 
1.33, respectively. It has been shown earlier that the 1.33 ratio ensures the highest 
transfection efficiency of pDNA/GL67 complexes 170. A549 cells were incubated with 
the complexes for 4 hours. Transfection efficiency was evaluated 4, 8, 24, 48 and 72 
hours after adding the complexes to the cells by flow cytometry. As shown in Figure 
3.5A, transfection with mRNA resulted in a very rapid production of GFP. The highest 
percentage of GFP-positive cells was achieved 8 hours after addition of the 
mRNA/GL67 complexes to the cells. At this time point 37 % of the cells were GFP-
positive. At later time points the number of GFP-positive cells progressively dropped 
to about 20 %. The MFI of the GFP-positive cells followed more or less the same 
profile: the MFI was maximal 24 hours after adding the complexes and showed a 
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strong drop at later time points. In case of pDNA transfection, the maximal levels of 
transfection were reached much later than with mRNA (Figure 3.5B). The number of 
GFP-positive cells was maximal 24-48 hours after adding of pDNA/GL67 complexes, 
which agrees with previous reports 104. At the 72 hour time-point, the number of GFP-
positive cells slightly decreased. The MFI of the cells transfected with pDNA peaked 
24 hours after addition of the complexes to the cells and gradually dropped at later 
time points. 
 
 
 
Figure 3.5. Expression kinetics after transfection of A549 cells with mRNA/GL67 
complexes (A) and pDNA/GL67 complexes (B). The A549 cells were transfected with 
mRNA/GL67 complexes or pDNA/GL67 complexes containing 500 ng mRNA or pDNA. 
The GFP expression kinetics were followed over 72 hours via flow cytometry by 
measuring the percentage of GFP positive cells (bars) as well as their mean 
fluorescence intensity (line). The results are presented as the mean ± SD (n≥5). 
 
 
Impact of cell division on transfection efficiency of mRNA/GL67 and pDNA/GL67 
complexes 
 
The ability of transfecting both dividing and non-dividing cells would be one of the 
strongest advantages of mRNA over pDNA. In order to confirm that mRNA unlike 
pDNA could efficiently transfect both dividing and non-dividing cells, we compared the 
transfection efficiency of mRNA and pDNA (encoding GFP) in dividing and non-
dividing A549 cells. To arrest the cell cycle, A549 cells were treated with roscovitine, 
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which is a cell permeable reversible selective inhibitor of cyclin-dependent kinase 1, 2 
and 5 171. Transfection efficacy was determined 8 and 24 hours after addition of the 
complexes by flow cytometry. As shown in Figure 3.6A, at the 24 hour time-point the 
percentages of GFP-positive cells after mRNA transfection were comparable both in 
dividing (~31 %) and non-dividing cells (30 %). In contrast, after pDNA transfection 
only 3 % of the non-dividing cells were GFP-positive. In dividing cells, pDNA 
transfection resulted in 20 % of GFP-positive cells. Interestingly, after mRNA 
transfection the MFI in proliferating cells is always lower than in cell cycle-arrested cells 
(Figure 3.6B). This is probably due to a dilution of both the mRNA and the expressed 
GFP in the daughter cells after cell division. The expression data after 8 hours in Figure 
3.5 further confirm the observation that mRNA transfection results in a much faster 
production of the reporter protein than pDNA transfection. 
 
 
 
Figure 3.6. Impact of cell division on the transfection efficiency of mRNA/GL67 and 
pDNA/GL67 complexes in A549 cells. The A549 cells were transfected with 
mRNA/GL67 complexes or pDNA/GL67 complexes containing 500 ng mRNA or pDNA. 
The cell-cycle was arrested by addition of 15 mM roscovitine. The percentage of GFP-
positive cells (A) and the mean fluorescence intensity of the cells (B) were determined 
by flow cytometry 8 and 24 hours after adding the complexes. The results are 
presented as the mean ± SD (n≥5;* if p<0.05, independent-samples t-test). 
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The mRNA concentration during preparation of the complexes affects the transfection 
efficiency 
 
The concentration of the mRNA/GL67 complexes prepared for the in vitro tests was 
too low for in vivo application. Therefore, we prepared mRNA/GL67 complexes at 
higher concentration and evaluated their gene expression in A549 cells before setting 
the experiment in vivo. The complexes were prepared at five concentrations at their 
optimal ratio: 0.08, 0.2, 0.4, 0.6 and 0.8 μg/μl of complexed mRNA in a final volume of 
25 μl (Figure 3.7). Surprisingly, the expression level of the mRNA/GL67 complexes 
increased when they were prepared at higher concentration. The highest expression 
was achieved when the complexes were prepared at an mRNA concentration of 0.8 
µg/µl. The possibility to formulate the mRNA/GL67 complexes at such high mRNA 
concentrations is an important advantage for their use in vivo. 
 
 
 
Figure 3.7. Impact of the mRNA concentration during preparation of mRNA/GL67 
complexes on the transfection efficiency. The luciferase expression of mRNA/GL67 
complexes prepared at five different concentrations was evaluated on A549 cells. The 
cells were treated with the same amount of complexes (500 ng mRNA/well). The best 
expression was obtained with the complexes prepared at the highest concentration. 
The results are presented as the mean ± SD (n≥4; * if p<0.05; ANOVA). 
 
 
In an effort to elucidate the reason for the differences in transfection efficacy observed 
in Figure 3.7, we measured the size and zeta potential of the complexes formulated at 
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the lowest and the highest concentration of mRNA. It appeared that the complexes 
prepared at an mRNA concentration of 0.8 µg/µl have a zeta potential of -5.8 mV and 
a size of 346 nm, while the zeta potential and size of the complexes prepared at a 10 
times lower mRNA concentration are -2.2 mV and 773 nm, respectively (Table 3.1). 
Complexes prepared at a higher mRNA concentration have thus a much smaller size 
than the complexes prepared at a lower mRNA concentration. It has been shown by 
Ross et al. 172 and Rejman et al. 173 that smaller complexes are taken up faster and 
are more efficient than larger complexes. Consequently, the higher transfection 
efficiency of mRNA/GL67 complexes prepared at higher concentrations may be due to 
their smaller particles size. 
 
 
 
Table 3.1. Size and zeta potential of mRNA/GL67 complexes prepared at a low and a 
high concentration. The mRNA/GL67 complexes were prepared at two mRNA 
concentrations, i.e. 0.08 and 0.8 µg/µl and their size and zeta potential were measured 
after dilution in Hepes buffer. Additionally, the complexes were also incubated with 10 
% serum for 30 minutes at 37°C. Subsequently, these particles were diluted in 1 ml of 
Hepes buffer (pH 7.4) and their size and zeta potential was measured. The 
measurements are represented as the mean of 3 measurements ± SD. 
 
 
In vivo transfection efficiency 
 
We subsequently compared the performance of the mRNA/GL67 and pDNA/GL67 
complexes in vivo using mRNA and pDNA encoding firefly luciferase. The used pDNA 
contained a reduced number of CpG-islands. The mRNA/GL67 and pDNA/GL67 
complexes were administered to the lungs of the mice via intranasal instillation and the 
luciferase production was determined in the mice by in vivo bioluminescence imaging 
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(BLI) after 6 hours and 24 hours for mice instilled with the mRNA/GL67 and 
pDNA/GL67 complexes, respectively. Additionally, the signal in mice that received 
pDNA/GL67 complexes was also determined after 48 hours post-administration. A 
clear bioluminescence signal was observed at all time points in the lungs of the four 
mice that received pDNA/GL67 complexes (Figure 3.8A and 8C). A positive signal was 
also detected in the noses of 3 mice. Additionally, pDNA/GL67 complexes prepared at 
a ratio 4 were also administered to mice as it has been reported that their optimal ratio 
for intranasal application is 4, while 1.33 is more suitable for aerosol delivery 174. The 
luciferase expression after intranasal delivery of the pDNA/GL67 complexes with a 
ratio 4 was 2.3-fold higher than with a ratio 1.33 (see supplementary Figure SB.2 and 
SB.3). Surprisingly, none of the mice that received the mRNA/GL67 complexes did 
show a clear signal in their lungs or noses (Figure 3.8B). 
 
 
 
Figure 3.8. Visualization of the in vivo luciferase production after intrapulmonary 
delivery of (A) pDNA/GL67 complexes (n=4) or (B) mRNA/GL67 complexes (n=4), and 
(C) the average bioluminescence of four mice that received either pDNA/GL67 or 
mRNA/GL67 complexes. The complexes, which contained 80 µg of mRNA or pDNA, 
were administered to the lungs of anesthetized mice via intranasal instillation. Animals 
that received pDNA/GL67 and mRNA/GL67 complexes were imaged 24 hours and 6 
hours after instillation, respectively. The amount and localization of the 
bioluminescent light was recorded via in vivo bioluminescence imaging. The data in 
graph C are obtained after subtracting the average bioluminescence signal of 
untreated mice (background) from the signals measured in panels A and B. The results 
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are presented as the mean ± SD (n=4;* if p<0.05, independent-samples t-test). 
 
 
Effect of serum on the physical properties and transfection efficacy of mRNA/GL67 and 
pDNA/GL67 complexes 
 
Messenger RNA is very vulnerable to degradation by ribonucleases, which are present 
in all organisms. Therefore, enzymatic degradation of the mRNA and/or a release of 
the bound mRNA from the mRNA/GL67 complexes after contacting biological fluids 
may be a possible explanation for the failure of the mRNA/GL67 complexes to 
generate detectable amounts of luciferase after intranasal instillation. To check this 
hypothesis we incubated the mRNA/GL67 complexes with 10 % serum and 
subsequently measured their zeta potential and size (Table 2.1). mRNA complexes 
incubated with serum had a much lower zeta potential and size. These data urged us 
to further evaluate the impact of serum (0 %, 10 % and 50 %) on the transfection 
efficiency of mRNA/GL67 as well as pDNA/GL67 complexes. The data in Figure 3.9 
show that mRNA/GL67 complexes are much more affected by serum than their 
pDNA/GL67 counterparts. The transfection of the pDNA/GL67 complexes dropped 
with only 30 % in the presence of 10 % serum, while the mRNA/GL67 complexes lost 
more than 90 % of their transfection capacity in 10 % serum (Figure 3.9A). At 50 % 
serum the changes in luciferase production were similar for both types of complexes. 
In order to elucidate why mRNA/GL67 complexes perform so poorly after contact with 
serum we performed a gel retardation assay using mRNA/GL67 complexes that had 
been exposed to 10 % serum for 30 minutes at 37°C. As a reference we also run 
mRNA/GL67 complexes that had been incubated with Hepes buffer only. In Figure 
3.9B a clear detachment and degradation of the mRNA can be observed when the 
mRNA/GL67 complexes were incubated with serum. 
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Figure 3.9. Impact of serum on the mRNA/GL67 and pDNA/GL67 complexes. To study 
the influence of serum on the transfection efficiency A549 cells were transfected with 
500 ng of mRNA/GL67 and pDNA/GL67 complexes (prepared at their optimal ratios) in 
the presence of 0 %, 10 % or 50 % serum (A). The luciferase production was measured 
8 hours and 24 hours after transfection with mRNA/GL67 and pDNA/GL67 complexes, 
respectively. The transfection efficacy in the absence of serum was set as 100 %. The 
results are presented as the mean of 3 measurements ± SD and considered significant, 
if p<0.05 compared to transfection in 0 % serum (ANOVA). In panel B a gel retardation 
assay of mRNA/GL67 complexes in the absence (-S) and presence (+S) of 10 % serum 
is shown (1 µg mRNA was loaded). An RNA ladder was run in lane M. Next to the RNA 
ladder, 1 μg of free mRNA was run as a reference. 
 
 
DISCUSSION 
 
In this work we prepared mRNA/GL67 complexes and compared their in vitro and in 
vivo transfection characteristics with pDNA/GL67 complexes. The GL67-lipid 
formulation was selected as the delivery agent because of its proven efficacy with 
pDNA in lung cells and its safety profile in clinical trials. The formulation contains three 
lipids, the GL67-lipid, DOPE and DMPE-PEG5000 in a molar ratio of 1:2:0.05. This lipid 
mixture is stored as a lyophilized powder. Upon hydration of this powder we obtained 
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positively charged PEGylated vesicles that can complex all the mRNA up to an 
mRNA/GL67 ratio of 4. The sharp drop of the surface charge of the GL67 vesicles after 
binding of the mRNA indicates that at least a part of the mRNA is bound to the surface 
of the vesicles. It has previously been shown that pDNA is also mainly bound to the 
surface of the GL67 vesicles 169. In vitro transfection of A549 cells with mRNA/GL67 
complexes prepared at different ratios revealed that the highest transfection was 
obtained at a ratio of 2. We have to remark that the optimal ratio for transfection seems 
to be cell type dependent as we observed that in HEK293 (human embryonic kidney) 
cells the highest transfection was obtained when the mRNA/GL67 complexes were 
prepared at a ratio of 4 (data not shown). 
The comparison of the expression efficacy and kinetics of mRNA/GL67 with 
pDNA/GL67 complexes in A549 demonstrates a very fast and relatively short 
production of GFP after mRNA transfection. This is in agreement with the work of Zou 
et al. 104, who also found that the highest number of GFP-positive cells occurred about 
8 hours following the addition of the mRNA/liposomes complexes to Chinese Hamster 
Ovary (CHO) cells. The highest mean fluorescence was observed after 24 hours. 
However, when we used mRNA encoding luciferase, instead of GFP, the maximal 
expression occurred after 8 hours and dropped rapidly after this time point (data not 
shown). Also Zou et al. 104 and Bettinger et al. 50 observed this shift in expression 
kinetics when using mRNA encoding luciferase. This shift can be explained by the fact, 
that the half-life of firefly luciferase is 3 to 6 hours 175, while the reported half-life of GFP 
is greater than 24 hours 176. The low percentage of GFP-positive cells after <8 hours 
following pDNA-transfection indicates the importance of the cell division for pDNA-
transfection. Indeed, the percentage of cells that divided after <8 hours is limited as 
the doubling time of A549 cells is about 22.3 hours 177. To study in more detail the 
importance of cell division we compared the transfection efficiency of mRNA/GL67 and 
pDNA/GL67 complexes in dividing and non-dividing cells. The data in Figure 3.5 clearly 
demonstrate that for pDNA-transfection the breakdown of the nuclear membrane 
during cell proliferation is really required. In contrast, the number of GFP-positive cells 
after mRNA-based transfection is independent of the cell cycle. However, 24 hours 
after mRNA-transfection we observed that the average amount of GFP per cell is lower 
in dividing cells than in non-dividing cells. This is most likely due to a dilution of both 
the mRNA and the expressed GFP reporter in the daughter cells after cell division. 
This dilution effect does not seem to play an important role after pDNA transfection as 
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the MFI after 24 hours is the highest in dividing cells. After pDNA transfection, the GFP-
positive cells probably contain many pDNA copies in their nucleus, which are divided 
over the daughter cells during cell division. These pDNAs in the daughter cells can 
continuously generate many new mRNA copies that are translated into GFPs. This 
phenomenon counterbalances the dilution of the produced GFP-mRNA and GFP 
during the first cell cycles. The faster drop in gene expression after mRNA transfection 
in comparison to pDNA transfection can be explained by the short half-life of mRNA 
and the fact, that many mRNA templates can be produced from a single pDNA 
molecule after reaching the nucleus. 
For the in vitro test we prepared the mRNA/GL67 complexes at a concentration of 0.12 
µg mRNA/µl. However, for intrapulmonary administration in mice a much higher 
concentration of mRNA/GL67 complexes is required. Indeed, to reach a dose of 50 µg 
of complexed mRNA per mouse we would have to administer about 400 µl of these 
complexes. This is far too much as it is our experience that the maximal volume that 
can be administered to the lungs of mice is about 80 µl/25 g body weight. Hence, more 
concentrated mRNA/GL67 complexes were needed. In general, the transfection 
efficacy of non-viral gene complexes decreases when they are prepared at high 
concentration due to a concentration dependent aggregation of the complexes 178. 
Surprisingly, the transfection efficacy of mRNA/GL67 complexes increased when they 
were prepared at a higher concentration. The mRNA/GL67 complexes prepared at the 
highest mRNA concentration (0.8 µg/µl) were 2.5-fold more efficient, compared to the 
complexes prepared at the lowest concentration. A similar profile of expression 
efficiency was observed by Ogris et al. 179 when using rising pDNA concentration 
during preparation of pDNA/Tf-PEI complexes. The observation that mRNA/GL67 
complexes do not lose their efficacy when prepared at a high concentration can be 
explained by the fact that the GL67-lipid formulation contains low amounts of DMPE-
PEG5000 lipids, which, as demonstrated for pDNA/GL67 complexes 174, prevent a 
massive aggregation of the mRNA/GL67 complexes when prepared at a high 
concentration. Moreover, we showed that the higher efficiency of the mRNA/GL67 
complexes prepared at the higher mRNA concentration is most likely due to their 
smaller size (Table 3.1). Indeed, it has been reported that smaller gene complexes 
have a higher cellular uptake and hence also a higher gene expression 172,173. 
Our in vitro transfection data (Figure 3.6) clearly demonstrate that in non-dividing cells 
mRNA/GL67 complexes are much more effective than pDNA/GL67 complexes. 
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Consequently, one would expect that also after pulmonary administration the 
mRNA/GL67 complexes would be superior to the pDNA/GL67 complexes. However, 
our in vivo data did not confirm this hypothesis. All the mice that received pDNA/GL67 
complexes showed a clear bioluminescent signal, while no bioluminescence could be 
detected in the mice receiving mRNA/GL67 complexes. This observation is in 
agreement with the data reported in a poster abstract of Painter et al. 180. In this study 
the gene expression in the lungs after intranasal instillation of mRNA/GL67 complexes 
was slightly higher than the background signal, but much lower than the expression 
obtained after instillation of pDNA/GL67 complexes. The low efficiency of mRNA/GL67 
complexes in the lungs may be due to the fact that negatively charged 
bio(macro)molecules in respiratory fluids caused a detachment and enzymatic 
degradation of the mRNA in the mRNA/GL67 complexes. This hypothesis is supported 
by our data in Figure 3.9. Kormann et al. recently demonstrated in the lungs of mice a 
therapeutic effect after administration of 20 µg of naked mRNA. Importantly, their 
mRNA contained chemically modified nucleotides, which may increase the stability 
and avoid the recognition of mRNA by the innate immunity 6. Nevertheless, it is 
generally believed that naked pDNA and mRNA have difficulties in crossing cell 
membranes. It is well-known in the field that the use of distilled water gives rise to 
much better transfection data after pulmonary gene delivery 181,182. Pulmonary 
administration of distilled water or hypotonic liquids will create a hypotonic environment 
in the lungs. Cells placed in a hypotonic solution tend to swell and this may induce 
pores in the cell membrane through which naked pDNA or mRNA can enter the cell. 
This hypothesis can explain how naked mRNA can enter cells after pulmonary delivery. 
Alternatively, a receptor for DNA and RNA may be present on the surface of lung cells 
183,184. Unfortunately, in our hands administration of 50 µg of naked and unmodified 
mRNA into the lungs of mice did not result in a detectable luciferase expression (data 
not shown). Also Su et al. reported a positive bioluminescent signal in the nose of the 
mice after instillation of firefly luciferase-encoding mRNA-loaded particles 185. In our 
work luciferase expression in the nose was only observed in 3 out of 4 mice that 
received the pDNA/GL67 complexes. In vivo optical imaging was used in our study to 
reduce the number of animals and to comply with the 3 R’s principle in animal research. 
However, the in vivo BLI method is less sensitive than an ex vivo luciferase assay. 
Therefore, it is possible that the expression of the mRNA/GL67 complexes or the 
naked mRNA in the lungs inside the animal is too weak to be detected. In future 
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experiments, the use of more stable mRNA would be interesting. The stability of the 
mRNA can be increased by incorporating the UTR sequences from β-globine 186 and 
by adding a longer poly(A)-tail 187. Additionally, in this study we used the regular cap 
analog during IVT. It is known, that this cap is bound incorrectly to 50 % of the capped 
mRNAs. Messenger mRNAs that are not correctly capped are inactive. The incorrect 
incorporation of the cap can be prevented by the use of anti-reverse cap analog 
(ARCA) 188 or by enzymatic capping 189. Finally, the use of modified nucleosides in the 
mRNA can further increase the stability and prevent that mRNA is recognized by the 
innate immune system 6,190. In this study we used the same mass of mRNA and pDNA 
encoding firefly luciferase. As a result, the copy number of mRNAs was 5.8-fold higher 
than the copy number of pDNA. However, only 50 % of the mRNA transcripts are 
functional as half of the mRNAs are capped wrongly during IVT. On the other hand, 
one has to consider that each pDNA that reaches the nucleus can produce many 
mRNA copies. 
 
 
CONCLUSIONS 
 
In conclusion, the claimed advantages of mRNA delivery urged us to study the 
potential of mRNA delivery to respiratory cells. Up till now, carrier-mediated mRNA 
delivery to respiratory cells has not been studied in detail. In this work we demonstrated 
that mRNA delivery, using the GL67-lipid formulation, results in a fast and temporal 
expression of marker genes in alveolar cells. Additionally, in non-dividing cells the 
transfection efficacy of mRNA/GL67 complexes was much higher than that of 
pDNA/GL67 complexes. This confirms that mRNA delivery is independent of the cell 
cycle. Surprisingly, after pulmonary administration in mice we found a clear 
bioluminescent signal after administration of the pDNA/GL67 complexes but not after 
administration of the mRNA/GL67 complexes. We showed that mRNA/GL67 
complexes undergo dissociation and degradation of the mRNA after contacting the 
bio(macro)molecules present in serum. Such destruction of the mRNA/GL67 
complexes is also expected when they come in contact with the biofluids of the lungs 
and this may be one explanation for their low in vivo transfection efficiency. 
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SUPPORTING INFORMATION AVAILABLE (APPENDIX B) 
 
SB.1. Figure depicting impact of the dose of the mRNA/GL67 complexes on the cell 
viability. 
SB.2. Supporting figure showing comparison of the average bioluminescence after 
intranasal administration of pDNA/GL67 complexes prepared at a ratio 1.33 or 4. 
SB.3. Visualization of the in vivo luciferase production after intrapulmonary delivery of 
pDNA/GL67 complexes prepared at ratio 4. 
This information is available also free of charge via the Internet at http://pubs.acs.org/. 
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INTRODUCTION 
 
Genetic vaccination, using pDNA or mRNA, is a very attractive strategy that offers 
many advantages over vaccines based on proteins, polysaccharides, or inactivated 
pathogens 191. Indeed, gene-based vaccines have a lower production cost, a higher 
pharmaceutical stability, a better safety profile and they can encode for multiple 
antigens 192,193. Furthermore, the antigens expressed by genetic vaccines can be 
presented in a MHCI as well as a MHCII context leading to both cellular and humoral 
immune responses 193-195. The use of non-viral carriers for the delivery of genetic 
vaccines is gaining more and more attention as they may improve the efficacy of 
unformulated gene-based vaccines 196. Additionally, also mRNA vaccines recently 
attracted much attention. The main advantage of using mRNA is that it is translated in 
the cytosol, and hence does not have to cross the nuclear membrane, which is the 
biggest obstacle in non-viral DNA delivery 161,162. Moreover, in contrast to pDNA, the 
use of mRNA excludes an important FDA safety concern, namely the risk of insertion 
mutagenesis 197. Additionally, transfection of unmodified mRNA results in a rapid and 
short-lived expression of the encoded protein (antigen), which is long enough to give 
an immunological response but not too long to cause tolerance towards the antigen 
50,198,199. It has been shown that carrier-mediated delivery of mRNA in immune cells 
may, besides producing the antigen for the adaptive immune reaction, induce an innate 
immune response 122,200-202. This response leads to the induction of cytokines that may 
stimulate the adaptive immune response after carrier-mediated delivery of genetic 
vaccines 203. The stimulation of the innate immune system is due to recognition of in 
vitro transcribed (IVT) mRNA by pattern recognition receptors (PRRs) 204-206. An 
important family of PRRs are the TLRs, which detect pathogen-associated molecular 
patterns (PAMPs) of various origin, such as e.g. viral dsRNA or unmethylated CpG 
motifs in bacterial pDNA 207. The first reports on recognition of mRNA by PRRs found 
that IVT mRNA can interact with TLR3 202 and TLR7 122,166. 
After administration of gene-based vaccines most of them might end-up in non-
immune cells, and it is known that cross-presentation of the antigen by these cells 
plays an important role in the establishment of the adaptive immune response 196,208. 
However, the cytokine signature that is associated with recognition of mRNA by PRRs 
of non-immune cells has not been studied in detail. Additionally, it is also not 
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completely clear whether the recognition of IVT mRNA by PRRs has negative effects 
on the viability of the transfected cells and on the translatability of the delivered mRNA. 
Therefore, the aim of this work was to study the effect of carrier-mediated delivery of 
mRNA on the innate immune response, the viability and translatability of the delivered 
mRNA. In this study we used lung epithelial cells because of our interest in mucosal 
immunization against respiratory pathogens and lung cancer 209. Pulmonary 
vaccination can increase the efficacy of a vaccine as this delivery strategy may induce 
local immune responses that can neutralize pathogens at the entry port 210,211. Human 
as well as murine lung cells were used to compare their transfection efficiency, protein 
expression, cytotoxicity and eventually the innate immune responses. For the delivery 
of the mRNA we used the GL67-lipid formulation, which is considered as the golden 
standard in non-viral respiratory gene transfer 153,212-214. The therapeutic potential, the 
low toxicity and safety of this formulation has been extensively demonstrated in many 
pre-clinical and clinical trials 215,216. 
 
 
 
MATERIALS AND METHODS 
 
Cell culture  
 
Human lung adenocarcinoma cells (A549 cells, ATCC n° CCL-185) and murine lung 
adenoma cells (LA-4, ATCC n° CCL-196) were plated onto 24-well plates one day 
before transfection. At the moment of transfection their confluency was around 80%. 
Human embryonic kidney cells (HEK293) and HEK293 stably overexpressing TLR3 
(HEK293-TLR3 cells) were a generous gift from Prof. Rudi Beyaert (Department for 
Molecular Biomedical Research, VIB, Belgium). The HEK293 cells were seeded in the 
same format as the lung cells. All cells were cultured at 37°C in a humidified 
atmosphere containing 5 % CO2. DMEM supplemented with 10% fetal bovine serum 
(FBS), 50 μg penicillin/ml, 50 μg streptomycin/ml and 2 mM L-glutamine (Invitrogen, 
Merelbeke, Belgium) was used as culture medium. Above that, neomycin (Sigma 
Aldrich, Bornem, Belgium) was added to the culture medium of HEK293-TLR3 cells. 
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Plasmids 
 
The pBlue-LucA50 containing a poly(A)-tail of 50 adenosines and the cDNA of firefly 
luciferase was used for the in vitro transcription (IVT) of mRNA. This pDNA was a kind 
gift of Dr. Peter Ponsaert (University of Antwerp, Antwerp, Belgium) and was previously 
described by Sheets et al. 167. The pGEM4Z[eGFP]A64 containing a poly(A) of 64 
adenosines and the cDNA of eGFP was used for IVT of mRNA encoding eGFP. The 
latter was provided by Prof. dr. Smita Nair (Duke University Medical Center, NC, USA). 
pGL2 plasmid encoding firefly luciferase was purchased from Promega (WI, USA). The 
plasmids were purified with QIAGEN Plasmid Giga Kit (Qiagen, Venlo, The 
Netherlands). 
 
In vitro transcripton of mRNA 
 
The modified mRNA containing pseudouridine and 5-methylcytidine nucleotides was 
purchased from Stemgent (Miltenyi Biotec, Leiden, The Netherlands). This modified 
mRNA codes for eGFP. Prior to in vitro transcription the pBlue-LucA50 and the 
pGEM4Z[eGFP]A64 were linearized downstream of the insert with respectively DraI 
and SpeI restriction enzyme (Promega, WI, USA) and examined on a 1 % agarose gel. 
mRNA was transcribed with a mMESSAGE mMACHINE kit according to the 
manufacturer’s instructions (Ambion, Austin, TX, USA). The mRNA was dissolved in 
RNase-free water (Ambion, Austin, TX, USA) and the purity and size was checked by 
formaldehyde gel electrophoresis. The formaldehyde gel was prepared as follows. One 
gram of Ultra Pure Agarose (Invitrogen, Merelbeke, Belgium) was dissolved in 100 ml 
of MOPS/formaldehyde-buffer (20 mM MOPS, 2.1 M formaldehyde, pH 7 prepared in 
RNase-free DEPC-treated water) (Sigma Aldrich, Bornem, Belgium). As a reference, 
a RiboRulerTM High Range RNA Ladder was used (Fermentas, St. Leon-Rot, 
Germany). The mRNA concentration was determined by measuring the absorbance 
at 260 nm by NanoDrop (Thermo Scientific, DE, USA) and its purity was assessed by 
measuring the 260/280 nm absorbance ratio. 
 
Preparation of complexes and transfection experiments 
 
The GL67:DOPE:DMPE-PEG5000 liposomes were prepared by adding 2,667 ml of 
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RNAse-free water (Ambion, Austin, TX, USA) to the vials containing 4 µmol GL67, 8 
µmol DOPE and 0.2 µmol DMPE-PEG5000. The mRNA/GL67 and pDNA/GL67 
complexes were prepared by mixing the mRNA or pDNA (dissolved in RNAse-free 
water) with the GL67 liposomes at their optimal ratios, namely 2:1 (mRNA:GL67 lipid 
molar ratio) 217 and 1.33:1 (pDNA:GL67 lipid molar ratio) 169. The liposomes and the 
nucleic acids were shortly incubated at 30°C before mixing them. The mRNA/GL67 or 
pDNA/GL67 molar ratios were calculated based on the molar concentration of the 
GL67 lipid in the GL67:DOPE:DMPE-PEG5000 liposome formulation and the 
nucleotide concentration in the mRNA or pDNA solutions. To calculate the nucleotide 
concentration an average nucleotide molecular mass of 340 g/mol (330 g/mol for 
pDNA) was used. After mixing, the complexes were incubated for 15 min at 30°C and 
subsequently they were further diluted in OptiMem (Invitrogen, Merelbeke, Belgium) 
and added to cells seeded in 24 well plates. The complexes were removed 4 hours 
after addition and replaced by fresh culture medium. 
 
Protein expression measurements and viability assay 
 
The luciferase expression was examined 24 hours post-transfection by a luciferase 
assay following the manufacturer’s protocol (Promega, WI, USA). The measurements 
were carried out in a GloMax microplate luminometer (Promega, WI, USA). The 
luciferase activity was expressed as the number of relative light units (RLU) per µg of 
protein. The protein concentration was determined by a BCA assay (Thermo Scientific, 
DE, USA) measured on EnVision Multilabel Reader (Perkin Elmer, Waltham, MA, 
USA). Transfection efficiency of lipoplexes containing mRNA encoding eGFP was 
determined by flow cytometry (FACSCalibur, Becton Dickinson, Erembodegem, 
Belgium). A549 cells were washed with PBS and subsequently resuspended in a flow 
buffer (BD FACSFlow). Percentages of eGFP positive cells and their mean 
fluorescence intensity were used for analysis. 10000 cells per sample were analyzed. 
Data analysis was performed with CellQuest software (Becton Dickinson). 
In order to check the viability of the cells, the MTT proliferation kit (Roche, Vilvoorde, 
Belgium) and the luminescent cell viability assay CellTiter-Glo (Promega, WI, USA) 
were used. 
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Total RNA extraction and determination of its quality and quantity 
 
During the experiment 3 biological replicates were evaluated from A549 and LA-4 cells 
for each treated and untreated cells. The untreated cells were conditioned in the same 
manner as the treated cells, besides the step including adding the mRNA/GL67 
complexes. Total RNA was isolated with RNeasy Mini Kit (Qiagen, Venlo, Netherlands) 
24 hours after adding complexes on cells according to the manufacturer’s protocol. 
The extraction included on-column treatment with DNAse. Before performing qPCR 
total RNA was confirmed to be free from genomic DNA by minus RT-PCR according 
to the following protocol: 8 min 45 s at 95ºC followed by 40 cycles of (15 s at 95ºC, 15 
s at 57ºC, 30 s at 72ºC) and finally 2 min at 72ºC. 1 µl of primermix (5 µM each: ACTB 
+1 AGGGAAATCGTGCGTGACAT, ACTB -1 GAGCAGTAATCTCCTTCTGC ATCC) 
was added to 1 μL FastStart buffer (10x), 0,1 μL FastStart Polymerase (5 Units/μL), 
0,2 μL dXTPs (deoxyribonucleotide triphosphates) (10 mM each) and DNA (gDNA or 
cDNA) or RNA. Water was added up to 10 µl per reaction. Water and genomic DNA 
with primers specific for beta-actin (ACTB) gene were used as the negative and 
positive control, respectively. The concentration was evaluated spectrophotometrically 
by NanoDrop (Thermo Scientific, DE, USA). The samples with the ratio 260 nm/280 
nm between 1,96 and 2,21 as well as 260 nm/230 nm between 1,92 and 2,29 were 
further evaluated for their quality. The integrity of the total RNA was determined both 
by the formaldehyde gel electrophoresis and the Experion automated electrophoresis 
system (BioRad, Nazareth, Belgium). 
 
cDNA first strand generation. 
 
The cDNA first strand was generated with the RT2 First Strand Kit (SABiosciences, 
MD, USA) primed with random hexamers and oligo-dT, according to the 
manufacturer’s protocol. The cDNA was synthetized out of 1 μg of total RNA. Following 
the reaction, the presence of cDNA in the sample was confirmed by the same PCR as 
for the minus RT-PCR. For one qPCR array (96 well plate), 106 µl of template was 
dissolved 20 times in SYBR Green Master Mix (SABiosciences, MD, USA). 20 µl of 
sample working solution was added per well. 
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TLR-related pathway qPCR array 
 
The upregulation or downregulation of genes associated with the human (cat # 
00188255) and mouse (cat # 00188196) toll-like receptor signaling pathways were 
evaluated with Lonza standard 96 StellARray™ qPCR arrays (Lonza, Basel, 
Switzerland). The StellARray system profiles 94 different TLR-associated genes (see 
the supplementary data S1). For both qPCR experiments RT² SYBR® Green qPCR 
Master Mix (SABiosciences, MD, USA) was used. The cycling conditions were: 1 cycle 
at 50°C for 2 min, 1 cycle at 95°C for 10 min and 40 cycles at 95°C for 15 s and 60°C 
for 1 min. Melting curve was set according to a protocol: 70ºC → 95ºC; (10 s/0,5 ºC) x 
50. The melting curve analysis confirmed that a single amplicon was produced. 
According to the company the PCR efficiency of all primers is between 90-100 %. The 
data analysis of the qPCR arrays was performed using the Global Pattern 
Recognition™ (GPR) 2.0 Analysis Tool (Lonza, Switzerland). The Global Pattern 
Recognition chose 18 genes for A549 and 9 genes for LA-4 unchanged in expression 
as normalizers (supplementary data S1). Global Pattern Recognition™ Software 
globally positions the expression level of each gene with respect to all genes within an 
experiment. For the statistical analysis, the genes that were not detectable during 
qPCR got a Cq value of 40. 
 
ELISA assays 
 
Mouse IFN-β, mouse IL-6, mouse IL-12 and mouse TNF-α ELISA kit were purchased 
from BioLegend (Antwerp, Belgium) and used to determine the concentration of 
secreted cytokines in the medium of LA-4 cells treated with mRNA/GL67 complexes, 
naked mRNA or GL67 liposomes only. Human IFN-β ELISA kit was purchased from 
Thermo Scientific (Erembodegem, Belgium). Human IL-6 and human TNF-α were 
obtained from BioLegend (Antwerp, Belgium). The human cytokines were measured 
in the medium of A549 cells treated with mRNA/GL67 complexes, naked mRNA or 
GL67 liposomes only. Briefly, 100 µl of the media and the cytokines’ standards were 
added in triplicates to the wells of the 96 well microtiter plates that were pre-coated 
with an antibody against specific cytokine. After 60 minutes of incubation the wells 
were washed 3 times with the provided wash solution. Subsequently, the wells were 
incubated with a detecting antibody labeled with horseradish peroxidase (HRP). After 
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60 minutes unbound detecting antibodies were washed away as described above and 
the microtiter plates were incubated for 15 minutes with Tetramethyl-benzidine (TMB) 
substrate. The reaction was stopped by addition of stop solution and the absorbance 
was measured at 450 nm with an Envision Multilabel Reader (Zaventem, Belgium). 
 
In vivo experiment 
 
Balb/c mice were obtained from Janvier (Le Genest St Isle, France). Mice were 
anesthetized with 4 % isoflurane and 80 µg of unmodified mRNA/GL67 complexes 
were intranasally instilled to a group of 3 animals. The respective volume of dissolvent 
(RNAse-free water) was administered in the same way to a control group (n=3). The 
mice were imaged 4 and 24 hours later with in vivo bioluminescent imaging system 
(IVIS Lumina II, Caliper Life Sciences). After that, the animals were euthanized by 
cervical dislocation and their lungs were removed and homogenized. The samples 
were evaluated for IFN-β, IL-6, IL-12 and TNF-α cytokines production by ELISA 
assays. 
 
Statistics 
 
All obtained data sets had a normal distribution as assessed by the Kolmogorov–
Smirnov test. An independent-samples t-test was performed in order to compare two 
groups. ANOVA followed by the Bonferroni test were conducted for multiple group 
analysis. The differences were considered significant when p<0.05. The results are 
presented as the mean ± standard deviation (SD). 
 
 
RESULTS 
 
Cytotoxicity kinetics after transfection of A549 cells with mRNA 
 
Cytotoxic effects associated with mRNA delivery are often studied only shortly after 
transfection. Consequently, the cytotoxicity associated with mRNA transfection may 
have been underestimated. Therefore, we monitored the viability of lung epithelial cells  
up to three days after transfection with mRNA/GL67 complexes. Four hours after 
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mRNA transfection the viability dropped with 30 % (Figure 4.1). The drop in viability of 
the mRNA-transfected cells continued the following hours and started to level off at 
day 2 post-tranfection. Three days after transfection only 10 % of the mRNA 
transfected cells were still viable. In contrast, the viability of cells transfected with pDNA 
was much higher. Transfection of the cells with lower amounts of nucleic acids showed 
similar cytotoxicity kinetics, although the toxicity was lower (data not shown). 
 
 
Figure 4.1. Cytotoxicity kinetics after transfection of A549 cells with mRNA/GL67 and 
pDNA/GL67 complexes. A549 cells were transfected with mRNA/GL67 and pDNA/GL67 
complexes containing 500 ng of complexed nucleic acids. Their viability was 
measured 4 h, 24 h, 48 h and 72 h after addition of the complexes using an MTT assay. 
The cell viability was calculated relatively to the viability of untreated cells. The results 
are presented as the mean ± SD. 
 
 
Cytotoxicity of the constituents of the mRNA/GL67 complexes 
 
The huge drop in cell viability after mRNA transfection urged us to unravel which 
constituents of the mRNA/GL67 complexes were most responsible for the cell death. 
Therefore, the effect of mRNA/GL67 complexes, naked mRNA or empty GL67 
liposomes on the viability of human lung epithelial (A549) cells was measured 2 days 
after transfection. This experiment was repeated with murine lung epithelial (LA-4) cells 
to determine the differences between the human and mouse cell line model. 
Interestingly, neither naked mRNA nor the GL67 liposomes alone caused a significant 
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reduction in cell viability (Figure 4.2A and 4.2B). In contrast, mRNA complexed to the 
GL67 liposomes induced a substantial and significant cytotoxicity in both cell lines 
(Figure 4.2A and 4.2B). These results suggest that mRNA becomes toxic for the cells 
when it is taken up by the cell, a process mediated by the GL67 liposomes. Figure 4.2 
also shows that the toxic effects are significantly different between the two cell lines. 
Indeed, 2 days after mRNA transfection the viability of the murine LA-4 cells was 50 % 
higher than the viability of the human A549 cells. Additionally, the transfection 
efficiency of the mRNA/GL67 complexes was checked in both cell lines. Transfection 
of A549 cells with mRNA/GL67 complexes resulted, 24 hours after transfection, into 
more than 46 % of eGFP positive cells, while only 5 % of the transfected LA-4 cells 
were eGFP positive (Figure 4.3). 
 
 
 
Figure 4.2. Cytotoxic effect of the constituents of the mRNA/GL67 complexes. A549 (A) 
and LA-4 cells (B) were transfected with 750 ng of mRNA/GL67 complexes, the same 
amount of naked mRNA or just GL67 liposomes. The viability of the cells was 
measured 48 h post-transfection using CellTiter-Glo (A549) and MTT (LA-4) assay and 
compared to the viability of untreated cells. The bars represent the mean ± SD (*, 
p<0,05; ***, p<0,001 ANOVA). 
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Figure 4.3. Comparison of the transfection efficiency of mRNA/GL67 complexes in 
human (A549) and murine (LA-4) respiratory cells. The A549 and LA-4 cells were 
transfected with 500 ng of complexed mRNA. Transfection efficiency was measured 
by flow cytometry 24 h after adding the complexes on the cells. The results are 
presented as the mean ±SD (n=6; ***, p<0,001, independent samples t-test). 
 
 
Activation of TLR-related pathways and innate immune responses in respiratory cells 
after liposome-mediated delivery of IVT mRNA 
 
The observation that only mRNA/GL67 complexes were toxic for the cells and not their 
constituents may indicate that the intracellular delivery of mRNA triggers cell death. 
Previous experiments in HEK cells and immune cells have shown that transfected IVT 
mRNA is recognized by several TLRs, such as TLR3 202 and TLR7 122,166, which are 
mainly localized in endosomes. It is well known that nucleic acid containing 
nanoparticles are taken up by cells via endocytosis. Consequently, carrier-mediated 
delivery of mRNA may bring the mRNA to these endosomal TLRs and promote TLR 
signaling, which, as shown for poly(I:C), may induce cell death 218. Therefore, we 
measured the upregulation of TLR associated genes after liposome-mediated delivery 
of IVT mRNA. We first set out to determine the expression level of all known TLRs in 
untreated A549 and LA-4 cells (Figure 4.4A and 4.4B). Figure 4.4 presents the Cq 
values at which the cDNA encoding each TLR was detected. Ten different TLR typical 
for human cells (TLR1-10) were evaluated in A549 cells. TLR6 was expressed at the 
highest level in untreated human cells (Cq<30). A low expression was observed for 
TLR1, 3 and 4 (30<Cq>35). Non-detectable or almost non-detectable amounts were 
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found for TLR2, 5 and 7-10 (Cq>35). The extremely low expression of TLR7 and the 
lack of TLR8 expression in A549 agrees with previous report of Tissari et al., who also 
noted no expression of these TLRs in A549 219-221. In case of murine LA-4 cells, thirteen 
different TLRs (TLR1-13) typical for murine cells were evaluated. The highest 
expression in non-treated cells was observed for TLR1 and TLR7 (Cq<30). TLR3, 4 
and 6 were expressed at low levels (30<Cq>35), while TLR2, 5, 8-13 were expressed 
at extremely low to undetectable levels (Cq>35). 
 
 
 
Figure 4.4. The expression level of TLRs in untreated A549 and LA-4 cells. The Cq 
value at which the cDNA of each TLR was detected in untreated human A549 (A) and 
murine LA-4 (B) epithelial cells were determined via qPCR. A gene is considered to be 
highly expressed when its Cq value is lower than 30. A Cq value between 30 and 35 
stands for a low expression, while a Cq value higher than 35 indicates that the 
expression is extremely low or nihil. Notice that the scale of the Y-axis is inverted so 
that higher bars represent higher expression levels. The data are presented as mean 
values ± SD (n=3). 
 
 
Next, we evaluated whether liposome-mediated delivery of IVT mRNA resulted in an 
activation of TLR pathways. Therefore, the expression levels of 94 TLR-associated 
genes were determined in A549 and LA-4 cells 24 hours after exposure to mRNA/GL67 
complexes or medium only (an overview of the analyzed genes can be found in the 
supplementary data, table SC.1 and SC.2). The time-point of 24 hours was chosen as 
the most suitable to evaluate the activation of cytokines connected to TLRs signaling 
222. At this time, the cells do not achieve the highest cytotoxicity level yet but they 
71 
 
express the specific factors responsible for the cell death. The genes that were 
significantly upregulated or downregulated after liposome-mediated delivery of IVT 
mRNA are summarized in Table 3.1. Transfection of A549 cells and LA-4 cells with 
mRNA caused an upregulation of 27 and 14 TLR-associated genes, respectively. 
Interestingly, in A549 cells not only more TLR-associated genes are induced upon 
mRNA transfection, but also the extent of upregulation of these genes is much higher 
than in LA-4 cells. Indeed, the four most induced genes were upregulated more than 
4000-fold in A549 cells, while only a 20-fold induction was detected for the four highest 
upregulated genes in LA-4 cells. Nine genes were substantially upregulated by both 
cell lines after carrier-mediated mRNA delivery, i.e. IFN-β, CCL5 (also called 
RANTES), CXCL11, CCL4 (also called MIP-1β), IL-6, IRF-7, CXCL10 (also called IP-
10), TNF-α and TLR3. Remarkably, IFN-α and caspase-1 were significantly and highly 
induced by mRNA delivery in human A549 cells only. 
 
72 
 
 
Table 4.1: Effect of carrier-mediated delivery of mRNA on TLR associated genes. 
Overview of TLR associated genes that were significantly up- or down-regulated after 
carrier-mediated delivery of mRNA in human A549 (A) and murine LA-4 cells (B) in 
comparison to untreated cells. The cells were transfected with mRNA/GL67 complexes 
and 24 h later the total RNA was extracted and checked for quantity and quality. 
Subsequently the expression level of TLR associated genes was determined in mRNA 
transfected and untreated cells (n=3). The fold change in gene expression induced by 
carrier-mediated mRNA delivery was calculated using the global pattern recognition 
analysis tool as described in Materials and Methods. 
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Secretion of IFN-β and IL-6 by respiratory cells after liposome - mediated delivery of IVT 
mRNA 
 
In general, gene upregulation is reflected in a higher production of the encoded protein. 
IFN-β and IL-6 were highly upregulated in LA-4 as well as in A549 cells after carrier-
mediated delivery of mRNA (Table 4.3). IFN-β is expressed and secreted after 
recognition of a danger pattern by TLR3 in order to (1) sensitize the cells against viral 
infection, (2) inhibit the viral proliferation, (3) promote Th1 response by increasing the 
synthesis and expression of MHC-I as well as the release of other cytokines 223. IL-6 
is considered an activator of acute phase responses and a lymphocyte stimulatory 
factor 224. Therefore, as these cytokines play an important role in the TLR3 signaling 
pathway we decided to investigate, if a similar upregulation of IFN-β and IL-6 is also 
observed at the protein level. Figure 4.5 shows the extent of the cytokines secretion 
by respiratory cells after incubating them with the mRNA/GL67 complexes and the 
single constituents of the complexes. Additionally, complexes with mRNA encoding 
luciferase (1.7 kb) and eGFP (0.7 kb) were compared, as we previously observed 
differing viability pattern between them (data not shown). Longer luciferase mRNA 
bound to GL67 liposomes gave typically rise to a higher amount of measured cytokines 
(besides hIL-6), what agrees with their stronger cytotoxic effect. It might confirm the 
assumption, that longer mRNA chains may be responsible for more frequent 
interactions with PRRs. Moreover, longer mRNA contains statistically higher number 
of unmodified nucleotides responsible for innate immunity recognition 225. The IFN-β 
and IL-6 cytokines were not detected in a medium of untreated cells and neither after 
treatment with naked mRNA nor the GL67 liposomes. On the contrary, carrier-
mediated delivery of mRNA to both A549 and LA-4 cells provoked a substantial and 
significant IFN-β and IL-6 secretion. The data in Figure 4.5 mirrors the effect of 
mRNA/GL67 complexes and its constituents on the cell viability (Figure 4.2) and 
complements the qPCR data in Table 4.1. 
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Figure 4.5. IFN-β and IL-6 production after treatment of A549 and LA-4 with 
mRNA/GL67 complexes and their constituents. The cells were transfected with either 
mRNA/GL67 complexes containing 750 ng of complexed mRNA, the same amount of 
naked mRNA or just GL67 liposomes. 24 h post-transfection the secretion of the 
cytokines by the cells was measured using an ELISA assay. The bars represent the 
mean ± SD (n=3, *, p<0,05; **, p<0,01; ***, p<0,001 ANOVA). 
 
 
Impact of mRNA mediated activation of TLR3 on the transla-tion efficiency of the 
delivered mRNA 
 
Based on the observed upregulation of TLR3 and its downstream signaling molecules, 
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we can conclude that TLR3 plays an important role in the induction of the innate 
response after carrier-mediated delivery of mRNA to respiratory cells. It has been 
shown that the type I interferons that are produced during signaling through TLR3 
cause a global suppression of translation 226-228. Therefore, we decided to explore the 
impact of TLR3 signaling on the translation efficiency of the delivered mRNA. For this 
purpose, GL67 liposomes with mRNA encoding luciferase were used to transfect 
HEK293 and HEK293-TLR3 cells, which overexpress TLR3. 24 hours after 
transfection we determined the amount of luciferase produced by the cells and the cell 
viability. In case of HEK cells overexpressing TLR3, the luciferase levels were about 
25-fold lower than in regular HEK cells. Additionally, cells overexpressing TLR3 
demonstrated higher cell death after mRNA transfection (Figure 4.6). 
 
 
 
Figure 4.6. Impact of TLR3 on recombinant protein expression and viability after 
carrier-mediated delivery of mRNA. HEK cells and HEK cells overexpressing TLR3 
were transfected with 750 ng of mRNA/GL67 complexes. 24 h post-transfection the 
luciferase expression was measured (bars). The viability of cells was measured after 
48 h with MTT assay (line). The results are expressed as the mean ± SD (n=3, ** for 
p<0.01; independent-samples t-test). 
 
 
Effect of modified mRNA on the cell viability and transfection efficacy 
 
It has been described in the past that the use of modified mRNA can decrease the 
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activation of the innate immune system 6,229. Therefore, we determined whether 
incorporation of modified nucleotides in the mRNA could also prevent the cytotoxic 
effect caused by mRNA mediated stimulation of the innate immune system. We used 
modified mRNA that contained pseudouridine and 5-methylcytidine nucleotides. Both 
A549 and LA-4 cells were transfected with mRNA/GL67 complexes containing either 
unmodified or modified mRNA. Twenty hours after transfection the viability of the A549 
cells transfected with unmodified mRNA was below 30 %, while the viability of the cells 
transfected with modified mRNA was above 80 % . The viability of LA-4 cells 24 hours 
after adding the complexes with unmodified mRNA was at the level of 64 % where the 
modified mRNA/GL67 complexes gave the result of 88 % (Figure 4.7). Next, we 
evaluated whether the use of modified mRNA can also increase the gene transfer 
efficacy. Surprisingly, as shown in Figure 4.8 the use of modified mRNA does not 
increse the number of transfected cells. However, the level of gene expression in the 
eGFP positive cells was much higher with the modified mRNA. 
 
 
 
Figure 4.7. Cytotoxicity kinetics after transfection of A549 and LA4 cells with 
mRNA/GL67 complexes containing unmodified or modified nucleotides. The modified 
mRNA contains both pseudouridine and 5-methylcytidine. The viability was measured 
24 h after addition of the complexes using an MTT assay. The cell viability was 
calculated relatively to the viability of untreated cells. The results are presented as the 
mean ± SD (n=3, ***, p<0,001, independent samples t-test). 
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Figure 4.8. Effect of modified mRNA on the transfection efficiency of mRNA/GL67 
complexes. A549 cells were transfected with mRNA/GL67 complexes containing 500 
ng of unmodified or modified mRNA. The modified mRNA contained both 
pseudouridine and 5-methylcytidine. Transfection efficiency (bars) and mean 
fluorescence (line) was measured by flow cytometry 24 h after adding the complexes 
on cells. The results are presented as the mean ± SD (n=6). 
 
 
Cytokine expression after intrapulmonary administration of mRNA/GL67 complexes in 
vivo 
 
Transfection efficiencies and hence immunological effects in vitro may differ in vivo. 
Residing pulmonary APCs, such as macrophages or dendritic cells, are specialized in 
phagocytosis of any self and unself molecules and production of a proper innate 
immune response followed eventually by an adaptive immune response specific for 
the antigen. This system is also employed in pulmonary vaccination. A pilot in vivo 
study was carried out and 80 µg of complexed unmodified mRNA (dissolved in RNAse-
free water) was instilled intranasally to lungs of mice (n=3). In order to evaluate a pure 
effect of the lipoplexes, as the control group we treated mice (n=3) with the same 
volume of RNAse-free water. Both groups of the animals were imaged 4 and 24 hours 
later by in vivo bioluminescence imaging system, however no signal was detected. 
After removing lungs from the animals the ELISA assays were performed and the 
concentration for following cytokines was measured: IFN-β, IL-6, IL-12 and TNF-α 
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(Figure 4.9). After intrapulmonary treatment with unmodified mRNA/GL67 complexes, 
the mice developed significant overexpression of inflammatory cytokines, such as IL-
6 and TNF-α as well as cytokine typical for professional APCs: IL12. Production of IL-
12 and GM-CSF (not shown semi-quantitative data) confirms the hypothesis, that the 
complexes are phagocytized by the professional APCs residing in the lungs, what also 
prevents the transfection of pulmonary epithelial cells and eventually expression of the 
encoded proteins. 
 
 
 
Figure 4.9. Inflammatory cytokines expression after unmodified mRNA/GL67 
intrapulmonary delivery in vivo. 24 hours after intranasal instillation of unmodified 
mRNA/GL67 complexes in water (n=3) or adequate volume of just water (n=3) the lungs 
of mice were removed and homogenized. After that ELISA assay were performed for 
IFN-β, IL-6, IL-12 and TNF-α. The bars represent the mean ± SD (***, p<0.001 ANOVA). 
 
 
DISCUSSION 
 
The presented study demonstrates a powerful stimulation of the innate immune system 
after carrier-mediated delivery of mRNA in respiratory cells. Most of the genes that 
were upregulated after mRNA transfection can be brought back to the TLR3 signaling 
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pathway and its downstream effectors, i.e. type I interferons as well as inflammatory 
cytokines. Figure 4.10 schematically depicts these upregulated genes in the TLR3 
signaling pathway. The clear upregulation of TLR3 and its adaptor protein TICAM1, 
also called TRIF, indicates that mRNA is recognized by TLR3, which is one of the 
PRRs of the innate immune system responsible for interaction with dsRNA, usually of 
viral origin. One would expect that the delivered mRNA interacts with TLR7 and TLR8, 
which are known to interact with ssRNA. However, they were not upregulated after 
mRNA transfection. Moreover, TLR8 was not expressed in respiratory cells and only 
LA-4 cells showed a clear expression of TLR7. Although mRNA is transcribed as a 
single strand, it often contains double stranded regions. This may explain the 
recognition of mRNA by TLR3. We confirmed the presence of such secondary 
structures in our mRNA using the RNAfold Website predictor software 
(http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). 
Almost all of the upregulated genes in Table 1 are directly linked to the TLR3 signaling 
pathway (Figure 4.10). TICAM-1, IRF3 and 7 are responsible for the induction of type 
I interferons (IFN-α and IFN-β) 230,231 and IL-12 232 following TLR3 activation. These 
type I interferons subsequently activate, via STAT1, the CXCL and CCL chemokines. 
The downstream TLR3 signaling to NF-κB can explain the upregulation of IL-6 231, IL-
12 233 and TNF-α 231. The upregulated genes SOCS1, MUC1, TRAFD1, IRAK2 and 
MyD88 are known as negative regulators of TLR3 signaling. The induction of these 
negative regulators after TLR3 activation has also previously been reported and it is 
believed that they prevent an overstimulation of the innate immune system 234-237. 
All the cytokines that are induced after carrier-mediated delivery of mRNA are known 
to support the adaptive immune response. Indeed, type I interferons, which are highly 
induced after carrier-mediated mRNA delivery, are strong vaccine adjuvants as they 
increase the expression of MHCI 238, tumor antigens 239, activate NK cells 240,241 and 
facilitate the cross-priming 242. Their function in bridging innate with adaptive immunity 
is being unraveled 223,243-245. Furthermore, the massive production of TNF-α, CXCL and 
CCL chemokines may also increase the immune response after mRNA vaccination 
because these chemokines will attract immune cells to the injection spot and activate 
them 246-249. CCL5 or RANTES has gained much attention as it recruits dendritic cells 
(DCs) and induces a cytokine cascade in these cells 250. Therefore, CCL5 is currently 
evaluated as a vaccine adjuvant 251. Moreover, a recent study showed that CCL5 is 
essential for sustaining a CD8+ T cell response during infection 252. The two 
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upregulated interleukins, i.e. IL-6 and IL-12, play pivotal roles during the transition from 
innate to antigen-specific adaptive immunity. IL-6, which was highly upregulated after 
mRNA delivery is responsible for the attraction of monocytes and T-cells after the acute 
inflammation phase. Furthermore, it inhibits TGFβ mediated differentiation of T cells 
into regulatory T cells and skews T cell differentiation towards Th2 cells or, when also 
TGFβ is present, towards Th17 cells 253. IL-12, which was slightly induced by mRNA 
transfection, skews T cell differentiation towards Th1-cells, stimulates cytotoxic T cells 
and NK cells, and induces IFN- production by these cells and DCs 232,254. 
Surprisingly, carrier-mediated delivery of mRNA caused, in contrast to pDNA delivery, 
an extensive and delayed cell death. The cytotoxicity of mRNA was much more 
pronounced in the human A549 cells than in the murine LA-4 cells. This is in line with 
the data both on mRNA and protein level, which show that the innate immune response 
after mRNA delivery is much higher in the human than in the murine respiratory cells. 
It is well known that type I interferons exhibit antiproliferative and apoptotic effects 
255,256. As discussed above, type I interferons were heavily upregulated after mRNA 
delivery. Consequently, it is very likely that they play a role in the observed cytotoxicity. 
Additionally, based on Kubo et al. 257, who studied the dose-dependent effect of IFN-β 
on the viability of melanoma cells, we can conclude that the amount of IFN-β produced 
by the LA-4 cells after mRNA transfection (see Figure 4.5) is enough to affect their 
viability. Interestingly, in A549 cells, but not in LA-4 cells, caspase-1 is hugely 
upregulated together with RIPK2, which is involved in the processing of pro-caspase-
1. Therefore, we may conclude that carrier-mediated delivery of mRNA in A549 cells 
results in pyroptosis, i.e. a caspase-1 mediated form of programmed cell death 258,259. 
IRF1, which is especially upregulated in A549 cells, is known to induce the transcription 
of the caspase-1 gene 260. Caspase-1 was also slightly, although not significantly, 
upregulated in LA-4 cells transfected with mRNA (see supplementary table SC.1). It 
has been reported that such a small upregulation of caspase-1 can stimulate lipid 
production and prevent cell death, especially in epithelial cells 261. When caspase-1 
overexpression passes the critical threshold, as observed in the A549 cells, pyroptosis 
occurs. Activation of caspase-1 can potentially increase vaccination efficacy. Indeed, 
pyroptosis is accompanied with IL-18 secretion and cell lysis, which will result in the 
release of the produced antigen in the extracellular space 259. 
We cannot exclude that the observed innate immune response after carrier mediated 
delivery of mRNA is also partly due to detection of the mRNA by cytosolic receptors 
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such as the RIG-I-like receptors or the nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLRs). It is even very likely that the delivered mRNA was sensed 
by NLRs (also called inflammasomes). Indeed, activation of caspase-1 is a typical 
hallmark of inflammasome stimulation by DAMPs or PAMPs 258,262. Consequently, our 
data indicate that IVT mRNA may be a new stimulant of the inflammasome. 
The stimulation of the innate immune system may potentially also have negative 
effects on the vaccination efficacy. Indeed, we found that TLR3 recognition of mRNA 
decreases the translation of the mRNA. Type I interferons are known to induce protein 
kinase R (PKR) and 2′,5′-oligoadenylate synthetase (OAS) 263. Activated PKR inhibits 
translation by phophorylating the alpha subunit of the eukaryotic translation initiation 
factor 2 (eIF2a) 228,264, while OAS activates RNase L which causes an extensive 
cleavage of cytosolic RNA 265. Also Fotin-Mleczek et al. attributed the drop in protein 
expression of mRNA:protamine complexes, prepared at high mRNA:protamine ratios, 
to their capacity to stimulate the innate immune system. Interestingly, these authors 
also found that, in vivo, naked mRNA resulted in a higher protein expression than 
mRNA:protamine complexes. Therefore, they suggested a two-component mRNA 
vaccine that contains both free mRNA, which produces the antigen, and 
mRNA:protamine complexes, which induce the innate immune response. The 
stimulation of the innate immune system by their mRNA:protamine complexes was 
essential to obtain a good anti-tumor vaccination effect with their two-component 
vaccine. Nucleic acid complexes based on protamine are known to induce a slow and 
inefficient endosomal release of the nucleic acids 266. Consequently, at the moment 
that the mRNA is released in the cytosol, the cell probably already turned off its protein 
expression. Therefore, carriers which cause a rapid release of the mRNA may enable 
a sufficient protein production before the innate immune system starts to suppress the 
translation activity of the cell. A second concern one may have is the observation that 
carrier-mediated delivery of mRNA caused a much higher innate immune response 
and cell death in human respiratory cells, than in murine respiratory cells (Figure 4.2 
and Table 4.1). However, this difference in innate immune response and toxicity is not 
necessarily a species-specific effect. Indeed, the mRNA transfection efficacy, i.e. the 
number of eGFP positive cells, was much lower in the murine than in the human lung 
cells (see Figure 4.3). Therefore, the intracellular concentration of the transfected 
mRNA was most likely much lower in the murine cells. A massive production of 
cytokines (so called “cytokine storm”) in the respiratory tract can be life-threatening 267. 
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Moreover an increased mortality associated with a cytokine storm has recently been 
reported in mice after peptide vaccination 268. The risk of a too strong innate immune 
response and the negative effects of this immune response on the translatability of the 
delivered mRNA brings us to the question whether mRNA for vaccination purposes 
should not be made non-immunogenic. This question can only be answered by a 
comparative vaccination study using immunogenic and non-immunogenic mRNA. We 
showed that the cytotoxic effects of the mRNA disappear when they contain modified 
nucleotides. This is in agreement with previous reports that showed that modified 
mRNA is much less recognized by the innate immune system. Besides modified 
nucleotides 229 also a long poly(A) tail (i.e. > 150 adenosines) 269 is known to reduce 
the immune stimulatory capacity of mRNA. 
It has been reported that type I interferons, IL-6, IL-12, and CXCL10 can suppress 
tumor growth in mice and/or humans 270-272. In our study we found that carrier-mediated 
mRNA delivery heavily induced the production of these cytokines. IL-6, IL-12 and TNF-
α were additionally significantly (p<0,001) overexpressed in vivo after intrapulmonary 
administration of the complexes (Figure 4.9). Therefore, inclusion of a control mRNA 
vaccine to enable discrimination between real vaccination effects and “off-vaccine” 
effects, caused by the induced cytokines, is recommended. The “off-vaccine” effects 
may also be a wanted side-effect in case of tumor vaccination. Therefore, to increase 
the effect of the induced cytokines by carrier-mediated delivery of mRNA one could 
consider intratumoral injection of mRNA vaccines. A substantial production of IL-12 
and GM-CSF after mRNA/GL67 administration in vivo suggests phagocytosis of the 
complexes by professional APCs residing in the lungs, such as macrophages or 
dendritic cells. 
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Figure 4.10. Scheme of the TLR3 signaling pathway with the most important TLR3-
associated genes that are induced by carrier-mediated delivery of mRNA in lung 
epithelial cells. mRNA/GL67 complexes are endocytosed by the lung epithelial cells 
and double-stranded secondary structures of mRNA are recognized by TLR3 residing 
in endosomes. Following the interaction of TLR3 with its specific adaptor protein TRIF 
(TICAM1), the TLR3-dependent signaling pathway leads to the production of type I 
interferons and inflammatory cytokines. The genes presented in green (boxes) were 
significantly overexpressed in both human (A549) and murine (LA-4) cell lines. The 
genes presented in blue (boxes) were significantly overexpressed only in A549 cells 
and the genes presented in yellow boxes were not found to be significantly 
overexpressed or they were not evaluated during the qPCR experiment. → shows the 
positive regulation of a gene, while ┤represents an inhibition of a gene. 
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CONCLUSIONS 
 
In this paper, we demonstrated for the first time that carrier-mediated delivery of mRNA 
activates TLR3 signaling in respiratory cells leading to production of type I interferons 
and other immunostimulating cytokines. The activation of the innate immune response 
was much higher in human than in murine respiratory cells. Additionally, human 
respiratory cells transfected with mRNA underwent a delayed cell death that exhibited 
features of caspase-1 mediated programmed cell death. This indicates that NOD-like 
receptors, which are cytosolic receptors of PAMPs and DAMPs, also recognize the 
delivered mRNA as caspase-1 production is regulated by NOD-like receptors. The 
viability of murine respiratory cells was much less affected by mRNA transfection. This 
was in line with the lower innate immune response and the absence of a massive 
caspase-1 upregulation in these cells. The induction of immunostimulating cytokines 
and pyroptosis in lung epithelial cells after carrier-mediated delivery of mRNA may help 
the residing professional antigen presenting cells in the lungs, such as macrophages 
and dendritic cells, to present the antigens encoded by the mRNA and to create a 
suitable cytokine environment to obtain the appropriate immune answer. However, the 
induction of the innate immune response does also decrease the translation of the 
mRNA. Whether this will decrease the efficacy of mRNA vaccines will dependent on 
the system used for mRNA delivery. 
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INTRODUCTION 
 
mRNA as a gene expression platform has numerous advantages over pDNA-based 
expression modalities. For instance, unlike pDNA, mRNA does not need to enter the 
nucleus to carry out its function. Therefore mRNA can immediately express proteins 
inside a cell, including those that are not rapidly dividing  273. Moreover, mRNA vectors 
are safer than pDNA vectors in that they have virtually no risk of genomic integration 
and mutagenesis of critical regions of the host genome. 
While the concept of using mRNA as a modality for protein replacement therapy had 
been originally demonstrated 25 years ago 274, this approach was not popular for a 
long time due to the general instability and immunogenicity of the RNA molecule. 
However, a series of studies initiated by Kariko et al. provided a breakthrough in the 
field of mRNA therapy by demonstrating that the incorporation of base modifications 
found in natural RNAs such as 5-methylcytidine (m5C), N6-methyladenosine (m6A), 
Ψ, 5-methyluridine (m5U), and 2-thiouridine (s2U) or combinations thereof into mRNA 
can reduce Toll-like receptor (TLR) mediated immunogenicity of RNA 16 and increase 
the translational capacity and biological stability of RNA 23. The increased translational 
capacity of Ψ-modified mRNA was due to 1) the diminished activation of protein kinase 
R (PKR) by the modified RNA and reduced phosphorylation of the α subunit of 
eukaryotic translation initiation factor 2 (eIF2-α) 21,275 and 2) reduced activation of 2’-
5’-oligoadenylate synthetase (OAS) by the modified RNA and reduced cleavage of the 
RNA by RNase L 21. 
Various pre-clinical studies have demonstrated the vast potential of modified mRNA 
for therapeutic applications including the work of Kormann et al. 6 which used 
m5C/s2U-modified mRNA to treat mice with surfactant protein B (SP-B) deficiency, a 
lethal congenital lung disease, the work of Warren et al. 54 which used m5C/Ψ-modified 
mRNA to reprogram and differentiate human cells, and the work of Zangi, Lui et al. 276 
which used m5C/Ψ-modified mRNA to treat a mouse model of myocardiac infarction. 
Given the pre-clinical success in using mRNA with various modified bases for in vitro 
and in vivo therapeutic applications, we sought to identify RNA base modifications that 
could further reduce the immunogenicity and translational capacity of mRNA by using 
mRNA containing Ψ as a benchmark. 
Here we demonstrate that the incorporation of m1Ψ, a modification naturally found in 
18S rRNA as a precursor of 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine 
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(m1acp3Ψ) 277 drastically improved the translational capacity of mRNA compared to 
Ψ-modified mRNA in A549 human lung epithelial cells, BJ human foreskin fibroblasts, 
C2C12 murine myoblast cells, HeLa human cervix epithelial cells, human primary 
keratinocytes from neonatal foreskin, as well as when the mRNA was injected 
intradermally (i.d.) or intramuscularly (i.m.) into mice. We show in the various cell lines 
that m1Ψ-modified mRNA had reduced cytotoxicity compared to Ψ-modified mRNA. 
m1Ψ-modified mRNA also had reduced activation of intracellular innate immunity. 
Finally, we show that the superiority of m1Ψ-modified mRNA over Ψ-modified mRNA 
may be due to its improved ability to evade TLR3 activation. Thus, m1Ψ-modified 
mRNA could be a potentially more optimal alternative to Ψ-modified mRNA for 
therapeutic applications. 
 
 
MATERIALS AND METHODS 
 
Cells and Reagents 
 
Human lung epithelial cell line (A549, ATCC® CL-185™), human foreskin fibroblasts (BJ, 
ATCC® CRL-2522™), murine muscle cells (C2C12, ATCC® CRL-1772™), human 
cervix epithelial cells (Hela, ATCC® CCL-2™), human primary keratinocytes from neonatal 
foreskin cells (ATCC® PCS-200-010™) were purchased from ATCC and cultured 
according to their recommendations. Modified nucleoside triphosphates, 5-methylcytidine-
triphosphate (m5C), pseudouridine-triphosphate (Ψ) and N1-methylpseudouridine-
triphosphate (m1Ψ) were purchased from TriLink (San Diego, CA, USA). Lipofectamine 
2000 was obtained from Invitrogen (Merelbeke, Belgium). D-Luciferin for in vivo 
measurement of firefly luciferase activity was purchased from Gold Biotechnology (St. 
Louis, MO, USA). 
 
Plasmids 
 
Plasmids used for in vitro transcription of firefly luciferase and mVenus encoding 
mRNA were constructed using standard cloning procedures including In-Fusion PCR 
cloning (Clontech) and Gateway cloning (Invitrogen). The plasmids included a 
bacteriophage T7 polymerase promoter, the open reading frame (ORF) of interest 
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flanked by the 5’ UTR of the Venezuelen equine encephalitis virus (VEEV) subgenomic 
RNA and two tandem repeats of the 3’ UTR of VEEV subgenomic RNA, a 40 nucleotide 
poly(A) sequence, and a consensus recognition sequence for the I-SceI homing 
endonuclease. Plasmids sequences and maps are available upon request. 
 
mRNA in vitro transcription 
 
mRNA was produced by in vitro transcription (IVT) of I-SceI (NEB)-linearized plasmid 
DNA using the MEGAscript® T7 Transcription Kit (Invitrogen) with unmodified 
nucleotides or a combination of the modified nucleotides (replacing the nonmodified 
equivalents) described above. RNA was subsequently purified using the RNeasy® 
Mini Kit (Qiagen), denatured at 65 ºC, enzymatically (cap1) capped using the 
ScriptCap™ 2'-O-Methyltransferase Kit (Cellscript) and ScriptCap™ m7G Capping 
System (Cellscript), poly(A) tailed using the A-Plus™ Poly(A) Polymerase Tailing Kit 
(Cellscript), and purified again using the RNeasy® Mini Kit (Qiagen) following the 
manufacturers’ protocols. 
 
mRNA electroporation 
 
All cell lines were electroporated in 0.2 cm gap cuvettes (BioRad, Temse, Belgium) 
with a square wave electroporator, BTX ECM 830 Harvard Apparatus (VWR 
International, Leuven, Belgium). Electroporation conditions were optimized for each 
cell line and are as follows: A549 (400 V, 1.4 ms, 1 pulse), BJ (250 V, 1.4 ms, 1 pulse), 
C2C12 (300 V, 1.4 ms, 1 pulse), HeLa (300 V, 1.4 ms, 1 pulse), primary keratinocytes 
(300 V, 1.4 ms, 1 pulse). Prior to electroporation, the cells were washed twice with ice-
cold PBS (Gibco, Merelbeke, Belgium), counted, and resuspended in Opti-MEM I 
reduced serum medium (Gibco, Merelbeke, Belgium) at a concentration of 1 x 106 
cells/ml. 100 µl of cell suspension was electroporated with 1 µg of unmodified or 
modified mRNA. 
 
mRNA lipofection 
 
mRNA was mixed with Lipofectamine 2000 at a ratio of 1:2 (µg mRNA: µl 
Lipofectamine 2000) in Opti-MEM I. The complexes were allowed to form for 30 
90 
 
minutes at room temperature and afterwards 1 µg of complexed mRNA was 
transferred to cells pre-seeded in 24 well plates. The complexes were removed from 
cells 4 hours later and Opti-MEM I was replaced with the standard ATCC 
recommended culture media containing serum. 
 
ELISA assays 
 
Cell culture supernatants were collected 24 hours after transfection with mRNA and 
stored at -80 ºC until performing the ELISA assays, unless stated otherwise. ELISA 
MAX Deluxe kits for IL-6 and CCL5, ELISA LEGEND MAX for mouse IFNβ were 
purchased from BioLegend (ImTech Diagnostics, Antwerp, Belgium). The human IFNβ 
ELISA kit - LumiKine was obtained from Life Technologies (Merelbeke, Belgium). 
ELISAs were performed according to the manufacturers’ recommendations, as 
published previously 14. 
 
Intracellular staining assays 
 
24 hours after transfection with mRNA, cells were collected, washed with PBS and 
incubated in the dark, at room temperature for 1 hour in 1 x Fixation Buffer 
(eBioscience, Vienna, Austria). Subsequently, the fixed cells were washed twice with 
1 x Permeabilization Buffer (eBioscience, Vienna, Austria). After centrifugation, the 
cells resuspended in 1 x Permeabilization Buffer  were incubated in the dark for 30 
minutes with fluorescent-dye conjugated antibodies against TLR3 (BioLegend, ImTec 
Diagnostics N.V. Belgium). Afterwards, the cells were washed twice to get rid of any 
unbound antibodies, and resuspended in PBS. Fluorescence signal was measured on 
an Accuri C6 flow cytometer (BD Biosciences, Erembodegem, Belgium) and analyzed 
as described below. 
 
Flow cytometry assays 
 
Flow cytometry was performed on an Accuri C6. Data were analysed using the CFlow 
Plus Analysis software (BD Biosciences, Erembodegem, Belgium). Live cells were 
gated based on forward and side scatter. 
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Mouse experiments 
 
7-week-old Balb/c mice were obtained from Janvier (Le Genest St Isle, France). Mice 
were housed in individually ventilated cages (IVC) under the 12:12 h dark-light cycle 
conditions. Access to food and water was maintained ad libitum. All experiments were 
carried out with approval of the Ghent University Ethics Committee (nº EC 2014/57). 
Mice were anesthetized with constant flow of isoflurane during injections and 
intradermal (i.d.) or intramuscular (i.m.) electroporations. 50 μg of naked mRNA 
resuspended in PBS were injected i.d. or i.m into the tibialis anterior muscle. Naked 
mRNA injections were followed by calliper-mediated electroporation with the BTX ECM 
830 Harvard Apparatus using previously optimized conditions (100 V, 40 ms, 6 pulses 
for i.m. and 75 V, 40 ms, 6 pulses for i.d.). A small amount of conductive gel was 
applied to the calliper-plates before electroporation. 
 
In vitro firefly luciferase and viability assays 
 
The used mammalian cells were transfected in 24 well plates with 1 µg of nonmodified 
or modified mRNA as described above (section: mRNA electroporation, mRNA 
electroporation). 24 hours after transfection, cells were lysed with 100 µl of 1 x Passive 
Lysis Buffer (Promega, Leiden, The Netherlands). In vitro firefly luciferase assay was 
performed with Luciferase Assay Kit (Promega) according to manufacturer’s protocol. 
Luminescence was measured by Glomax instrument (Promega). 
Viability of mRNA-transfected cells was measured 24 hours later by MTT proliferation 
assay according to manufacturer recommendations (Roche, Vilvoorde, Belgium). All 
experiments were performed in triplicates. 
 
In vivo imaging of firefly luciferase expression 
 
The expression level of firefly luciferase in murine tissue was measured over time using 
the in vivo bioluminescent imaging system, IVIS Lumina II (PerkinElmer, Zaventem, 
Belgium) until no detectable signal could be acquired from the injected mRNA. Mice 
were injected intraperitoneally (i.p.) with 50 mg/kg of D-Luciferin (Gold Biotechnology, 
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St. Louis, MO, USA). Luminescence was measured 10 minutes after the i.p. injection 
of D-Luciferin. Acquisition settings were set at f-stop: 1, binning: 8, and auto-exposure. 
 
Statistics 
 
The experiments are represented as the mean ± SD. Statistical analysis was 
performed in a GraphPad Prism 6 software. In order to check significance of the 
variance among different experimental groups, ANOVA test was calculated followed 
by ad hoc Tukey’s test. The differences were considered significant when p<0.05.  
 
 
RESULTS 
 
m1Ψ-incorporated mRNA has a higher translational capacity than Ψ-incorporated mRNA 
in vitro 
 
In order to test whether there are natural nucleobase modifications which are superior 
to Ψ at enhancing the translational capacity of mRNA, we incorporated m1Ψ into RNA 
by in vitro transcription to compare it to RNA containing Ψ. Ψ and m1Ψ are natural 
derivatives of uracil that can be distinguished by the N1 positions of their bases (m1Ψ 
is methylated at N1) (Figure 5.1). 
 
 
 
Figure 5.1. Chemical structure of nucleoside modifications used in this study. The 
chemical structures of pseudouridine (Ψ), N1-methylpseudouridine (m1Ψ), and 5-
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methylcytidine (m5C). Adapted from the Modomics database 278. 
 
In addition to Ψ or m1Ψ single modified mRNA, we decided to compare m5C/Ψ or 
m5C/m1Ψ double modified mRNAs, since it had been shown previously by others that 
m5C (a natural derivative of cytosine; see Figure 5.1) can increase the translational 
capacity of Ψ single modified mRNA 54. The RNAs used in this study contained, at the 
5’ end, an N7-methyl-guanosine cap and a 2’-O-methyl at the penultimate nucleoside 
(i.e. a cap 1 structure), a poly(A)-tail at the 3’ end, and the 5’ UTR and two repeats of 
the 3’ UTR sequence of the VEEV subgenomic RNA flanking the ORF of interest. We 
transfected unmodified or modified mRNAs encoding the firefly luciferase gene into 
several cell lines (A549 [human lung carcinoma cells], BJ [human foreskin fibroblasts], 
C2C12 [mouse myoblasts], and HeLa [human cervical adenocarcinoma cells]) as well 
as primary cells (human neonatal foreskin primary keratinocytes) by lipofection. We 
chose cell lines or primary cells of different cell types or derived from diverse tissues 
to ensure that the effects we observe are general. Luciferase assays were performed 
24 hours after mRNA transfection. As shown in Figure 5.2 and Supplementary table 
SD.1, we observed a statistically significant difference in luciferase activity in all of the 
cell types transfected with the differentially modified mRNAs. In particular, the 
m5C/m1Ψ double modified mRNA resulted in the highest amount of luciferase activity 
in every cell type transfected with the exception of C2C12 cells in which m1Ψ was the 
highest. Similar results were obtained when mVenus-encoding mRNAs were 
transfected into the same group of cells Supplementary figure SD.1 and table SD.2. 
Therefore, we demonstrate that m1Ψ containing modified mRNA (particularly the 
m5C/m1Ψ combination) outperforms the previous state-of-the-art Ψ modified mRNA 
expression platform. 
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Figure 5.2. Comparison of luciferase activity 24 hours after lipofection of unmodified 
or modified (Ψ, m1Ψ, m5C/Ψ, m5C/m1Ψ) mRNAs encoding firefly luciferase in various 
cell lines. Luciferase activities for each mRNA species are shown for (A) A549 human 
lung carcinoma cells, (B) BJ human foreskin fibroblasts, (C) C2C12 mouse myoblasts, 
(D) HeLa human cervical adenocarcinoma cells, and (E) human neonatal foreskin 
primary keratinocytes. 1 μg of each mRNA species was transfected into each cell type 
by lipofection. The results are presented as the mean ± SD (n=3, ANOVA results in 
supplementary table SD.1). 
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The translational lifetime of m1Ψ-incorporated mRNA is longer than that of Ψ-
incorporated mRNA in vitro 
 
We next assessed whether the duration of protein expression from m5C/m1Ψ mRNA 
was longer than that of the other mRNAs by performing a time course assay for 
luciferase activity. For this, we lipofected the various mRNAs into the A549 cell line 
and measured luciferase activity at 3, 6, 12, 24, and 48 hr. As shown in Figure 5.3, 
there was a statistically significant difference (ANOVA, p<0.05) in luciferase production 
at each of the different time points. At each of the time points, the m5C/m1Ψ-modified 
mRNA outperformed the rest of the mRNAs. We observed an initial burst in luciferase 
activity at the 3 h time point, where m5C/m1Ψ mRNA produced ~916.7-fold more 
activity than unmodified mRNA, ~118.1-fold more than Ψ mRNA, 23.0-fold more than 
m1Ψ mRNA and 44.1-fold more than m5C/Ψ mRNA. Subsequently, the expression 
from the mRNAs dropped drastically between the 3 and 6 h time points after which the 
drop in luciferase activity was less severe. Importantly, the luciferase signal between 
the 24 and 48 h time points decreased the least for the m5C/m1Ψ RNA. Thus the m1Ψ 
outperformed the Ψ mRNA expression platform with regards to the duration of 
expression.
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Figure 5.3. Kinetics of luciferase activity after lipofection of unmodified or modified (Ψ, 
m1Ψ, m5C/Ψ, m5C/m1Ψ) mRNAs encoding firefly luciferase in A549 cells. Luciferase 
activities for each mRNA species at 3, 6, 12, 24, and 48 h time points are graphed. 
Luciferase activity (RLU) was normalized to the amount of total cellular protein 
concentration measured by a BCA assay to correct for the differences in the number 
of cells at the different time points of the time series. 1 μg of each mRNA species was 
transfected into A549 cells. The results are presented as the mean ± SD (n=3, ANOVA 
p<0.05). 
 
 
m1Ψ-incorporated mRNA is less cytotoxic than Ψ-incorporated mRNA when delivered 
using lipid-based carriers in vitro 
 
We previously demonstrated that the transfection of in vitro transcribed mRNAs into 
mammalian cells can negatively affect the health of the transfected cells 14. Since 
m5C/Ψ incorporated mRNA had drastically less cell death upon transfection compared 
to unmodified RNA, we next sought to determine how the cytotoxicity of m1Ψ mRNA 
compared to Ψ mRNA. For this, we first lipofected the RNAs containing either no 
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modification or the various combinations of modifications described above and 
performed an MTT assay to quantify the amount of viable cells after transfection of 
each RNA species into various cell lines. As shown in Figure 5.4, the effects of the 
various RNAs on cell viability were dependent on the cell type and delivery method. In 
the case of lipofection (Figure 5.4.A), all cell types except primary keratinocytes 
showed a statistically significant difference in the overall viability pattern. Specifically, 
in the A549, C2C12, and HeLa cell lines, m1Ψ was less toxic than Ψ, however, both 
m5C/m1Ψ and m5C/Ψ were equally non-toxic. In the BJ cell line, m5C/m1Ψ was 
superior to all other combinations of modifications upon lipid-based transfection 
(supplementary table SD.3). However, when we delivered the various RNAs into the 
cells by electroporation, only the A549, BJ, and HeLa cells showed a statistically 
significant difference in the overall viability pattern (Figure 5.4.B). Specifically, in A549 
cells, m1Ψ was less toxic than Ψ. Thus, we found that the toxic effects of IVT mRNA 
on cells is dependent on both cell type and the delivery method. However, when we 
did observe a noticeable difference of base modifications on cellular viability, m1Ψ 
outperformed the Ψ platform. 
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Figure 5.4. Viability of mammalian cells 24 hours after transfection of unmodified or 
modified (Ψ, m1Ψ, m5C/Ψ, m5C/m1Ψ) mRNAs determined using an MTT assay. 1 μg of 
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each mRNA species was transfected into A549, BJ, C2C12, HeLa, and primary 
keratinocytes by (A) lipofection or (B) electroporation. The results are presented as 
the mean ± SD (n=3, ANOVA results in supplementary table SD.3). 
 
 
m1Ψ-incorporated mRNA stimulates intracellular innate immune signaling pathways less 
than Ψ-modified mRNA in vitro 
 
Since the superior translational capacity and reduced cytotoxicity of modified mRNAs 
are generally known to correlate with reduced activation of the intracellular innate 
immune pathway, we next asked whether there was a difference in the activation of 
key cytokines upon transfection of the differentially modified RNAs. For this, we 
lipofected A549 cells with the various mRNAs and measured the levels of secreted 
interferon-β (IFN-β) and Chemokine (C-C motif) ligand 5 (CCL5, also known as 
RANTES) by ELISA. As shown in Figure 5.5, there was a statistically significant 
difference in the expression levels of IFN-β. Specifically, the IFN-β production from 
cells transfected with Ψ, m1Ψ, m5C/Ψ and m5C/m1Ψ RNAs were respectively 
reduced by ~3.2, 10.6, 4.3, and 13.7-fold relative to unmodified RNA (N). For CCL5, 
as shown in Figure 5.6, the m5C/Ψ and m5C/m1Ψ double modified mRNAs showed 
the lowest amount of cytokine induction and for the single modified RNAs, m1Ψ mRNA 
induced less cytokine expression than Ψ mRNA. Thus, overall, the m1Ψ platform was 
less immunogenic than Ψ when assessed by the amounts of IFN-β or CCL5 activation.  
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Figure 5.5. Levels of secreted IFN-β measured by ELISA 24 h after lipofection of 
unmodified or modified (Ψ, m1Ψ, m5C/Ψ, m5C/m1Ψ) mRNAs into A549 cells. 1 μg of 
each mRNA species was lipofected into A549 cells and the supernatants were 
subjected to ELISA to detect IFN-β. The results are presented as the mean ± SD (n=3, 
ANOVA) 
 
 
Figure 5.6. Levels of secreted CCL5 (RANTES) measured by ELISA 24 hours after 
lipofection of unmodified or modified (Ψ, m1Ψ, m5C/Ψ, m5C/m1Ψ) mRNAs into A549 
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cells. A) 1 μg of each mRNA species was lipofected into A549 cells and the 
supernatants were subjected to ELISA to detect CCL5. B) The results are presented as 
the mean ± SD (n=3, p<0.0001, ANOVA). 
 
 
TLR3 overexpression is sufficient to convert HEK cells from being not modification 
sensitive to preferential expressers of m1Ψ-incorporated modified mRNA 
 
We next sought to address the mechanism by which cells preferentially translate m1Ψ-
incorporated mRNA over Ψ-mRNA. Since base modifications such as Ψ are known to 
reduce intracellular innate immune activation by evading TLR signaling, we asked 
whether TLR signaling could explain the difference in translation. To test this 
hypothesis, we took advantage of the HEK cell line, which normally does not express 
endosomal TLRs (supplementary figure SD.2). We transfected unmodified and various 
modified mRNAs encoding luciferase into normal HEK cells and HEK cells ectopically 
expressing TLR3. In normal HEK cells, we did not observe a difference in luciferase 
activity between the different RNAs. Strikingly, the HEK cells overexpressing TLR3 
showed a statistically significant difference in expression where m1Ψ expressed 5.6-
fold more luciferase activity than Ψ incorporated RNA (Figure 5.7). The data are 
consistent with the hypothesis that differential activation of the TLR3 signaling pathway 
may explain why the m1Ψ platform has superior translational capacity and less innate 
immune activation compared to the Ψ mRNA platform. 
 
 
Figure 5.7. Comparison of luciferase activity 24 hours after lipofection of unmodified 
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or modified (Ψ, m1Ψ, m5C/Ψ, m5C/m1Ψ) mRNAs encoding firefly luciferase in HEK and 
TLR3 overexpressing HEK (HEK-TLR3) cells. Luciferase activities for each mRNA 
species are shown for (A) HEK cells and (B) HEK-TLR3 cells. 1 μg of each mRNA 
species was transfected into each cell type by lipofection. 
 
 
m1Ψ-incorporated mRNA has a higher translational capacity than Ψ-incorporated mRNA 
in mice in vivo 
 
Finally, we assessed whether m1Ψ mRNA had superior translational effects over Ψ 
when injected in vivo, into mice. For this, we delivered naked (uncomplexed) luciferase 
mRNAs encoding firefly luciferase by i.d. or i.m. injection into mice and immediately 
electroporated the injection area. The kinetics of expression was then followed by 
bioluminescent imaging (BLI) over a period of 42 days. As shown in Figure 5.8A,B, as 
expected, the luciferase signal after e.p. decayed over time. Importantly, as shown in 
Figure 5.8C,D, the RNA modifications affected the total amount of protein expressed 
in vivo (as measured by quantifying the area under the curve of each series in Figure 
5.8A,B). Specifically, the m5C/m1Ψ double modified mRNA expressed the best 
followed by m5C/mΨ, mΨ, Ψ, and lastly, unmodified mRNA (N). Thus the m1Ψ 
platform has a translational advantage over the Ψ platform in vivo. 
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Figure 5.8. Comparison of in vivo luciferase activity following injection of unmodified 
(N) or modified (Ψ, m1Ψ, m5C/Ψ, m5C/m1Ψ) mRNAs administered through i.d. or i.m. 
routes by e.p. Luciferase activities measured by BLI for each mRNA species followed 
over a course of 42 days (A) and (B). The results are presented as a mean ± SD (n ≥ 4). 
The area under the curve of each series was calculated and plotted to estimate the 
total amount of protein expression per series (C) and (D). 50 μg of each mRNA species 
was administered to mice for each delivery method and route. 
 
 
DISCUSSION 
 
A decade has passed since Kariko et al. discovered that incorporation of modified 
bases into mRNA can reduce the innate immunogencity of RNA 16. The subsequent 
demonstration that modified mRNA enhances the translational capacity and stability of 
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RNA 23 inspired a series of successful pre-clinical studies in which mRNAs with 
different combinations of modifications were used for various therapeutic applications 
6,54,276,279,280. 
In this manuscript, in light of the enormous therapeutic potential of modified mRNA 
demonstrated in these previous studies, we sought to identify naturally existing base 
modifications that may enable further improved translational capacity and reduced 
immunogenicity of mRNA beyond the current state-of-the-art Ψ-modified mRNA 
platform. Indeed, we find that m1Ψ-modified mRNA can express reporter genes at 
levels more than an order of magnitude higher than Ψ-modified mRNA in multiple cell 
lines and in mice. m1Ψ-modified mRNA also had reduced cytotoxicity and 
immunogenicity compared to Ψ-modified mRNA. These superior properties of m1Ψ-
modified mRNA in comparison to Ψ-modified mRNA may be due to the ability of m1Ψ-
modified mRNA to more effectively evade endosomal TLR receptors such as TLR3. 
Previously, the use of chemical modified nucleotides that do not naturally exist in 
nature has been explored for the purpose of antiviral therapy 281. Unnatural chemical 
base modifications could also be used in theory to enhance the properties of mRNA. 
However, great safety precautions must be taken when doing so as the administration 
of unnatural modified nucleotides into human patients had previously resulted in 
mitochondrial toxicity, liver failure, and death during clinical trials 282. Furthermore, 
unlike native modifications, unnatural modifications may elicit an adaptive immune 
response against the RNA. 
Therefore, a more prudent strategy may be to restrict the investigation of mRNA 
enhancing modifications to those that exist in nature. Currently, 66 nucleoside 
modifications have been demonstrated to be post-transcriptionally incorporated into 
eukaryotic RNA, 51 of which are incorporated into tRNA, 23 in rRNA, 13 in mRNA, 11 
in snRNA 283. The current state-of-the-art mRNA modification Ψ is the most prevalent 
nucleoside modification found in nature and was originally thought to be only 
incorporated into tRNA, rRNA, and snRNA mainly to stabilize the structure of the RNA 
284. However, recent genome-wide mapping studies have demonstrated that Ψ is also 
naturally incorporated into mRNA as well as snoRNA 285,286. Incorporation of Ψ into 
mRNA was upregulated by cellular stress conditions such as heat shock or nutrient 
deprivation thus implicating Ψ as a possible native regulator of mRNA function. While 
the function of m1Ψ, a precursor of m1acp3Ψ in 18S rRNA 277, is not entirely known, it 
would be interesting to test whether it is also naturally incorporated into native cellular 
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mRNA. 
Future studies may address the mechanisms by which m1Ψ-modified mRNA provides 
further enhanced translational capacity and reduced immunogenicity compared to Ψ-
modified mRNA. Our results implicated that m1Ψ may be able to evade the endosomal 
TLRs more efficiently than Ψ. However, it is also possible that m1Ψ could evade 
retinoic acid-inducible gene-I (RIG-I)-like receptors or PKR more efficiently, is more 
resistant to RNase L, or has a generally increased rate of ribosomal translation. 
Moreover, as it had previously been shown that Ψ-containing stop codons have an 
increased rate of translational readthrough 287,288, this may be true for m1Ψ as well. 
Nevertheless, in this manuscript, we showed that m1Ψ-containing mRNA is more 
superior than Ψ-containing mRNA in its capacity to produce protein and also its ability 
to reduce the intracellular innate immune response. Future work may demonstrate the 
enhanced capability of m1Ψ-containing mRNA for applications such as protein 
replacement therapy. 
 
 
SUPPLEMENTARY DATA (Appendix D) 
 
Figure SD.1. Comparison of mVenus expression level 24 hours post-transfection from 
unmodified and modified mRNA in various cell lines 
Figure SD.2. flow cytometry data TLR3 and RIG-I ICS 
Table SD.1. ANOVA statistics followed by ad hoc Tukey’s multiple comparisons test 
after transfection of luciferase-encoding mRNA/Lipofectamine 2000 
Table SD.2. ANOVA statistics followed by ad hoc Tukey’s multiple comparisons test 
after transfection of mVenus-encoding mRNA/Lipofectamine 2000 
Table SD.3. One-way ANOVA statistics followed by ad hoc Tukey’s multiple 
comparisons test based on results in Figure 5.4 depicting viability 
Table SD.4. Characterization of complexes – Zeta Potential. 
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CHAPTER 6  
 
 
 
GENERAL DISCUSSION, 
CONCLUSIONS and SUMMARY 
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GENERAL DISCUSSION 
 
 
In this Ph.D. dissertation, I conducted a comprehensive investigation of messenger 
RNA as a potent and safe gene-based therapeutic modality to identify its advantages 
and understand the source of its weaknesses. The properties (half-life, expression 
level, innate immune-stimulatory activity) of the mRNA-based pharmaceutical can be 
defined by 1) its fundamental structure: the cap, the polyA-tail, sequences of the 5’ 
UTR, 3’ UTR, and ORF, 2) its fundamental building blocks: the ribonucleotides, their 
nucleobase modifications, and respective ratios, and 3) intracellular physical and 
chemical interactions: inter-RNA interactions, interactions between RNAs and 
intracellular ions, and interactions between RNAs and proteins responsible for 
translation, degradation, and recognition of PAMPs and DAMPs as reviewed in 
Chapter 2 of this dissertation. As mRNA has the potential to become a cost-effective 
and exceptionally safe therapeutic modality for combating an array of diseases, such 
as cancer, infectious diseases, genetic disorders, metabolic disorders, or allergies, it 
is critical for the scientific community to gather the multidisciplinary knowledge required 
to realize these goals and also to understand the possible pitfalls for using mRNA as 
a drug. 
My doctoral research was initiated by first characterizing and comparing the 
transfection efficiencies of lipocomplexed DNA and RNA in vitro and in vivo. While the 
transfection efficiency of formulated RNA was higher than that of DNA in vitro, it did 
not give rise to a detectable reporter signal in vivo (Chapter 3). This promoted us to 
question whether the exogenously produced RNA was triggering an innate immune 
response in vivo. Indeed, we discovered that the RNA was activating an immune 
response through TLR3 (Chapter 4). This innate immune “alert” mediated by 
endosomal TLRs or cytoplasmic RLRs, which in nature is indicative of a potential viral 
infection, can serve a self-adjuvanting function during mRNA vaccination or 
immunotherapy. The prompt production and secretion of type I interferons, followed by 
other proinflammatory cytokines, such as IL-6, IL-28, RANTES or IL-12 (Chapter 4 and 
5), creates a chemoattractive microenvironment for immune cells. Moreover, this 
cytokine profile based on type I interferons subsequently orchestrates an adaptive 
immune response that enhances CD8+ and Th1 CD4+ cells with the additional help of 
NK cells. This type of immune response is especially desirable in the treatment of 
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cancer or vaccination against intracellular pathogens, such as viruses (see Figure 6.1). 
 
 
Figure 6.1: Schematic representation of the impact of innate immunity on gene-based 
vaccination. 
 
 
While the immunogenic effect of mRNA is an apparent advantage for the purpose of 
vaccination, it should be noted that in reality there is a trade-off between self-adjuvancy 
and diminished antigen expression or “translational shutdown” (Chapter 4). Such 
innate immune stimulation, which reduces protein expression from RNA or even 
induces cell death (Chapter 4) is certainly undesirable for protein replacement 
therapies. To overcome this problem, we characterized how the incorporation of 
various different natural nucleoside modifications into RNA would affect the 
immunogenicity of the RNA (Chapter 5). We found that mRNA with novel combinations 
of base modifications including N1-methylpseudouridine (m1Ψ) outperformed the current 
state-of-the-art pseudouridine (Ψ)-modified mRNA platform by providing up to 44-fold or 
13-fold reporter gene expression upon transfection into cell lines or intradermal (i.d.) 
injection into mice, respectively. We showed that m1Ψ-modified mRNA resulted in reduced 
intracellular innate immunogenicity and improved cellular viability compared to 
pseudourudine-modified mRNA upon transfection in vitro. The enhanced capability of 
m1Ψ-modified mRNA to express proteins may be due to an increased ability of the RNA 
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to evade activation of endosomal Toll-like receptor 3 (TLR3) and downstream innate 
immune signalling. We believe that the combination of modifications presented here may 
serve as a new standard in the field of modified mRNA-based therapeutics. 
The results obtained in this dissertation suggest that the properties of the mRNA can 
be carefully adapted for each application to balance protein production and 
immunostimulation. As discussed in Chapter 2, one possible solution to achieving the 
highest level of protein production while still obtaining an adjuvant effect may be to co-
express cytokines such as IL-12 encoded on pDNA or mRNA or in the form of a 
recombinant protein along with an antigen. However, many reports have described 
that these cytokines may manifest a severe toxic effect upon systemic delivery if the 
protein concentration in the body becomes too high. Hence, m1Ψ modified mRNAs 
that could express such potent but toxic therapeutic proteins in a regulatable manner 
would provide additional safety measures. Such ON/OFF switches that can be 
controlled using small molecules and genetic circuitry can be engineered using the 
latest advances in the field of synthetic biology as discussed in Chapter 7. I believe 
that the creation of such RNA “smart vaccines” from which the levels of antigen and 
adjuvants can be controlled on-demand will be the next endeavor of RNA-based 
vaccines. 
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GENERAL CONCLUSIONS 
 
 
mRNA-based drugs are among the most promising therapeutic modalities in the fight 
against cancer, metabolic disorders or even allergies. Thus, the general goal of the 
proposed project was to further develop this safe and potent protein expression 
platform. Chapter 2 of this dissertation reviews the strengths and weaknesses of the 
current state-of-the-art mRNA pharmaceutical and emphasizes how its inherent safety 
features may enable it to surpass the more traditional pDNA- or viral DNA-based gene 
therapeutic. This critical feature of RNA motivated me to identify the molecular 
mechanisms underlying any potentially undesirable effects of mRNA (e.g. 
immunostimulation or cytotoxicity) as well as to optimize in vivo delivery and search 
for more effective solutions to enhance the stability and protein production capacity of 
RNA. To this end, as described in Chapter 3, I initiated my studies by comparing the 
in vitro and in vivo performance of unmodified mRNA and pDNA upon lipofection. I was 
able to clearly demonstrate, in vitro, an important advantage of mRNA in transfecting 
slowly- or non-dividing cells (similar to cells in a living organism). However, I also 
realized that unmodified RNA caused cellular cytotoxicity and did not express proteins 
for a long period of time. Thus, in Chapter 4, I sought to understand the molecular 
mechanisms that were behind this shortcoming. I confirmed that carrier-mediated 
delivery of mRNA resulted in the endosomal recognition of exogenous mRNA by TLR3, 
followed by type I interferon overexpression/secretion and subsequent expression of 
proinflammatory cytokines. Additionally, I detected significant overexpression of 
caspase-1 and cell death, which indicated the activation of pyroptosis, a type of 
programmed cell death. Finally, in Chapter 5, I investigated how incorporating different 
nucleoside modifications into RNA affects the various properties of the therapeutic 
modality (i.e. expression level, duration, immunostimulatory effects). I discovered that 
m1Ψ modified RNA was superior to the current state-of-the-art modification (Ψ) with 
regards to cellular viability and lack of innate immune stimulation, and level and 
duration of protein expression both in vitro and in vivo. 
Thus in summary, through my doctoral studies, after characterizing how to formulate 
and deliver RNA in vitro and in vivo, I identified the molecular mechanisms underlying 
the disadvantages of RNA as a therapeutic and ultimately was able to discover a 
method to counteract this shortcoming by further improving upon the state-of-the-art 
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mRNA molecule. Thus, I believe that my dissertation has made a significant 
contribution towards the mRNA therapeutics community. 
 
Future perspectives 
 
Any therapeutic that is approved by regulatory agencies must not only be effective but 
also safe. A current problem related to mRNA drugs is that we do not have full control 
over the exact amount of protein production in a patient upon administration of the 
therapeutic. Hence, the effective total therapeutic protein dose cannot be reliably 
predicted, raising the concern of overdosing. Despite all of the efforts in the mRNA 
therapeutics industry to optimize and modulate the quantity and duration of protein 
expression from RNA, interpatient and intrapatient variation in protein production from 
RNA calls for a mechanism to fine-tune the expression levels of a protein post-
administration of the RNA drug. The RNA-based genetic devices and regulatory 
circuits described in Chapter 7 of this dissertation may enable doctors to control the 
amount of protein production in a patient depending on how the patient is responding 
to the RNA drug. Furthermore, genetic circuits that can distinguish different cell types 
by sensing the gene expression pattern of different cells can also be used in addition 
to delivery-based cell-type specific targeting techniques as a method to reduce the 
toxic side-effects of protein expression in unwanted cell types. I predict that the future 
of RNA therapeutics will involve the use of such sophisticated mechanisms to enhance 
the efficacy and safety of RNA as a drug modality. 
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Summary 
 
For many years, the instability of RNA had raised doubts as to whether it was possible 
to effectively use mRNA for gene therapy. However, rapid advances in messenger 
RNA-based technologies in the last decade have transformed mRNA into an 
increasingly popular therapeutic modality, especially in the field of vaccination against 
cancer and viral infections. Today, mRNA is considered a safer alternative to pDNA-
based therapeutics, as it does not pose the risk of genomic integration, unlike DNA. 
Furthermore, mRNA-based approaches offer immediate expression of a protein of 
interest even in non-dividing cells. 
In Chapter 2 of this dissertation we reviewed the general properties and advantages 
of RNA as a therapeutic modality. Moreover, we discussed specific attributes, 
limitations and benefits of unmodified, modified and self-replicating mRNA platforms. 
Additionally, this chapter also provides insights into the instability of the mRNA 
molecule and strategies to improve the delivery efficiency of in vitro transcribed (IVT) 
mRNA. We discussed how the inclusion of modified nucleotides, such as 5-
methylcytidine (m5C) or pseudouridine (Ψ), can increase the half-life and translatability 
of IVT mRNA or decrease its immunogenicity, where necessary. Furthermore, this 
chapter gave an in-depth overview of the various techniques and vehicles used for 
intracellular mRNA delivery including electroporation, gene gun injection, and lipo- and 
polyplex based methods that have been exploited by us and other groups, mostly for 
the purpose of mRNA-based vaccination. 
In Chapter 3 of this dissertation, we compared DNA and RNA-based strategies for 
heterologous gene expression using cationic liposomes as a delivery vehicle. We 
showed that transfection of human lung adenocarcinoma cells with mRNA complexes 
results in much faster expression compared to pDNA complexes. While the efficacy of 
mRNA complexes is independent of the cell cycle, pDNA complexes result in weak 
expression in nondividing cells. Thus, these data demonstrate that the nuclear barrier 
is a crucial obstacle for pDNA but not for mRNA. However, when mRNA and pDNA 
complexes encoding luciferase were administered intranasally to the lungs of mice, 
only the pDNA complexes gave rise to a detectable bioluminescent signal. This is likely 
due at least in part to the differences in the stability of the complexes as we showed 
that mRNA complexes are less stable in biological fluids compared to DNA complexes. 
However, as described in the next chapter (Chapter 4), the innate immune response 
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of the cells in the mouse lungs is also likely to be a major cause of the reduced 
expression from mRNA. Regardless, these results demonstrated the functional 
limitations of the traditional unmodified mRNA platform and encouraged us to develop 
a more stable and efficient RNA platform for mammalian cells applications as we 
described in Chapter 5. 
In Chapter 4, we showed that carrier-mediated delivery of mRNA may activate TLR3 
signaling in respiratory cells. Carrier-mediated delivery of mRNA following intranasal 
instillation caused activation of the innate immune system and massive production of 
immunostimulatory cytokines such as IL-6 or TNFα in vitro as well as in mice. 
Additionally, significant production of IL-12, typically expressed from immune cells, was 
detected 24 hours after instillation of mRNA complexes in murine lungs. 
Overexpression of the immunostimulatory cytokines was most likely caused by 
immune cells residing in the lung including antigen-presenting cells (APCs) such as 
dendritic cells (DCs) or macrophages, which are capable of phagocytosing the 
administered mRNA complexes. Furthermore, the data demonstate that the 
recognition of mRNA by the innate immune system is also associated with cell death, 
which proceeds in human respiratory cells via pyroptosis, a form of programmed cell 
death mediated by overexpression of caspase-1. This indicates that the transfected 
mRNA also activates the NOD-like receptors, which in turn regulate caspase-1 
production. Finally, we showed that recognition of the delivered unmodified mRNA by 
the innate immune system had a negative effect on mRNA translation by comparing 
unmodified mRNA with innate immune-evading double modified 5-methylcytidine and 
pseudouridine (m5C/Ψ) mRNA. 
Finally, in Chapter 5 of this dissertation, with the lessons learned in the previous two 
chapters in mind, we advanced the state-of-the-art modified RNA expression platform 
by discovering that incorporation of N1-methylpseudouridine (m1Ψ) into mRNA 
enables stronger and more sustained gene expression compared to pseudouridine 
(Ψ)-modified mRNA. The impact of this modification on the level and duration of gene 
expression, cellular viability, and the innate immune response was evaluated in vitro 
in different cell types as well as in vivo in mice. While endocytosis-dependent delivery 
(lipofection) of unmodified mRNA caused overexpression of TLR3 in respiratory cells, 
electroporation of the RNA into the same cell types resulted in a reduced innate 
immune response and less in vitro cytotoxicity. 
Nevertheless, mRNA therapeutics still have limitations that we are aware of and should 
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be addressed in future research. Chapter 7 (Appendix A) provides a thorough review 
of the latest advances in synthetic biology, which may contribute to overcoming the 
existing challenges in the mRNA therapeutics field. 
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Samenvatting 
  
Jarenlang had de instabiliteit van RNA twijfel gezaaid over de vraag of het mogelijk is 
om mRNA effectief te gebruiken voor gentherapie. Snelle vooruitgang in mRNA-
gebaseerde technologieën in het laatste decennium heeft mRNA echter omgezet in 
een steeds populairdere vorm van behandeling, vooral op het gebied van vaccinatie 
tegen kanker en virale infecties. Tegenwoordig wordt mRNA beschouwd als een 
veiliger alternatief voor pDNA-gebaseerde therapieën omdat er geen risico op 
genomische integratie is, in tegenstelling tot pDNA. Bovendien biedt de mRNA-
gebaseerde aanpak een onmiddellijke expressie van het eiwit dat van belang is, zelfs 
in niet-delende cellen. 
In Hoofdstuk 2 van dit proefschrift beoordeelden we de algemene eigenschappen en 
voordelen van RNA als een therapeutische modaliteit. Bovendien hebben we 
gesproken over de specifieke attributen, beperkingen en voordelen van niet-
gemodificeerde, gemodificeerde en zelf-replicerende mRNA platformen. Voorts geeft 
dit hoofdstuk ook inzicht in de instabiliteit van de mRNA-molecule en strategieën om 
de efficiëntie van de transfectie van in vitro getranscribeerde (IVT) mRNA te 
verbeteren. Eerst hebben we besproken hoe de opname van gemodificeerde 
nucleotiden, zoals 5-methylcytidine (m5C) of pseudouridine (Ψ), de halfwaardetijd en 
de translatie van IVT mRNA kan verhogen alsook de immunogeniciteit kan verlagen, 
indien nodig. Bovendien geeft dit hoofdstuk een diepgaand overzicht van de 
verschillende technieken en non-virale afgiftesystemen voor intracellulaire levering 
van mRNA, waaronder elektroporatie, gene-gun injectie en lipo- of poly-plex 
gebaseerde methoden, die door ons en andere groepen geëxploiteerd werden, vooral 
ten behoeve van mRNA-gebaseerde vaccinatie. 
In Hoofdstuk 3 van dit proefschrift vergeleken we experimenteel pDNA- en mRNA-
gebaseerde strategieën voor heterologe genexpressie met behulp van kationische 
liposomen als afgiftesysteem. We hebben aangetoond dat een transfectie van 
menselijke long adenocarcinoom cellen met mRNA complexen in veel snellere 
expressie resulteerde in vergelijking met pDNA complexen. Terwijl de werkzaamheid 
van mRNA complexen onafhankelijk van de celcyclus is, resulteren pDNA complexen 
in zwakke expressie in niet-delende cellen. Deze gegevens tonen dus aan dat de 
nucleaire barrière een cruciaal obstakel is voor pDNA, maar niet voor mRNA. Toen 
mRNA en pDNA complexen die firefly luciferase codeerden echter intranasaal in de 
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longen van muizen toegediend werden, zorgden enkel de pDNA complexen voor het 
ontstaan van een detecteerbaar bioluminescent signaal. Dit komt waarschijnlijk, ten 
minste gedeeltelijk, door de verschillen in de stabiliteit van de mRNA complexen. We 
hebben namelijk aangetoond dat mRNA complexen minder stabiel zijn in biologische 
vloeistoffen, vergeleken met pDNA complexen. Zoals beschreven in het volgende 
hoofdstuk (Hoofdstuk 4), is de aangeboren immuunrespons van de cellen in de 
muizenlong echter waarschijnlijk ook een belangrijke oorzaak van de verminderde 
expressie van mRNA. Desalniettemin toonden deze resultaten de functionele 
beperkingen van de traditionele ongemodificeerde mRNA platformen, wat ons 
aanspoorde om een meer stabiel en efficiënt mRNA platform te ontwikkelen voor 
zoogdiercellen toepassingen, zoals wij beschreven in Hoofdstuk 5. 
In Hoofdstuk 4 hebben we getoond dat carrier-gemedieerde levering van mRNA de 
TLR3 signalering kan activeren in de longcellen. Carrier-gemedieerde afgifte van 
mRNA veroorzaakte in vitro zowel als bij muizen, na intranasale indruppeling, een 
activering van het aangeboren immuunsysteem, wat gepaard ging met een massale 
productie van immuunstimulerende cytokinen, zoals IL-6 en TNFα. Daarnaast werd 
een significante overexpressie van IL-12, typisch voor immuuncellen, in muriene 
longen gedetecteerd 24 uur na de toediening van mRNA complexen. Dit zou een 
betrokkenheid suggereren van de antigen-presenterende cellen (APC's) aanwezig in 
de longen, zoals dendritische cellen (DCs) of overvloedig aanwezige macrofagen, die 
de toegediende mRNA complexen fagocyteren en adaptieve immuunreacties 
aansturen. Bovendien wijzen de gegevens erop dat de erkenning van mRNA door het 
aangeboren immuunsysteem ook geassocieerd is met celdood, wat in menselijke 
ademhalingscellen via pyroptosis verloopt, een vorm van geprogrammeerde celdood 
gemedieerd door overexpressie van caspase-1. Dit geeft aan dat het getransfecteerde 
mRNA waarschijnlijk ook de NOD-achtige receptoren activeert die caspase-1 
reguleren. Tot slot hebben we getoond, dat de erkenning van het geleverde 
ongemodificeerde mRNA door het aangeboren immuunsysteem een negatief effect 
had op de translatie van mRNA door het vergelijken van de dubbele gemodificeerde 
5-methylcytidine en pseudouridine (m5C/Ψ) mRNAs, die het aangeboren 
immuunsysteem ontwijken. 
Tenslotte, in Hoofdstuk 5 van dit proefschrift, de ervaringen uit de voorbije twee 
hoofdstukken indachtig, verbeterden we het state-of-the-art gemodificeerde RNA 
expressie platform. We hebben namelijk ontdekt dat de incorporatie van N1-
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methylpseudouridine (m1Ψ) in mRNA voor een sterkere en constante genexpressie 
zorgt, in vergelijking met pseudouridine (Ψ)-gemodificeerde mRNA. De impact van 
deze wijziging op de omvang en duur van genexpressie, cellulaire levensvatbaarheid 
en de aangeboren immuunrespons werd in vitro bestudeerd op verschillende celtypes 
maar ook in vivo in muizen. Terwijl endocytose-afhankelijke afgifte (lipofectie) van 
ongemodificeerd mRNA overexpressie van TLR3 veroorzaakte in respiratoire cellen, 
resulteerde de elektroporatie van mRNA in dezelfde celtypen in een verminderde 
aangeboren immuunrespons en minder in vitro cytotoxiciteit. 
Toch hebben de mRNA geneeswijzen nog steeds beperkingen waar we van bewust 
zijn en waarnaar er in de toekomst verder onderzoek moet worden gevoerd. Dat is de 
redenering om onze visie en voorspelling voor mRNA’s toekomst in Hoofdstuk 
7 (Appendix A) te presenteren. Dit hoofdstuk omvat een grondige beschrijving van de 
nieuwste ontwikkelingen van de synthetische biologie waar we RNA apparaten voor 
eiwitexpressie-controle bespreken met het oog op mRNA-gebaseerde vaccinatie. 
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ABSTRACT 
 
Nucleic acid vaccines have been gaining attention as an alternative to the standard 
attenuated pathogen or protein based vaccine. However, an unrealized advantage of 
using such DNA or RNA based vaccination modalities is the ability to program within 
these nucleic acids regulatory devices that would provide an immunologist the power 
to control the production of antigens and adjuvants in a desirable manner by 
administering small molecule drugs as chemical triggers. Advances in synthetic 
biology have resulted in the creation of highly predictable and modular genetic parts 
and devices that can be composed into synthetic gene circuits with complex behaviors. 
With the recent advent of modified RNA gene delivery methods and developments in 
the RNA replicon platform, we foresee a future in which mammalian synthetic biologists 
will create genetic circuits encoded exclusively on RNA. Here, we review the current 
repertoire of devices used in RNA synthetic biology and propose how programmable 
“smart vaccines” will revolutionize the field of RNA vaccination. 
 
 
INTRODUCTION 
 
Synthetic biology is a radically new style of genetic engineering in which living 
organisms are “programmed” using genetic circuits to systematically engineer novel 
and useful biological properties. The earliest accomplishments in the field included the 
construction of simple genetic circuits such as oscillators 289 and toggle switches 290 in 
bacterial species using mathematical modeling and rational network design. Since 
then, increasingly more complex circuits have been engineered in prokaryotes as well 
as in mammalian systems using principles of synthetic biology 291-301. This process 
typically involves the top-down decomposition of the high-level behavior (sensing-
processing-actuation) of a genetic circuit followed by the physical implementation of 
the circuit via bottom-up assembly of categorized or novel biological devices with 
standardized functions 302,303. The construction of synthetic gene circuits has been 
greatly facilitated by drastic improvements in our ability to assemble large DNA 
constructs as well as by the increase in the number of well characterized devices from 
which we can build such circuits. 
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By combining regulatory devices that function according to transcriptional, translational 
or post-translational logic, we and others have created various therapeutic circuits that 
operate in mammalian systems. These include circuits that selectively kill cancer cells 
304, treat the symptoms of metabolic disorders 305-308, or profile allergies of people 309. 
An attractive area of application for such RNA circuits is the emerging field of RNA 
vaccination. While RNA-based vaccines are completely synthetic, provide 
compositional control, and cost five to ten times less to manufacture than protein-
based therapeutics 25, the creation of effective and universal nucleic acid-based 
prophylactic solutions is still challenging. Additionally, researchers aim to create 
vaccines that would simplify the process of immunization and increase accessibility 
around the globe by offering effective one-shot injections, as booster injections can 
pose a challenge to communities with limited means of access to vaccination clinics. 
We propose here that “smart vaccines” with programmable adjuvant expression and 
prime-boost behavior could provide a solution to these problems. 
 
 
Devices for post-transcriptional gene regulation 
 
Devices that can be used in RNA-based genetic circuits include: RNA binding proteins 
(RBPs), synthetic riboswitches, devices that modulate the RNAi machinery, devices 
that modulate protein stability and devices that sense the environment (see Table 7.1). 
Some of these devices, including a few widely used RBPs and their cognate binding 
motifs, were transferred from other species (e.g. phage, archaea and bacteria) in their 
original form into mammalian systems, whereas others such as aptamers were 
engineered from scratch. The majority of these devices function by inhibiting 
translation initiation or inducing RNA degradation. 
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Device Origin Function(s) 
(Potential) vaccine 
application 
Ref. 
RNA binding proteins 
L7Ae Archaeoglobus 
fulgidus 
 Translational 
regulation 
 ON/OFF switch for 
expression of 
antigens and 
adjuvants 
310-313 
   RNP nanostructure  Immunomodulation 314,315 
   shRNA processing 
regulation 
 Immunomodulation 316 
MS2-CP Bacteriophage 
MS2 
 Translational 
regulation 
 ON/OFF switch for 
expression of 
antigens and 
adjuvants 
317,318 
TetR E. coli  Translational 
regulation 
 ON/OFF switch for 
expression of 
antigens and 
adjuvants 
319-322 
   RNA-localization 
regulation 
 Immunomodulation 323 
PUF Eukaryotes  Splicing regulation  Cell fate regulation of 
immune cells 
324 
   RNA cleavage  ON/OFF switch for 
expression of 
antigens and 
adjuvants 
325 
   Translational 
regulation 
 ON/OFF switch for 
expression of 
antigens and 
adjuvants 
326-330 
Synthetic riboswitches 
Aptamer Synthetic  Translational 
regulation 
 ON/OFF switch for 
expression of 
antigens and 
adjuvants 
331-340 
   Splicing regulation  Cell fate regulation of 
immune cells 
341-343 
   Viral RNA 
replication 
regulation 
 ON/OFF switch of 
vaccine circuit 
344 
   shRNA processing 
regulation 
 Immunomodulation 345,346 
   Receptor targeting  Immunomodulation, 
antigen delivery to 
APCs and de novo 
antigen presentation 
347,348* and 
reviewed in 
349* 
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Aptazyme Synthetic  Translational 
regulation 
 ON/OFF switch of 
vaccine circuit 
350-354 
   shRNA processing 
regulation 
 Immunomodulation 355 
RNAi modulators (other than those listed above) 
Oligonucleotide Synthetic  Drosha inhibition  Immunomodulation 356 
Small molecule Synthetic  Dicer or Drosha 
inhibition 
 Immunomodulation 357 
miRNA 
sponges 
Synthetic  Endogenous 
miRNA 
sequestration 
 Immunomodulation 358 
Protein (de)stabilization domains 
DD Synthetic  Protein stability 
regulation 
 Immunomodulation 359-362 
LID Synthetic  Protein stability 
regulation 
 Immunomodulation 363 
Sensors 
miRNA 
target site 
Synthetic  miRNA sensing  Cell type specific 
vaccine circuit 
activation 
304,364-367 
mRNA strand 
displacement 
Synthetic  mRNA sensing  Cell type specific 
vaccine circuit 
activation 
368 
Protein 
aptamer 
Synthetic  Protein sensing  Detection of immune 
cell activity 
369 
Kinase 
translocation 
reporter 
Synthetic  Kinase activity 
sensing 
 Detection of immune 
cell activity 
370 
*References in which devices were used for vaccination. 
RNP: ribonucleoprotein; shRNA: short hairpin RNA; TetR: Tet repressor; PUF: Pumilio and FBF homology; APC: 
Antigen presenting cell; RNAi: RNA interference; miRNA: microRNA; DD: destabilizing domain; LID: ligand-induced 
degradation. 
 
Table 7.1. Devices for post-transcriptional gene regulation. 
 
 
However, other devices may regulate splicing, modulate innate immune activation, 
control protein stability or act as an interface module between the environment and 
other regulatory devices. Figure 7.1 provides a summary of the representative 
mechanisms by which these devices function. 
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Figure 7.1. Devices for post-transcriptional gene regulation and their modes of action. 
Operation of (A) RNA binding proteins, (B) aptamers (C) aptazymes and (D) 
destabilizing domains. 
m7G: 7-methyl-guanosine; ORF: open reading frame; AAAn: poly(A) tail; RBP: RNA 
binding protein; DD: destabilizing domain. 
 
 
Apart from the advantages discussed above, post-transcriptional devices have 
additional benefits such as their fast response time (they directly modulate the 
expression of proteins) and their resource-friendliness (they bypass the use of cellular 
metabolites and energy involved in transcription). Furthermore, RNA-based devices 
can be versatile compared to DNA as they can carry the information of a protein output 
as well as form three-dimensional structures with enzymatic activities 371 or even 
rearrange into higher order assemblies 372. However, general disadvantages of RNA 
include its inherent instability and immunogenicity, although moderate levels of innate 
immune stimulation by the RNA may be beneficial for certain applications such as 
cancer vaccination. In the following sections, we discuss in more detail the properties 
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of these RNA encoded devices and how they have been used to regulate RNA related 
processes. 
 
RNA binding proteins 
 
Many RNA binding protein (RBP)-based devices discussed in this section function by 
inhibiting translation initiation. Thermodynamically stable secondary structures within 
the 5’ UTR of an mRNA have been shown to be inhibitory for translation 373. Thus, this 
provides an opportunity for RBPs to regulate translation by binding to the 5’ UTR of 
mRNAs to prevent scanning of ribosomes through steric hindrance, secondary 
structure formation or both. 
 
L7Ae 
 
The archaeal ribosomal protein L7Ae binds with high affinity to RNA motifs known as 
kink-turns (K-turns) and K-loops 374,375. L7Ae was first used to regulate translation by 
Saito and colleagues who inserted a K-turn motif into the 5’ UTR region of a reporter 
gene in HeLa cells 310. Similarly, insertion of the K-loop motif, which binds L7Ae with 
slightly lower affinity, can also be inserted into the 5’ UTR of a gene for repression 311. 
The level of repression by L7Ae can be increased by positioning the K-turn or K-loop 
motifs closer to the 5’ end of the mRNA or by increasing the number of motifs inserted 
into the 5’ UTR 312. The L7Ae/K-turn system can also be inverted to an ON switch by 
coupling it with the nonsense-mediated decay (NMD) pathway in which mRNAs with 
premature termination codons (PTCs) are rapidly degraded 313. This ON switch was 
created by inserting an NMD “bait ORF” with PTCs upstream of an IRES and a reporter 
gene. While this mRNA is normally rapidly degraded by NMD, if the bait ORF is 
translationally repressed by L7Ae, then the PTCs are no longer recognized by the NMD 
pathway. Thus, the mRNA remains intact, and the reporter gene can be translated. 
L7Ae can also be used to create interesting ribonucleoprotein (RNP) nanostructures 
with therapeutic potential 314,315. Binding of L7Ae to a K-turn motif is known to bend the 
RNA at an angle of ~60º 376. Saito and colleagues used this property to design an 
equilateral triangular RNP nanostructure containing a dsRNA circle with three K-turn 
motifs bound by three L7Ae proteins. Formation of the triangular structure was 
confirmed by atomic force microscopy (AFM) 314. Formation of this RNP nanostructure 
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provides enhanced stability to the RNA when incubated in serum 315. By incorporating 
a fusion protein between L7Ae and a HER2 receptor affibody (a 6 kDa engineerable 
three-helix peptide affinity motif) into the triangular nanostructure labeled with Alexa-
647, the RNP was able to function as a detector of HER2-positive cancer cells. Finally, 
when the RNA strands in the nanostructure were redesigned so that three siRNA 
modules would protrude perpendicularly from the sides of the triangular RNP, the 
siRNA modules were able to undergo processing by Dicer and reporter gene 
expression was knocked-down in HeLa cells 315. 
 
MS2 coat protein 
 
The coat protein of the MS2 RNA bacteriophage (MS2-CP), in its native context, is a 
bifunctional protein which may exist in one of two distinct higher-order structures. 
When MS2-CP aggregates, it becomes the bacteriophage capsid, which functions to 
encapsulate and protect the bacteriophage genome. However, when MS2-CP forms 
an anti-parallel homodimer, it binds a stem loop region within its genomic RNA that 
contains the start codon of the MS2 replicase gene, thereby inhibiting translation of the 
gene. As expression of MS2-CP is tolerated well in eukaryotic cells, the MS2-CP/stem 
loop system has been used extensively in the field of RNA biology to tether and study 
the effect of a protein of interest on reporter RNAs (reviewed in 377). MS2-CP is also 
capable of directly affecting various eukaryotic RNA processes via steric hindrance. 
Hentze and colleagues targeted MS2-CP to the 5’ UTR of a reporter gene in HeLa 
cells and achieved ~16-fold repression of gene expression 317. Repression was strictly 
translational as the abundance of the reporter mRNA was not affected by MS2-CP 
binding as shown by Northern blotting and a primer extension assay. Smolke and 
colleagues recruited MS2-CP to various locations within the introns of a three exon-
two intron mini gene RNA and showed that the inclusion/exclusion rate of the middle 
exon can be increased or decreased depending on where MS2-CP was recruited to 
378. Modulation of the splicing pattern was speculated to be due to decreased binding 
of spliceosome components or trans-acting splicing factors through steric hindrance or 
by recruitment of such factors by MS2-CP. 
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TetR 
 
The E. coli Tet repressor (TetR) protein and the various TetR fusion proteins (e.g. 
tetracycline-controlled transactivator: tTA 379 and reverse tetracycline-controlled 
transactivator: rtTA 380) are arguably the most commonly used regulatory devices for 
creating synthetic gene circuits on DNA. Recently, the Suess group and Niles group 
performed SELEX (Systematic evolution of ligands by exponential enrichment 381,382) 
and independently identified RNA aptamers that tightly bound TetR (Kd in the low nM 
range in the absence of tetracycline derivatives) 319-321. The aptamers shared a similar 
stem loop structure with two stems and an inner loop. The inner loop portion of the 
identified aptamers contained conserved sequence motifs that were shown to directly 
interact with the TetR protein using in-line probing 319. It was shown using site-
directed mutagenesis that, not surprisingly, the aptamer binding domain of the TetR 
protein was located within the DNA binding domain of TetR (the N-terminal helix-turn-
helix motif). Using rational design and functional testing, the Niles group engineered 
a minimal TetR aptamer that could repress translation when placed in the 5’ UTR of 
several genes in S. cerevisiae in the presence of TetR 322. Translational repression 
was relieved when a tetracycline derivative such as doxycycline was added to the 
culture media. Thus this system provides a general mechanism for small molecule 
regulated control of gene expression using an RNA binding protein. 
 
PUF proteins 
 
The Pumilio and FBF homology (PUF) proteins are a family of highly conserved 
eukaryotic translational regulators that play a role in a wide array of processes 
including differentiation, mitochondrial biogenesis, cell cycle regulation and memory 
formation (reviewed in 383). In the native context, PUF proteins are recruited to the 3’ 
UTRs of target mRNAs through their RNA binding domains (Pumilio homology domain: 
PUM-HD). By doing so, PUF proteins exert their effects as repressors or activators by 
interacting with or influencing the binding of other proteins such as decapping 
enzymes, deadenylases and possibly poly(A)-polymerases 383. The RNA binding 
PUM-HD consists of eight α-helical PUM repeat motifs which assemble into a “half-
doughnut” shaped structure 384. PUF proteins are attractive targets for engineering due 
to their highly modular nature: each of the eight PUM repeats within a PUM-HD 
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recognizes a single nucleotide base of an RNA sequence according to a simple RNA 
recognition “code” 385. Thus, using this code, it is possible in theory to engineer PUF 
proteins that target any arbitrary eight-nucleotide RNA sequence. Wang and 
colleagues demonstrated the potential for using PUF proteins as targeting domains for 
regulation of RNA related processes by fusing them to glycine-rich splicing repressors 
and arginine/serine-rich splicing activators 324. When targeted to specific exons, these 
PUF-splicing activator/repressor fusion proteins were capable of 
promoting/suppressing exon skipping or influencing alternative splicing of reporter 
mRNAs in 293T cells. Strikingly, by engineering PUF-splicing repressor fusion proteins 
that bind to an exon within the cancer related Bcl-X pre-mRNA, the authors were able 
to facilitate splicing of the pro-apoptotic Bcl-xS isoform of the mRNA. This induced 
apoptosis of the HeLa, MDA-MB-231 (breast cancer) and A549 (lung cancer) cell lines. 
Subsequently, Wang and colleagues also fused a RNA endonuclease to a PUF protein 
to create synthetic RNA “restriction enzymes” 325. Wickens and colleagues 
demonstrated the use of PUF-deadenylase or poly(A) polymerase fusion proteins for 
downregulation or upregulation of reporter/endogenous gene expression in Xenopus 
oocytes 326 and human cells 327. Similarly, Schaffer, Kane and colleagues repressed 
translation of reporter genes by using PUF to cause steric hindrance or activated 
translation by recruitment of a PUF-eIF4E (i.e. an eukaryotic translation initiation 
factor) fusion protein 328. Furthermore, by connecting eIF4E and PUF to CRY2 and 
CIB1 (components of a light inducible heterodimerization system) the authors were 
able to activate translation of a reporter gene using light. Other efforts to facilitate the 
use of PUF proteins as RNA devices include work from Zhao and colleagues who 
created a PUM repeat library for high-throughput cloning of synthetic PUF proteins 329 
using Golden Gate cloning 386 and work from Rackham and colleagues who 
engineered synthetic PUF proteins with 16 PUM repeats to increase targeting 
specificity 330. 
Another family of RNA binding proteins with great engineering potential is the 
pentatricopeptide repeat (PPR) protein family. PPR proteins are highly modular RNA 
binding proteins made up of an array of 2-30 modular PPR repeats. Like the PUM 
repeats of PUF proteins, each PPR motif can recognize a base of one nucleotide within 
a target RNA sequence. While the underlying RNA recognition code for PPR proteins 
was only recently elucidated 387,388, the potential for using PPR proteins as versatile 
tools for manipulating RNA has been recognized and reviewed elsewhere 389. 
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Synthetic riboswitches 
 
Natural riboswitches, frequently found in bacteria, are RNA based molecular switches 
with a defined three-dimensional structure that undergo conformational changes upon 
intracellular metabolite binding and affect the outcome of specific biological processes 
including transcription, translation, and RNA processing (reviewed in 390). Unlike most 
other RNA based regulators, riboswitches do not require additional protein factors to 
sense metabolites of interest or influence downstream biological processes. Synthetic 
riboswitches work in a similar manner except that they have been artificially engineered 
by combining synthetic small molecule binding aptamers with various RNA devices 
such as ribozymes. Thus by creating synthetic riboswitches that respond to non-toxic 
exogenous small molecules, orthogonal control of RNA based processes can be 
achieved. 
 
Engineering small molecule binding aptamers 
 
RNA aptamers are short highly structured RNA motifs that can bind with high affinity 
and selectivity to specific ligands. Using SELEX, hundreds of aptamers that can bind 
to a wide variety of molecules such as metal ions, nucleotides, carbohydrates, amino 
acids, peptides, proteins, and antibiotics have been engineered (reviewed in 391). 
However, while SELEX has been successful in discovering aptamers that bind to 
molecules of interest in vitro, very few of these aptamers can be engineered into 
riboswitches that function in vivo. Recently, Suess and colleagues compared the 
thermal stability and conformation of various neomycin-binding aptamers (some that 
are functional in vivo and others that are non-functional) in the presence or absence of 
ligand using UV melting analysis and NMR 331. Indeed, they found that high ligand-
binding affinity and thermal stability upon ligand binding is required but not sufficient 
for the aptamer to serve as a functional switch. Instead they showed that the functional 
aptamers are those that have a destabilized basal unbound state and undergo 
extensive conformational changes upon ligand binding. Another issue related to the 
use of aptamers is the often cytotoxic high ligand concentration required for regulatory 
activity. It has been speculated that this may be due to discrepancies between the 
intracellular environment and the experimental conditions of SELEX 392. For instance, 
folding or accessibility of an aptamer may be disrupted by RBPs inside a cell or the 
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ionic concentrations in vivo may be different from SELEX conditions. Thus, ultimately, 
to engineer an aptamer that functions in vivo, functional screening must be performed 
in cells 332. 
 
Non-catalytic synthetic riboswitches 
 
Despite the challenges described above, aptamers have been used successfully to 
modulate cellular processes. Green and colleagues inserted an aptamer for Hoechst 
33258 upstream of a beta-galactosidase reporter gene and showed that small 
molecule dependent repression can be achieved in eukaryotic cells using aptamers 
333. Subsequently, Pelletier and colleagues definitively demonstrated this concept in 
wheat germ extracts and Xenopus oocytes by inserting aptamers for biotin or 
theophylline in the 5’ UTR of reporter genes 334. Translational inhibition was due to 
reduced 40S ribosome complex binding as well as 80S ribosome complex assembly. 
Similarly, Suess and colleagues developed a synthetic riboswitch that responded to 
the cell permeable and non-toxic small molecule tetracycline 335. The tetracycline 
riboswitch functioned in a dose and position dependent manner by blocking 43S 
initiation complex formation when inserted in the proximity of the cap or by blocking 
ribosome scanning when positioned close to the AUG initiation codon 335,336. The 
strength of repression increased as more aptamers were inserted in the 5’ UTR 337. 
Smolke and colleagues rationally designed trans-acting RNA sequences termed 
“antiswitches” that hybridized to regions encompassing the initiation codon of a 
reporter mRNA in yeast 338. These antiswitches contained aptamer domains and were 
designed so that the portion of the antiswitch that hybridizes to the reporter mRNA 
would only be exposed upon small molecule binding to the aptamer. They were able 
to engineer antiswitches that repressed reporter gene translation in the presence of 
theophylline or tetracycline. Furthermore, they were also able to design an “on” 
antiswitch that responded to theophylline in the reverse manner (repressed translation 
in the absence of theophylline). More recently, using a rational design approach, 
Ogawa showed that internal ribosome entry site (IRES) mediated translation can also 
be regulated with small molecules using a theophylline aptamer 339. Ogawa 
accomplished this using a Plautia stali intestine virus (PSIV) IRES by first inserting an 
anti-IRES (aIRES) sequence within the IRES that forms an aberrant hybrid and 
disrupts its function. He then inserted an anti-anti-IRES (aaIRES) sequence into the 
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IRES so that the aaIRES hybridizes with the aIRES and restores the function of the 
IRES. Finally, he inserted an aptamer between the aIRES and aaIRES so that in the 
presence of theophylline, the aIRES-aaIRES hybrid will preferentially form, thereby 
facilitating theophylline dependent translation from an IRES. Ogawa has also 
modulated a phenomenon known as “ribosome shunting” observed in certain viruses 
such as the cauliflower mosaic virus (CaMV). Ribosome shunting is a process by which 
a ribosome translates an upstream short ORF (sORF) and is then shunted to a 
downstream ORF (dORF) after encountering a properly positioned rigid stem structure. 
By modifying the CaMV 35S RNA and replacing the rigid stem structure with a 
theophylline aptamer, Ogawa achieved ~14 fold induction of a reporter dORF in a 
theophylline dependent manner 340. 
Aptamers have also been used to regulate RNA related processes other than 
translation in a small molecule dependent manner. Gaur and colleagues showed in 
vitro that a theophylline aptamer inserted near a 3’ splice site of a pre-mRNA can inhibit 
splicing 341 and that one inserted near the branch point can inhibit splicing in vitro or in 
vivo 342 in a theophylline dependent manner. Similarly, Suess and colleagues 
demonstrated that a tetracycline aptamer positioned near the 5’ splice site of a pre-
mRNA in yeast inhibited splicing in a tetracycline dependent manner 343. The 
theophylline aptamer has also been used to control the replication of the positive strand 
RNA virus, tombusvirus. By replacing a stem loop structure whose stability is required 
for replication with a theophylline aptamer, White and colleagues were able to induce 
replication of the viral RNA by ~10-fold using theophylline 344. 
Finally, Fussenegger and colleagues created an aptamer that was a fusion between 
the TetR aptamer (that binds the TetR protein) described above and a theophylline 
aptamer 393. This TetR-theophylline fusion aptamer enabled proper folding of the TetR 
aptamer portion only when the theophylline aptamer portion was stabilized by 
theophylline. This fusion aptamer enabled disruption of tTA mediated transcriptional 
activation in a theophylline or doxycycline dependent manner, by inhibiting tTA binding 
to the promoter of a reporter gene by blocking the DNA binding domain with the TetR 
aptamer (by theophylline administration) or by inducing a conformational change in the 
structure of TetR (by doxycycline administration), respectively. In theory, this fusion 
aptamer could also be used to regulate TetR mediated translational regulation of a 
reporter RNA using two small molecule inputs. 
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Aptazymes 
 
Another type of synthetic riboswitch, which combines small molecule sensing and 
cleavage of RNA, is the aptazyme. Aptazymes are allosteric ribozymes that undergo 
self-cleavage based on whether or not a small molecule is bound to the aptamer 
domain. The first aptazyme was created by Breaker and colleagues who modified a 
minimal hammerhead ribozyme (a ribozyme which consists of an 11 nucleotide 
conserved core sequence flanked by three stem regions) by replacing stem II of the 
ribozyme with an aptamer that binds ATP 394. Depending on the “connector” sequence 
between the aptamer and core region of the aptazyme, ATP binding to the aptamer 
either inhibited or induced self-cleavage activity presumably by causing steric 
hindrance or stabilizing folding of the aptazyme, respectively. However, activity of a 
minimal hammerhead ribozyme requires a Mg2+ concentration much higher than that 
inside a cell. Thus for intracellular operation, the full-length hammerhead ribozyme 
which contains additional sequence elements that stabilize folding of the structure 
through tertiary interactions must be used 395. Smolke and colleagues modified a 
hammerhead ribozyme from tobacco ringspot virus (TRSV) satellite RNA to create 
such an aptazyme that could function in yeast. Theophylline or tetracycline aptamers 
were embedded within loop II of the ribozyme so that binding of a small molecule to 
the aptamer would either disrupt or facilitate the proper formation of loop II and 
influence folding of the entire aptazyme. The aptamer sequences were rationally 
designed so that the aptazyme would be turned ON or OFF upon ligand binding via 
“strand-displacement” or “helix-slipping” based mechanisms. Insertion of these 
aptazymes into the 3’ UTR of an mRNA enabled small molecule induction of gene 
expression in yeast 350. Subsequently, by inserting two ON or OFF aptazymes that 
respond to different or identical small molecule inputs in the 3’ UTR of a reporter 
mRNA, the authors were able to regulate reporter gene expression according to AND 
or NOR logic using theophylline and tetracycline 351. They were also able to induce 
reporter gene expression when theophylline was within a certain concentration range 
but not higher or lower that that range (bandpass filter). Furthermore, by 
simultaneously inserting two different aptamers in loop I and loop II of the same 
hammerhead ribozyme or by connecting two aptamers in tandem in loop II, NAND or 
OR logic gates were, respectively, created. More recently, Hartig and colleagues 
created a theophylline responsive aptazyme based on the Schistosoma mansoni 
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hammerhead ribozyme that functions as an OFF switch in mammalian cells 352, and 
Smolke and colleagues adapted their TRSV hammerhead aptazymes to engineer T 
cells by expressing IL-2 or IL-15 in a small molecule dependent manner in mice 353. 
Finally, most recently, Yokobayashi and colleagues created a genomic hepatitis delta 
virus (HDV) aptazyme OFF switch which can repress reporter gene expression ~30-
fold in mammalian cells upon guanine administration 354. 
 
RNAi modulation 
 
Since its original discovery over two decades ago, RNA interference as a technology 
has transformed into one of the most predictable and effective tools to silence gene 
expression (reviewed in 396). Most commonly, RNAi based silencing is induced by 
either delivery of small interfering RNA (siRNA) duplexes which consist of ~20-30 
nucleotide long RNAs characterized by perfect base-pairing or in the form of primary 
miRNAs (pri-miRNAs; long single RNA molecules which contain characteristic stem 
loop structures) or short hairpin RNAs (shRNAs; engineered single RNA molecules 
which consist of minimal stem loop structures that resemble either pri-miRNAs or 
precursor miRNAs [pre-miRNAs] with perfectly base-paired stems) expressed from a 
vector. The unique stem loop structures of pri-miRNAs can be divided into four modular 
domains: the terminal loop, the upper stem, the lower stem, and the basal segments 
(5’ and 3’ single stranded RNA regions) 397. Whereas siRNA duplexes are loaded 
directly onto the RNA induced silencing complex (RISC) with the “guide strand” 
retained by RISC as siRNA, pri-miRNAs and shRNAs must first undergo processing 
by the endogenous miRNA biogenesis machinery. Pri-miRNA stem loop structures are 
first recognized by the Microprocessor complex (Drosha/DGCR8) and then cleaved 
between the upper and lower stems to produce pre-miRNAs. Subsequently, the Dicer 
endonuclease recognizes the pre-miRNA structure and clips off the terminal loop 
region from the pre-miRNA. Finally, the miRNA duplex (typically containing a 1 bp 
mismatch or “bulge”) originating from the upper stem region of the miRNA is loaded 
onto RISC, and the guide strand is selected as the mature miRNA to silence its target 
mRNA (reviewed in 398). 
Relatively recently, several groups have engineered regulatory devices based on 
aptamers, aptazymes and RBPs, or have just used small molecules to regulate gene 
expression by modulating shRNA or miRNA processing. Yokobayashi and colleagues 
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replaced the loop region of an shRNA with a theophylline aptamer and showed that 
processing of shRNA by Dicer was inhibited upon administration of theophylline, 
preventing Dicer mediated generation of siRNAs in HEK293 cells using theophylline 
inhibited reporter gene silencing (ON switch) 345. Subsequently, Yokobayashi’s group 
attached a theophylline aptazyme (a hammerhead ribozyme derived from 
Schistosoma mansoni with an aptamer inserted into stem III) to the 5’ end of an shRNA 
so that Drosha processing of the shRNA would be inhibited due to base paring in the 
5’ portion of the basal segment. Upon theophylline administration to HEK293 cells 
expressing this aptazyme-shRNA fusion, the aptazyme cleaved itself away from the 
shRNA thus enabling production of an siRNA duplex and knockdown of reporter gene 
expression (OFF switch) 355. Similarly, the same group attached a stem loop structure 
to an shRNA to prevent Drosha processing but this time dissolved the base pairing of 
the stem and enabled processing by transfecting a modified oligonucleotide that 
competes with the stem. Using this oligonucleotide induced OFF switch, they 
demonstrated reporter and endogenous gene knockdown in HEK293 cells 356. Smolke 
and colleagues also modulated Drosha processing by inserting aptamers into the basal 
region of an shRNA. They showed using three aptamers (theophyline, tetracycline, 
and hypoxanthine) that small molecule binding to the aptamers inhibited shRNA 
processing by Drosha and prevented knockdown of reporter genes (ON switch) 346. 
Saito and colleagues replaced the terminal loop of an shRNA with a K-turn motif and 
demonstrated that steric hindrance caused by L7Ae binding to the terminal loop can 
prevent siRNA processing by Dicer 316. They used this ON switch to control reporter 
genes as well as expression of the pro-apoptotic Bim and anti-apoptotic Bcl-xL genes 
to regulate cell fate. Disney and colleagues used a computational approach termed 
Inforna to predict that a heterocyclic aromatic compound benzimidazole may bind the 
Drosha cleavage site of miR-96, a miRNA upregulated in cancer, and prevent 
processing 357. Briefly, the Inforna pipeline uses a combination of experimentation and 
computation to identify RNA sequence motifs that may bind small molecule 
compounds of interest. The experimental part consists of a small molecule-RNA motif 
interaction screen, termed two-dimensional combinatorial screening (2DCS) 399. In 
2DCS, RNA hairpin structures with short randomized internal loops (e.g. six random 
nucleotide loops) are hybridized to small molecule ligands immobilized on an agarose 
microarray. Following gel extraction and sequencing of the RNA hairpins bound to a 
ligand of interest, the random nucleotide loop sequences are analyzed using the RNA 
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Privileged Space Predictor (RNA-PSP) program for statistically enriched motifs by 
calculating Z-statistics for each motif 400. Strikingly, when the experimentally 
determined binding affinities of RNA hairpin loops to a small molecule were plotted 
against the sum of the Z-statistics for the statistically enriched motifs identified by RNA-
PSP included within that specific internal RNA loop sequence, the data points could 
be fit well to a simple inverse first-order equation (R2 = 0.85) 401. This method termed 
Structure-activity relationships through sequencing (StARTS) was then used to 
successfully predict the binding affinities of various RNA hairpin loops (that were not 
captured by 2DCS) to the small molecule of interest. Finally, in silico folding of all 
human pri-miRNA sequences in miRBase 402 was performed using the RNAstructure 
program 403, and all secondary structural elements within the pri-miRNAs were 
extracted and queried against the 2DCS data for various small molecule compounds 
using StARTS or RNA-PSP v. 2.0 357. This Inforna platform predicted that 
benzimidazole would inhibit processing of miR-96. Indeed, when tested in primary 
cells, benzimidazole inhibited miR-96 processing by 90 %. Importantly, benzimidazole 
inhibition of miR-96 in the MCF7 cancer cell line caused upregulation in the protein 
levels of FOXO1 (Forkhead box protein O1), a target of miR-96, and induced 
apoptosis. This demonstrates the potential of this method for identifying drugs that 
could treat diseases by intervening with RNA related processes. Finally, an alternative 
way to modulate miRNA activity has been described previously by Sharp and 
colleagues who showed that miRNA target sites themselves (with perfect or mismatch 
complementarity to the miRNA), when overexpressed, could act as “sponges” that 
titrate away endogenous mature miRNAs and prevent them from degrading their 
exogenous or native RNA targets 358. 
 
Post-translational regulatory mechanisms 
 
Synthetic biology devices for RNA vaccination need not directly act on RNA but may 
function at the post-translational level. Post-translational devices are capable of 
actuating even more rapidly than devices that regulate RNA. An example of such a 
device is the destabilizing domain (DD) developed by Wandless and colleagues 359. A 
DD is comprised of a small-molecule ligand binding domain and a degron domain, 
which targets proteins for degradation in an ubiquitin and proteasome-dependent 
manner. When a DD is fused to a protein of interest, the half-life of the protein is 
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dramatically decreased. However, binding of a ligand to the DD induces a 
conformational change that masks the degron thus preventing subsequent 
ubiquitination and degradation. (De)stabilization occurs in a reversible manner, and 
the stability of the protein can be tuned by adjusting the concentration of the cognate 
ligand. The first DD developed (referred to here as DDf) was based on the human 
FKBP12 protein and was stabilized by a synthetic small molecule Shield-1 359. When 
a vaccinia virus harboring a fusion protein between DDf and the cytokine IL-2 was 
systemically delivered to tumor bearing mice, administration of Shield-1 to the mouse 
led to stabilization of IL-2 and a reduction in the size of the tumor 360. Later, DDs that 
respond to the FDA-approved small molecule drug trimethoprim (TMP) and 4-
hydroxytamoxifen (4-OHT; the active metabolite of another FDA-approved drug, 
tamoxifen citrate) were engineered using E. coli dihydrofolate reductase (DDd) and 
human estrogen receptor (DDe) 361,362. Since TMP can traverse the blood-brain barrier, 
DDd-fluorescent reporter proteins delivered to the brain of a rat using lentiviruses were 
capable of being stabilized by TMP administration. Thus, there is potential for using 
this system for clinical applications related to the brain. More recently, using the same 
FKBP protein, Wandless and colleagues developed a ligand-induced degradation 
(LID) domain, which operates in the opposite manner as a DD 363. LIDs induce 
degradation of a protein by exposing a cryptic degron upon binding of a ligand. DDs 
and LIDs are useful devices for simple protein (de)stabilization. However, another way 
to use these domains would be to fuse them to RBPs such as L7Ae, TetR and MS2 to 
regulate translation in a small molecule dependent manner as proposed later. 
 
Sensor modules 
 
Biological sensor modules sense endogenous or environmental signals such as small 
molecules, proteins, miRNAs, mRNAs, or enzymatic activity and relay information to 
other devices within a circuit. Thus, sensor modules are the interfaces between input 
signals and insulated processing modules of a circuit. For instance, Fussenegger and 
colleagues have developed sensor modules which use G protein-coupled receptors 
(GPCRs) to detect small molecules such as dopamine 308 and histamine 309 or changes 
in the pH 404 and communicate this information to downstream actuation devices 
through the cAMP signaling pathway. Smolke and colleagues adapted their MS2-CP 
based splicing modulation device described above to sense the p50 or p65 subunits 
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of NF-κB or the β-catenin protein of the Wnt signaling pathway 378. However, since 
these sensors are connected to processing modules which actuate through 
transcription of a transgene (for GPCR/cAMP signaling based sensors) or splicing, 
they cannot be directly integrated into RNA encoded circuits (at least in their current 
form). 
In contrast, one type of device that can be easily embedded into an RNA encoded 
circuit is a miRNA sensor. The basic unit of a miRNA sensor consists of a miRNA target 
site inserted into the 3’ UTR of an mRNA. Using this simple setup, Naldini and 
colleagues demonstrated the proof of concept that tissue specific miRNAs such as 
miR-142-3p could be exploited to suppress gene expression in undesirable cell types 
using a lentiviral gene therapy vector in mice 364. More recently, tenOever and 
colleagues applied the same concept to modulate the host tropism of an influenza A 
virus 365. They incorporated into the viral genome a target site for a miRNA (miR-192) 
that is differentially expressed in different host species so that transmission of a virus 
would occur in ferrets but be attenuated in mice (or humans, in theory). The concept 
of using RNAi for complex Boolean logic evaluation was demonstrated by Benenson 
and colleagues in collaboration with our group 366. In the study, logic gates were 
created by incorporating up to five different siRNA target sites into 3’ UTRs of two 
reporter mRNAs or alternatively, by incorporating siRNA target sites into lacI or lacI-
KRAB fusion repressor-encoding mRNA(s) which in turn repressed a reporter mRNA. 
Subsequently, Benenson and colleagues demonstrated that such Boolean logic gates 
can similarly be implemented in mammalian cells using artificial miRNAs embedded 
within the introns of genes regulated by transcriptional activators or repressors 367. 
Finally, Benenson and colleagues and our group created a miRNA-classifier circuit 
which “senses” the distinct miRNA expression pattern of certain types of cells and 
identifies them based on evaluation of the following Boolean logic function: miR-21 
AND miR-17/miR-30a AND NOT(miR-141) AND NOT(miR-142-3p) AND NOT(miR-
146a) 304. This was implemented using a combination of six miRNA target sites 
regulating three distinct ORFs encoding repressors, activators, and reporter or 
actuator proteins. This circuit was used to distinguish a HeLa cancer cell from a HEK 
cell and selectively kill the HeLa cell by expression of the pro-apoptotic BAX (Bcl2-
associated X protein) gene. 
Other types of sensing devices that are compatible with RNA encoded circuits include 
an mRNA sensor developed by Benenson and colleagues which was based on an 
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“RNA strand displacement” mechanism 368. In this device, input mRNA molecules 
release cryptic antisense strands of siRNAs from “protecting strand” RNAs through 
strand exchange. This results in the generation of siRNA duplexes which are loaded 
onto the RISC complex to knock-down downstream target RNAs. This mRNA sensing 
device was used to create simple Boolean logic evaluators in Drosophila extracts. 
Saito and colleagues developed an shRNA based protein sensing device which could 
potentially be integrated into RNA encoded circuits 369. In the study, structural modeling 
was used to observe the amount of steric hindrance that would be generated between 
Dicer and a protein of interest when the terminal loop of the shRNA was replaced by 
an aptamer which binds the protein of interest. Based on this information, it was 
possible to predict aptamer configurations that would maximize inhibition of Dicer 
mediated processing of the shRNA. This design process was used to create a device 
that senses the levels of the NF-κB p50 subunit in 293FT cells. Finally, Covert and 
colleagues created synthetic sensors for kinase activity dubbed “kinase translocation 
reporters” (KTRs) 370. KTRs have a modular structure which consists of a kinase 
docking site, a nuclear export signal (NES), and a nuclear localization signal (NLS). 
Phosphorylation of the NES and NLS moieties of the KTR enhances nuclear export 
and decreases nuclear localization activities, respectively. Thereby, KTRs sense 
kinase activity and communicate that information in the form of a nucleocytoplasmic 
shuttling event. KTRs were successfully engineered for the JNK, p38, ERK, and PKA 
kinases demonstrating the universality of this approach. 
 
 
RNA circuits 
 
The RNA devices discussed thus far with single inputs and outputs can be connected 
with one another to create modules with more complex behavior. A key aspect to 
consider when connecting devices is their “composability.” For instance, in order to 
directly connect device 1 (which operates in the form of: input 1 -> device 1-> output 
1) with device 2 (input 2 -> device 2-> output 2), output 1 of device 1 must be able to 
become input 2 of device 2. Thus, only devices with compatible inputs/outputs are 
considered composable. In over a decade, researchers in the field of synthetic biology 
have used composable devices to create numerous circuit modules including 
oscillators, toggle switches, and cascades. These modules can be assembled further 
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into integrated systems with more sophisticated functions. 
There are two complementary approaches by which devices can be assembled into 
modules and modules into systems: the first approach involves the rational matching 
of parts based on mathematical modeling and the other involves experimental testing 
of many circuit configurations by screening variations of individual parts. In actuality, 
gene circuit optimization cannot be accomplished solely by model-based methods and 
still involves a significant amount of experimental trial and error. While many 
sophisticated circuit modules and systems have been engineered to date, to our 
knowledge, none have been encoded entirely on RNA for use in mammalian systems. 
Although Fussenegger and colleagues used the L7Ae and MS2 devices to create 
“mammalian biocomputers” which perform programmable calculations based on NOT, 
AND, N-IMPLY, and XOR logic gates, this was done by combining transcriptional 
regulation and L7Ae/MS2 based translational repression 318. In the following section, 
we propose examples in which RNA devices could be composed into circuits and 
encoded exclusively on RNA for the purpose of vaccination. 
 
 
Synthetic gene circuits for “smart vaccination” 
 
Over the years, mRNA and replicating RNA have become well established as 
platforms for vaccination and immunotherapy (reviewed in 63-67). RNA based devices 
such as aptamers or aptazymes have also been used for immunomodulation (353 and 
reviewed in 349), cell specific targeting of antigens 347 and presentation of de novo 
antigens 348. However, such efforts to improve vaccines/immunotherapies using RNA-
based tools have thus far been limited to the use of standalone devices. Here, we 
propose how RNA-based “smart vaccines” with complex regulatory gene circuits inside 
may be used to solve unmet needs in this area, highlighting their potential as an 
enabling technology (Figure 7.2). 
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Figure 7.2. The RNA “smart vaccine” paradigm . Composable devices for post-
transcriptional gene regulation can be assembled into synthetic gene circuits in the 
form of RNA. Such RNA circuits may be used to control the expression kinetics of 
antigens and adjuvants using small molecule drugs to create potent RNA “smart 
vaccines.” 
m7G: 7-methyl-guanosine; AAAn: poly(A) tail; Gag: group-specific antigen; IL-12: 
interleukin 12; RBP: RNA binding protein; DD: destabilizing domain. 
 
 
“One-shot” vaccination 
 
The development of one-shot vaccines that do not require booster shots would be 
particularly beneficial in communities with limited means of transportation. 
Chadambuka et al. reported that a significant number of children (~35 %) drop-out from 
vaccination programs in rural Zimbabwe due to transportation barriers 405. Here we 
propose a “smart vaccine” solution to this problem in which prime-boost expression of 
an antigen can be achieved using a small molecule drug rather than a follow up 
injection of the antigen. This can be done as shown in Figure 7.3, using a replicon with 
two subgenomic promoters (SGPs) where one SGP expresses an RNA binding protein 
(RBP) fused to a DD domain and the other has a motif which binds the RBP upstream 
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of an antigen of interest. In this circuit, administration of a small molecule drug 
stabilizes DD-RBP and represses translation of the antigen. Thus, a small molecule 
can be used to suppress antigen expression, in effect, creating the prime and boost 
phases of vaccination. 
 
 
 
Figure 7.3. One-shot “smart vaccine” with small molecule enabled prime-boost. 
m7G: 7-methyl-guanosine; nsP: nonstructural protein; SGP: subgenomic promoter; 
DD: destabilizing domain; AAAn: poly(A) tail; TMP: trimethoprim. 
 
 
Multivalent cancer vaccine 
 
Intratumoral heterogeneity (the presence of many subclones of cancer cells within a 
tumor that are genetically different from one another) is one of the greatest hurdles in 
treating cancer. For cancer vaccination, heterogeneity of the tumor and the diverse 
gene expression pattern of individual cancer cells are a problem since not all cancer 
cells within a population may be targetable by immunization with a single tumor 
antigen. Thus, in order to attack and clear a heterogeneous population of cancer cells, 
it may be necessary to perform vaccination with multiple tumor antigens. However, 
induction of immune responses against multiple antigens by simultaneous 
injection/expression of antigens may be difficult for certain combinations of proteins 
due to “immunodominance”. Immunodominance causes CD4+ and/or CD8+ T cells to 
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preferentially respond to the most immunogenic epitopes and leave other epitopes 
unattended 107. Here, we propose a method to overcome this problem by creating a 
small molecule inducible sequential antigen expression cascade with additional 
adjuvant pulsing capabilities (Figure 7.4). This circuit is encoded on a replicon with 
three SGPs: the first SGP expresses DD-RBP1, the second SGP contains a binding 
motif for RBP1 and expresses RBP2 connected to Antigen 1 via a 2A “ribosome 
skipping” peptide 406 which enables co-translational separation of the antigen from 
RBP2, and the last SGP contains a binding motif for RBP2 followed by Antigen 2 fused 
to an adjuvant by a 2A peptide. In the absence of a DD-stabilizing small molecule drug, 
DD-RBP1 is degraded and allows expression of RBP2 and Antigen 1 (Antigen 2 is 
repressed by RBP2). Upon administration of the drug, DD-RBP1 is stabilized and 
represses RBP2-2A-Antigen 1 thereby allowing expression of Antigen 2 and the 
adjuvant. Here, an additional benefit of the cascade is that the potent adjuvant, which 
may be highly toxic when delivered systemically, is only expressed when the DD 
stabilizing drug is administered to the body. 
 
 
 
Figure 7.4. Multivalent cancer “smart vaccine” with small molecule induced antigen 
cascading and adjuvant pulsing. 
m7G: 7-methyl-guanosine; nsP: nonstructural protein; SGP: subgenomic promoter; 
DD: destabilizing domain; AAAn: poly(A) tail. 
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CONCLUSIONS 
 
Roughly a decade and a half has passed since the first synthetic gene circuits created 
in E. coli launched a field of research that has now come to be known as synthetic 
biology. By creating and cataloging standardized genetic parts and devices that can 
be assembled into modules and systems for reprogramming living organisms, 
synthetic biologists have transformed the field of biotechnology into a rigorous 
engineering discipline. In particular, mammalian synthetic biology has been 
experiencing rapid expansion over the past few years with successful implementations 
of genetic circuits in cell culture as well as in model organisms. However, we believe 
that mammalian synthetic biology is in fact at a crossroads. Ultimately, therapeutic 
gene circuit applications must graduate from the academic proof-of-concept phase and 
find a place in the real-world. Will mammalian synthetic biologists be able to identify 
society’s pressing needs and deliver gene circuit solutions that can withstand the public 
field test? Efforts aimed in the right direction could indeed make this happen. One 
absolute requirement for this would be that synthetic gene circuits for therapeutic 
purposes be safe. Encoding genetic circuits on RNA using the emerging modified or 
replicating RNA-based platforms rather than DNA-based platforms will greatly facilitate 
this transition. Building circuits that do not trigger unnecessary innate or adaptive 
immune responses against regulatory components of the circuit will also be necessary. 
An area of particular interest for synthetic biology applications using RNA is 
vaccination. The proven success of antigen-encoding RNA in eliciting protective 
immunity combined with the desire to control the dynamics of antigen/adjuvant 
expression to maximize an immune response makes vaccination an optimal target for 
RNA circuit applications. With the ever-expanding list of parts and devices for RNA 
regulation and our rapidly-developing ability to rationally compose devices into 
regulatory circuits, it is only a matter of time before RNA “smart vaccines” with 
programmable antigen/adjuvant circuits inside will deliver a solution to a real-world 
problem: the development of potent vaccines to protect humanity from the threats of 
infectious diseases. Both the selection of the best delivery method and the 
optimization of the mRNA molecule itself will be key to achieving these goals. Thus, 
mRNA delivery and optimization is the main topic of the experimental section of this 
dissertation. 
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Supplementary data from Chapter 3 
 
 
 
Figure SB.1. Impact of the dose of the mRNA/GL67 complexes on the cell viability. 
A549 cells were plated in 24-well plates and transfected with three different doses of 
mRNA/GL67 complexes (ratio 2), i.e. 500 ng, 750 ng and 1000 ng. Cell viability was 
assessed 24 hours after adding the complexes with an MTT assay. The impact of the 
amount of the complexes on the cellular viability was compared to untreated cells (set 
at 100 % viability). The results are presented as the mean ± SD (n=5) and considered 
significant, if p<0.05 compared to a dose of 500 ng/well (ANOVA). 
 
 
 
Figure SB.2. Comparison of the average bioluminescence after intranasal 
administration of pDNA/GL67 complexes prepared at a ratio 1.33 or 4. 80 µg of 
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pDNA/GL67 complexes prepared at a ratio 1.33 (n=4) or 4 (n=5) were given to 
anesthetized mice via intranasal instillation. 24 hours after administration the mice 
were imaged and the bioluminescent light was recorded via in vivo bioluminescence 
imaging. The data were obtained after subtracting the average bioluminescence signal 
of untreated mice (background) from the measured signals. The results are presented 
as the mean ± SD (* if p<0.05, independent-samples t-test). 
 
 
 
Figure SB.3. Visualization of the in vivo luciferase production after intrapulmonary 
delivery of pDNA/GL67 complexes prepared at ratio 4. Mice were anesthetized and 80 
µg of pDNA/GL67 complexes prepared at ratio 4 were administered intranasally. 24 
hours after instillation the mice were imaged and the bioluminescent light was 
recorded via in vivo bioluminescence imaging. 
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Supplementary data from Chapter 4 
Supplementary Data CS.1. qPCR array for A549 cells 
A549 
No. Symbol Gene Name P-value 
Fold 
Change 
Control 
1 
Control 
2 
Control 
3 
Exp 
1 
Exp 
2 
Exp 3 
1 CXCL10 
chemokine (C-X-C 
motif) ligand 10 
0.000043 4147.88895 40.0 40.0 40.0 26.6 26.2 26.6 
2 IFNA interferon. alpha 0.000046 653.224346 40.0 40.0 40.0 29.2 29.2 30.0 
3 CCL4 
chemokine (C-C 
motif) ligand 4 
0.000126 99.565208 40.0 40.0 40.0 32.3 32.2 32.9 
4 IRF7 
interferon regulatory 
factor 7 
0.000135 140.165855 33.7 33.0 33.0 24.8 25.2 25.7 
5 CCL3L1 
chemokine (C-C 
motif) ligand 3-like 1 
0.000164 83.408367 40.0 40.0 40.0 32.7 32.6 32.9 
6 IFNB interferon. beta 0.000184 6421.932725 37.2 38.1 37.1 23.1 22.8 23.6 
7 PTX3 pentraxin 3. long 0.000208 67.379841 40.0 40.0 40.0 32.9 32.8 33.6 
8 SOCS1 
suppressor of 
cytokine signaling 1 
0.000232 42.290321 34.8 33.6 33.7 27.8 27.7 28.2 
9 CCL5 
chemokine (C-C 
motif) ligand 5 
0.000494 8921.590778 37.0 35.5 37.1 21.8 21.6 21.6 
10 TLR3 toll-like receptor 3 0.000543 29.666660 34.4 34.0 33.5 28.7 28.1 28.4 
11 CIITA 
class II. major 
histocompatibility 
complex. 
transactivator 
0.000721 53.852692 40.0 40.0 40.0 34.1 32.9 33.4 
12 CXCL9 
chemokine (C-X-C 
motif) ligand 9 
0.000946 57.867356 40.0 40.0 40.0 33.6 32.5 34.1 
13 STAT1 
signal transducer and 
activator of 
transcription 1 
0.001335 8.006063 27.6 26.6 26.1 23.5 23.3 23.1 
14 IRAK2 
interleukin-1 
receptor-associated 
kinase 2 
0.002049 4.767101 30.8 30.2 30.0 27.9 27.4 27.8 
15 IRF1 
interferon regulatory 
factor 1 
0.002101 22.515945 34.0 32.9 32.5 27.6 28.4 28.2 
16 MYD88 
myeloid 
differentiation 
primary response 
gene (88) 
0.002460 5.499716 31.1 30.1 29.7 27.4 27.4 27.5 
17 IL6 
interleukin 6 
(interferon. beta 2) 
0.002549 498.079107 38.5 40.0 40.0 29.1 28.5 29.5 
149 
 
A549 
No. Symbol Gene Name P-value 
Fold 
Change 
Control 
1 
Control 
2 
Control 
3 
Exp 
1 
Exp 
2 
Exp 3 
18 TNF  tumor necrosis factor 0.002767 26.218345 40.0 40.0 38.0 34.7 33.4 33.5 
19 CXCL11 
chemokine (C-X-C 
motif) ligand 11 
0.002870 6214.771533 40.0 37.1 40.0 24.5 24.0 24.6 
20 IL12A 
interleukin 12A 
(natural killer cell 
stimulatory factor 1. 
cytotoxic 
lymphocyte 
maturation factor 1. 
p35) 
0.003389 4.568301 31.9 31.4 31.3 29.2 28.8 28.9 
21 CASP1 
caspase 1. apoptosis-
related cysteine 
peptidase 
(interleukin 1. beta. 
convertase) 
0.004914 384.312942 40.0 37.7 36.3 28.2 27.8 27.9 
22 CD14 CD14 molecule 0.006266 -3.179524 31.0 30.9 30.8 32.6 32.6 32.6 
23 TLR5 toll-like receptor 5 0.006867 4.352891 38.4 37.7 37.7 35.9 35.6 35.0 
24 MUC1 
mucin 1. cell surface 
associated 
0.011806 3.838419 34.7 34.8 34.1 32.3 32.6 31.9 
25 RIPK2 
receptor-interacting 
serine-threonine 
kinase 2 
0.011983 2.171515 32.9 31.8 31.8 31.1 30.7 30.6 
26 TRAFD1 
TRAF-type zinc 
finger domain 
containing 1 
0.012497 2.895765 29.0 28.6 28.3 27.1 26.6 26.7 
27 JUN jun proto-oncogene 0.013613 2.801582 27.4 26.8 26.6 25.6 24.9 25.0 
28 IL12B 
interleukin 12B 
(natural killer cell 
stimulatory factor 2. 
cytotoxic 
lymphocyte 
maturation factor 2. 
p40) 
0.014185 6.074074 40.0 40.0 38.3 36.6 36.0 36.3 
29 TICAM1 
toll-like receptor 
adaptor molecule 1 
0.015880 2.711301 31.3 30.7 30.9 29.6 29.0 29.1 
30 CNPY4 canopy 4 homolog 0.028357 -2.168024 30.0 29.5 29.2 31.1 30.6 30.4 
31 TLR1 toll-like receptor 1 0.033384 2.072206 31.8 30.9 31.0 30.0 30.2 29.7 
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1 
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32 SYK 
spleen tyrosine 
kinase 
0.050492 -3.174189 33.3 32.8 32.6 35.8 34.7 33.9 
33 NFKB1 
nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 1 
0.066514 1.554369 28.7 28.0 28.0 27.7 27.2 27.3 
34 CASP8 
caspase 8. apoptosis-
related cysteine 
peptidase 
0.067561 1.565698 27.6 26.8 26.6 26.6 25.9 26.0 
35 SARM1 
sterile alpha and TIR 
motif containing 1 
0.073721 -1.576050 27.6 27.0 26.7 27.9 27.5 27.7 
36 HMGB1 
high mobility group 
box 1 
0.074022 -1.512455 22.6 22.0 21.8 22.8 22.5 22.7 
37 TRAF6 
TNF receptor-
associated factor 6 
0.085535 1.432247 31.2 30.3 30.4 30.3 29.7 29.8 
38 CSK c-src tyrosine kinase 0.105771 -1.618020 31.3 30.9 30.7 31.2 31.9 31.9 
39 MAPK14 
mitogen-activated 
protein kinase 14 
0.152713 -1.377923 26.7 25.5 25.2 26.5 25.8 26.2 
40 CD44 
CD44 molecule 
(Indian blood group) 
0.153439 1.286669 27.7 26.8 26.5 26.5 26.4 26.5 
41 IFNAR1 
interferon (alpha. 
beta and omega) 
receptor 1 
0.162236 -1418806 30.6 29.7 29.8 30.8 30.6 30.1 
42 CNPY3 canopy 3 homolog 
 
0.164228 -1.417384 28.7 28.2 27.9 29.0 28.5 28.6 
43 IRF3 
interferon regulatory 
factor 3 
0.212622 1.190294 30.0 29.6 29.6 29.2 29.4 29.6 
44 RELA 
v-rel 
reticuloendotheliosis 
viral oncogene 
homolog A 
0.217995 1.276449 26.3 25.6 25.5 25.8 25.0 25.1 
45 IRAK1 
interleukin-1 
receptor-associated 
kinase 1 
0.227287 -1.361350 24.7 24.4 23.9 25.1 24.8 24.3 
46 UNC93B1 unc-93 homolog B1 0.227421 1.162799 27.0 26.2 25.9 26.3 25.8 25.9 
47 RAC1 
ras-related C3 
botulinum toxin 
substrate 1 (rho 
family. small GTP 
binding protein 
Rac1) 
0.251392 -1.140776 22.9 22.5 22.6 22.6 22.8 22.9 
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1 
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48 CHUK 
conserved helix-
loop-helix ubiquitous 
kinase 
0.253131 -1.145409 29.8 28.6 28.4 29.3 28.7 29.1 
49 NR3C1 
nuclear receptor 
subfamily 3. group 
C. member 1 
(glucocorticoid 
receptor) 
0.262862 1.274806 27.6 26.0 26.3 26.5 26.0 26.0 
50 PYCARD 
PYD and CARD 
domain containing 
0.275406 -1.290971 35.1 34.6 34.5 34.7 35.4 35.1 
51 MAPK8 
mitogen-activated 
protein kinase 8 
0.283591 -1.224079 28.8 28.1 28.0 28.8 28.3 28.4 
52 HSP90B1 
heat shock protein 
90kDa beta (Grp94). 
member 1 
0.297204 1.163799 27.1 26.5 26.0 26.2 26.2 26.1 
53 Hs18s  18S rRNA 0.326030 -1.232284 10.1 9.7 9.7 10.2 10.0 9.9 
54 IL1B interleukin 1. beta 0.337096 2.561520 36.9 36.9 36.2 37.0 34.1 35.6 
55 IRAK4 
interleukin-1 
receptor-associated 
kinase 4 
0.338157 1.145744 31.4 30.8 30.7 30.9 30.6 30.4 
56 AKT1 
v-akt murine 
thymoma viral 
oncogene homolog 1 
0.342013 -1.222811 25.6 25.1 24.7 25.7 25.1 25.2 
57 TIRAP  
toll-interleukin 1 
receptor (TIR) 
domain containing 
adaptor protein 
0.364523 -1.232323 28.8 28.5 28.4 29.1 28.6 28.6 
58 MAP3K7 
mitogen-activated 
protein kinase kinase 
kinase 7 
0.383591 -1.153736 28.2 27.6 27.3 28.0 27.6 27.8 
59 TICAM2 
toll-like receptor 
adaptor molecule 2 
0.396223 -1.083714 26.1 25.4 25.2 25.7 25.4 25.6 
60 TOLLIP  
toll interacting 
protein 
0.400273 -1.080157 30.9 30.1 29.8 30.3 30.0 30.6 
61 MAP3K7IP1 
TGF-beta activated 
kinase 1/MAP3K7 
binding protein 1 
0.401889 -1.123047 30.2 29.5 29.4 30.1 29.6 29.6 
62 TLR4 toll-like receptor 4 0.404190 1.513449 33.7 34.3 33.1 33.3 32.1 33.7 
63 TLR6 toll-like receptor 6 0.406092 -1.129900 29.3 28.7 28.6 29.2 28.7 28.9 
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64 SIGIRR 
single 
immunoglobulin and 
toll-interleukin 1 
receptor (TIR) 
domain 
0.406340 -1.042493 25.6 25.0 25.0 25.2 25.0 25.2 
65 BCL3 
B-cell 
CLL/lymphoma 3 
0.410684 -1.084639 27.5 27.0 26.7 27.1 26.9 27.2 
66 CYLD 
cylindromatosis 
(turban tumor 
syndrome) 
0.440739 1.032445 32.6 31.7 32.0 32.3 31.7 31.9 
67 DOK1 
docking protein 1. 
62kDa (downstream 
of tyrosine kinase 1) 
0.453150 1.036219 32.7 32.2 32.3 32.4 31.9 32.3 
68 TRAF3 
TNF receptor-
associated factor 3 
0.453613 -1.066725 26.0 25.6 25.4 25.8 25.4 25.7 
69 IRF5 
interferon regulatory 
factor 5 
0.477624 -1.091689 30.8 30.6 30.3 30.7 30.5 30.5 
70 FADD 
Fas (TNFRSF6)-
associated via death 
domain 
0.483384 1.087297 31.2 30.6 30.1 30.6 30.7 30.1 
71 TBK1 
TANK-binding 
kinase 1 
0.489963 1.050130 27.0 26.6 26.4 26.9 26.2 26.3 
72 HSPD1 
heat shock 60kDa 
protein 1 
(chaperonin) 
0.492120 1.015128 24.8 24.2 23.7 24.5 24.0 23.8 
73 TLR7 toll-like receptor 7 0.496414 -1.613721 34.2 36.7 34.8 40.0 34.6 34.8 
74 TLR10 toll-like receptor 10 0.600137 1.309166 36.7 37.0 36.7 35.5 36.7 37.2 
75 LY96 
lymphocyte antigen 
96 
NS -1.094964 40.0 40.0 40.0 40.0 40.0 40.0 
76 TLR8 toll-like receptor 8 NS -1.094964 40.0 40.0 40.0 40.0 40.0 40.0 
77 TREM2 
triggering receptor 
expressed on 
myeloid cells 2 
NS -1.094964 40.0 40.0 40.0 40.0 40.0 40.0 
78 IRAK3 
interleukin-1 
receptor-associated 
kinase 3 
NS -1.094964 40.0 40.0 40.0 40.0 40.0 40.0 
79 TLR2 toll-like receptor 2 NS -1.094964 40.0 40.0 40.0 40.0 40.0 40.0 
80 LY86 
lymphocyte antigen 
86 
NS -1.094964 40.0 40.0 40.0 40.0 40.0 40.0 
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81 CD80 CD80 molecule NS -1.094964 40.0 40.0 40.0 40.0 40.0 40.0 
82 HSGenomic  
Genomic DNA 
control 
NS -1.094964 40.0 40.0 40.0 40.0 40.0 40.0 
83 BTK 
Bruton 
agammaglobulinemia 
tyrosine kinase 
NS 1.579370 40.0 40.0 40.0 40.0 38.2 40.0 
84 NOX4 NADPH oxidase 4 NS 1.791224 40.0 40.0 40.0 40.0 40.0 38.1 
85 CD36 
CD36 molecule 
(thrombospondin 
receptor) 
NS 2.377010 40.0 40.0 40.0 40.0 38.2 38.2 
86 IFNG interferon. gamma NS 1.969557 40.0 40.0 40.0 40.0 40.0 37.9 
87 TLR9 toll-like receptor 9 NS 2.994596 40.0 40.0 40.0 40.0 37.4 38.3 
88 CARD9 
caspase recruitment 
domain family. 
member 9 
NS -1.265991 40.0 40.0 37.6 40.0 40.0 38.3 
89 CD86 CD86 molecule NS 3.977903 40.0 40.0 40.0 40.0 37.6 37.2 
90 MAL 
mal. T-cell 
differentiation 
protein 
NS 4.869186 40.0 40.0 40.0 37.2 37.6 38.1 
91 LBP  
lipopolysaccharide 
binding protein 
NS 1.046578 40.0 37.0 40.0 40.0 37.8 37.7 
92 TREM1 
triggering receptor 
expressed on 
myeloid cells 1 
NS 5.453114 40.0 40.0 40.0 40.0 37.8 36.4 
93 IL10 interleukin 10 NS 1.146065 40.0 37.3 40.0 40.0 36.9 40.0 
94 CD180 CD180 molecule NS 1.845353 40.0 40.0 37.9 36.9 40.0 40.0 
95 PELI1 pellino homolog 1 NS -2.311180 40.0 36.3 36.3 40.0 38.0 37.5 
96 ATF3 
activating 
transcription factor 3 
NS 8.004811 40.0 40.0 40.0 37.5 40.0 35.8 
97 
Tlr11 
 
toll-like receptor 11         
98 
Tlr12 
 
toll-like receptor 12         
99 
Tlr13 
 
toll-like receptor 13         
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Genomic Contamination Levels        
None The data is not compromised by the presence of 
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In bold  - significant changes 
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Supplementary Data CS.2.  qPCR array for LA-4 cells 
LA4 
No. Symbol Gene Name P-value 
Fold 
Change 
Control 
1 
Control 
2 
Control 
3 
Exp 
1 
Exp 
2 
Exp 3 
1 CXCL10 
chemokine (C-X-C 
motif) ligand 10 
0.01302 10.24525 24.2 25.7 25.1 21.6 21.2 21.5 
2 IFNA interferon. alpha NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
3 CCL4 
chemokine (C-C 
motif) ligand 4 
0.02674 22.93084 28.7 31.9 30.5 25.0 25.7 25.4 
4 IRF7 
interferon regulatory 
factor 7 
0.02632 20.22088 28.3 31.3 29.9 25.3 24.3 25.1 
5 IFNB interferon. beta 0.03388 22.73265 30.3 31.3 32.3 26.0 27.4 27.5 
7 PTX3 pentraxin 3. long 0.33584 1.13037 24.6 24.5 24.9 25.2 24.4 23.4 
8 SOCS1 
suppressor of 
cytokine signaling 1 
0.02377 3.64825 29.7 29.0 28.8 27.6 26.8 27.1 
9 CCL5 
chemokine (C-C 
motif) ligand 5 
0.02073 13.07951 25.7 27.2 26.7 22.4 22.8 23.1 
10 TLR3 toll-like receptor 3 0.00578 10.75578 30.6 30.9 29.9 27.4 26.4 26.7 
11 CIITA 
class II. major 
histocompatibility 
complex. 
transactivator 
NS 1.17025 40.0 40.0 38.3 40.0 38.1 38.3 
12 CXCL9 
chemokine (C-X-C 
motif) ligand 9 
NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
13 STAT1 
signal transducer and 
activator of 
transcription 1 
0.01390 5.95756 24.3 25.4 25.2 22.7 21.8 22.0 
15 IRF1 
interferon regulatory 
factor 1 
0.03500 4.37083 29.2 30.6 30.4 28.2 27.2 27.6 
16 MYD88 
myeloid 
differentiation 
primary response 
gene (88) 
0.03955 2.23052 27.3 27.7 28.1 27.0 26.1 26.0 
17 IL6 
interleukin 6 
(interferon. beta 2) 
0.01800 15.30461 28.1 29.3 29.1 24.5 25.0 25.2 
18 TNF tumor necrosis factor 0.01054 21.09833 39.05 40.0 38.1 34.5 34.5 33.8 
19 CXCL11 
chemokine (C-X-C 
motif) ligand 11 
0.01166 16.78909 26.9 28.0 29.1 23.6 23.8 23.7 
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1 
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2 
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3 
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1 
Exp 
2 
Exp 3 
20 IL12A 
interleukin 12A 
(natural killer cell 
stimulatory factor 1. 
cytotoxic lymphocyte 
maturation factor 1. 
p35) 
NS -1.69148 40.0 37.4 37.7 38.2 40.0 40.0 
21 CASP1 
caspase 1. apoptosis-
related cysteine 
peptidase (interleukin 
1. beta. convertase) 
0.24295 1.82246 37.1 35.0 36.5 36.90 34.1 34.5 
22 CD14 CD14 molecule 0.41695 -1.09289 30.6 30.6 30.9 32.0 29.9 30.3 
23 TLR5 toll-like receptor 5 NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
24 MUC1 
mucin 1. cell surface 
associated 
0.34636 -1.19550 32.2 31.4 32.4 33.6 31.6 31.2 
25 RIPK2 
receptor-interacting 
serine-threonine 
kinase 2 
0.23490 1.18268 25.0 24.9 25.3 25.7 24.2 24.1 
26 TRAFD1 
TRAF-type zinc 
finger domain 
containing 1 
0.01721 4.30988 25.0 25.5 25.5 23.5 22.8 23.0 
27 JUN jun proto-oncogene 0.10667 1.88638 34.7 35.1 36.0 34.8 33.7 33.8 
28 IL12B 
interleukin 12B 
(natural killer cell 
stimulatory factor 2. 
cytotoxic lymphocyte 
maturation factor 2. 
p40) 
NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
29 TICAM1 
toll-like receptor 
adaptor molecule 1 
0.17010 1.34264 28.6 28.6 29.0 28.8 28.1 27.5 
30 CNPY4 canopy 4 homolog 0.10609 -1.48839 24.1 23.7 24.3 25.7 24.0 23.7 
31 TLR1 toll-like receptor 1 0.19641 -1.27916 28.6 27.9 28.4 29.6 28.3 27.6 
32 SYK 
spleen tyrosine 
kinase 
NS 2.32043 40.0 37.9 38.2 38.4 37.8 35.7 
33 NFKB1 
nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 1 
0.29680 1.13086 26.9 25.9 26.4 26.9 25.8 25.4 
157 
 
LA4 
No. Symbol Gene Name P-value 
Fold 
Change 
Control 
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1 
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2 
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34 CASP8 
caspase 8. apoptosis-
related cysteine 
peptidase 
0.65924 -1.03613 34.4 32.0 31.6 33.9 31.7 31.2 
35 SARM1 
sterile alpha and TIR 
motif containing 1 
0.12157 -1.84926 32.6 32.1 32.7 34.9 33.0 32.0 
36 HMGB1 
high mobility group 
box 1 
0.19159 -1.22410 20.3 19.8 20.3 21.3 19.9 19.6 
37 TRAF6 
TNF receptor-
associated factor 6 
0.30643 1.12400 27.7 27.5 27.8 28.0 27.2 26.8 
38 CSK c-src tyrosine kinase 0.22816 1.17157 29.5 29.5 29.7 30.1 29.0 28.4 
39 MAPK14 
mitogen-activated 
protein kinase 14 
0.44544 -1.08026 25.3 24.4 25.5 25.6 25.2 24.2 
40 CD44 
CD44 molecule 
(Indian blood group) 
0.36242 1.00317 31.3 30.7 31.1 31.6 30.9 30.1 
41 IFNAR1 
interferon (alpha. 
beta and omega) 
receptor 1 
0.32739 1.04252 27.9 27.8 27.8 28.4 27.5 26.9 
42 CNPY3 canopy 3 homolog 
 
0.21233 -1.23671 25.9 25.8 26.4 27.2 25.8 25.5 
43 IRF3 
interferon regulatory 
factor 3 
0.27443 1.07177 27.7 27.4 28.1 28.5 27.3 26.6 
44 RELA 
v-rel 
reticuloendotheliosis 
viral oncogene 
homolog A 
0.39707 -1.12974 24.1 24.4 25.0 25.1 24.2 24.1 
45 IRAK1 
interleukin-1 
receptor-associated 
kinase 1 
0.20242 -1.24061 24.2 23.9 24.7 25.4 24.2 23.6 
46 
UNC93B
1 
unc-93 homolog B1 NS -1.17942 40.0 37.2 37.4 40.0 38.1 36.4 
47 RAC1 
ras-related C3 
botulinum toxin 
substrate 1 (rho 
family. small GTP 
binding protein 
Rac1) 
NS -1.48774 40.0 34.9 35.2 38.2 35.2 35.5 
48 CHUK 
conserved helix-loop-
helix ubiquitous 
kinase 
0.13579 -1.64484 26.8 26.5 26.7 28.8 26.6 26.5 
49 NR3C1 
nuclear receptor 
subfamily 3. group C. 
0.35574 1.11999 27.4 26.1 26.9 27.4 26.0 25.9 
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member 1 
(glucocorticoid 
receptor) 
50 PYCARD 
PYD and CARD 
domain containing 
NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
51 MAPK8 
mitogen-activated 
protein kinase 8 
0.26933 -1.02663 26.5 26.1 26.8 27.3 26.1 25.6 
52 HSP90B1 
heat shock protein 
90kDa beta (Grp94). 
member 1 
0.12283 -1.72694 19.5 19.2 19.7 21.7 19.6 19.2 
53 Hs18s 18S rRNA 0.31860 -1.02378 11.4 10.9 11.1 11.7 10.8 10.5 
54 IL1B interleukin 1. beta NS 1.56046 40.0 37.5 40.00 37.4 40.0 40.0 
55 IRAK4 
interleukin-1 
receptor-associated 
kinase 4 
0.24774 -1.14888 28.1 28.1 28.2 29.2 27.9 27.4 
56 AKT1 
v-akt murine 
thymoma viral 
oncogene homolog 1 
0.26122 -1.12185 26.7 26.3 26.5 27.4 26.2 25.9 
57 TIRAP 
toll-interleukin 1 
receptor (TIR) 
domain containing 
adaptor protein 
0.65909 -1.29428 35.2 32.6 32.8 34.7 32.5 33.5 
58 MAP3K7 
mitogen-activated 
protein kinase kinase 
kinase 7 
0.06666 -1.35195 29.2 29.0 29.3 30.5 29.3 28.8 
59 TICAM2 
toll-like receptor 
adaptor molecule 2 
NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
60 TOLLIP 
toll interacting 
protein 
0.24799 1.07048 24.7 24.4 24.9 25.3 24.2 23.7 
61 
MAP3K7
IP1 
TGF-beta activated 
kinase 1/MAP3K7 
binding protein 1 
0.48254 1.04828 28.4 28.4 28.0 28.7 28.3 27.1 
62 TLR4 toll-like receptor 4 0.45281 -1.18225 35.1 33.8 34.0 35.8 33.8 33.5 
63 TLR6 toll-like receptor 6 0.49642 1.01439 32.3 31.1 31.6 33.3 30.9 30.5 
64 SIGIRR 
single 
immunoglobulin and 
toll-interleukin 1 
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1 
Control 
2 
Control 
3 
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1 
Exp 
2 
Exp 3 
receptor (TIR) 
domain 
65 BCL3 
B-cell 
CLL/lymphoma 3 
0.44535 1.26524 37.0 37.2 35.5 37.1 35.9 34.6 
66 CYLD 
cylindromatosis 
(turban tumor 
syndrome) 
0.23020 -1.30825 31.8 30.9 31.3 32.8 31.1 30.8 
67 DOK1 
docking protein 1. 
62kDa (downstream 
of tyrosine kinase 1) 
0.25166 -1.10126 26.0 25.9 26.3 26.9 25.9 25.3 
68 TRAF3 
TNF receptor-
associated factor 3 
0.28324 -1.12688 29.2 28.4 28.8 29.8 28.5 28.1 
69 IRF5 
interferon regulatory 
factor 5 
NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
70 FADD 
Fas (TNFRSF6)-
associated via death 
domain 
0.27937 1.26277 27.7 27.9 28.5 28.2 27.6 26.7 
71 TBK1 
TANK-binding 
kinase 1 
0.25343 1.19439 28.2 27.4 27.7 28.2 27.0 26.8 
72 HSPD1 
heat shock 60kDa 
protein 1 
(chaperonin) 
0.25343 1.19439 28.2 27.4 27.7 28.2 27.0 26.8 
73 TLR7 toll-like receptor 7 0.50306 1.12634 26.6 25.9 26.3 26.2 25.9 25.9 
74 TLR10 toll-like receptor 10         
75 LY96 
lymphocyte antigen 
96 
0.22188 1.17581 27.7 27.6 27.9 28.3 27.0 26.7 
76 TLR8 toll-like receptor 8 NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
77 TREM2 
triggering receptor 
expressed on myeloid 
cells 2 
NS 1.85219 40.0 40.0 40.0 40.0 40.0 37.5 
78 IRAK3 
interleukin-1 
receptor-associated 
kinase 3 
0.28027 2.11947 36.2 36.3 40.0 36.5 35.2 35.0 
79 TLR2 toll-like receptor 2 0.01611 2.47109 36.7 36.8 36.7 36.1 35.3 34.4 
80 LY86 
lymphocyte antigen 
86 
NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
81 CD80 CD80 molecule 0.19687 1.28231 32.0 31.6 31.6 31.9 31.1 30.6 
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2 
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Exp 
1 
Exp 
2 
Exp 3 
82 
HSGeno
mic 
Genomic DNA 
control 
NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
83 BTK 
Bruton 
agammaglobulinemia 
tyrosine kinase 
0.06353 -3.22192 36.3 36.2 36.5 40.0 36.9 37.6 
84 NOX4 NADPH oxidase 4 NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
85 CD36 
CD36 molecule 
(thrombospondin 
receptor) 
NS -4.53509 40.0 38.2 36.9 40.0 40.0 40.0 
86 IFNG interferon. gamma NS -1.59922 40.0 36.7 36.5 40.0 36.5 37.6 
87 TLR9 toll-like receptor 9 NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
88 CARD9 
caspase recruitment 
domain family. 
member 9 
0.78415 2.08796 37.0 37.3 37.2 40.0 36.8 34.0 
89 CD86 CD86 molecule NS 1.12659 40.0 36.7 36.9 38.3 36.9 36.0 
90 MAL 
mal. T-cell 
differentiation 
protein 
NS -1.62038 40.0 40.0 37.3 40.0 37.9 40.0 
91 LBP 
lipopolysaccharide 
binding protein 
NS 1.59003 40.0 37.0 37.0 37.6 36.2 36.4 
92 TREM1 
triggering receptor 
expressed on myeloid 
cells 1 
NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
93 IL10 interleukin 10 NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
94 CD180 CD180 molecule NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
95 PELI1 pellino homolog 1 0.33138 1.15791 27.2 26.8 27.2 27.3 26.5 26.3 
96 ATF3 
activating 
transcription factor 3 
0.06130 4.21534 27.1 27.3 27.6 25.1 25.5 25.1 
97 
Tlr11 
 
toll-like receptor 11 NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
98 
Tlr12 
 
toll-like receptor 12 NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
99 
Tlr13 
 
toll-like receptor 13 NS -1.03215 40.0 40.0 40.0 40.0 40.0 40.0 
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LEGEND:        
Control                
GPR Normalizer                
Genomic Contamination Levels        
None The data is not compromised by the presence of 
genomic DNA,  
In bold  - significant changes 
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SUPPLEMENTARY DATA 
 
 
Figure SD.1. Comparison of mVenus expression level 24 hours post-transfection from 
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unmodified and modified mRNA in various cell lines A) human lung adenocarcinoma 
– A549, B) human foreskin fibroblasts – BJ, C) murine myoblasts – C2C12, D) human 
cervical epithelial cells – Hela and E) human primary keratinocytes (neonatal). The 
results are presented as the mean ± SD (n=3), statistical analysis ANOVA in the Table 
SD 2. 
 
 
Figure SD.2. flow cytometry data TLR3 and RIG-I ICS 
 
 
 
Table SD.1. ANOVA statistics followed by ad hoc Tukey’s multiple comparisons test 
after transfection of luciferase-encoding mRNA/Lipofectamine 2000 in A549, BJ, 
C2C12, HeLa and primary Keratinocytes cells (based on Figure 5.2); * p<0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001 (ANOVA). 
Luciferase
ANOVA summary
F 597235 80.16 4.627 33.99 8.105 3.844 9.437
P value < 0.0001 < 0.0001 0.0225 < 0.0001 0.0047 0.0383 0.004
P value summary **** **** * **** ** * **
Tukey's multiple comparisons test A549 BJ C2C12 HeLa Keratinocytes HEK HEK-TLR3
N vs.  **** ns ns ns ns ns ns
N vs. m1 **** *** * ns ns * ns
N vs. m5C **** *** ns ns ns ns ns
N vs. m5Cm1 **** **** ns **** * ns **
 vs. m1 **** ** ns ns ns ns ns
 vs. m5C **** ** ns ns ns ns ns
 vs. m5Cm1 **** **** ns **** ** ns **
m1 vs. m5C **** ns ns ns ns ns ns
m1 vs. m5Cm1 **** **** ns **** * ns ns
m5C vs. m5Cm1 **** **** ns **** * ns ns
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Table SD.2. ANOVA statistics followed by ad hoc Tukey’s multiple comparisons test 
after transfection of mVenus-encoding mRNA/Lipofectamine 2000 in A549, BJ, C2C12, 
HeLa and primary Keratinocytes cells (based on Figure SD.1); * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001 (ANOVA). 
 
mVenus
F 299.4 4.649 73.34 113.5 215.9
P value < 0.0001 0.0261 < 0.0001 < 0.0001 < 0.0001
P value summary **** * **** **** ****
Tukey's multiple comparisons test A549 BJ C2C12 HeLa Keratinocytes
N vs.  ns ns ns ns ns
N vs. m1 **** ns **** ns ns
N vs. m5C ns ns ** ns ns
N vs. m5Cm1 **** * **** **** ****
 vs. m1 **** ns **** ns ns
 vs. m5C ns ns * ns ns
 vs. m5Cm1 **** ns **** **** ****
m1 vs. m5C **** ns ** ns ns
m1 vs. m5Cm1 **** ns * **** ****
m5C vs. m5Cm1 **** ns **** **** ****
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Table SD.4. Characterization of complexes – Zeta Potential. 
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